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By Eloïse Cook 
 
As the population is becoming more aged, osteoporosis is becoming more prevalent and the 
number of fragility fractures that are occurring is increasing. One of the main predictors of 
developing osteoporosis in later life is a bone mineral density that is greater than 2.5 standard 
deviations below the young adult sex-matched mean, though studies have only been able to 
explain 5% of the variance seen in bone mineral densities between individuals. There is now 
increasing evidence that the development of osteoporosis can begin in utero and that epigenetic 
processes, such as DNA methylation, may be central to the mechanism by which early 
development influences bone mineral density and later bone health. 
  Previous work within the group has identified associations of a 300bp differentially methylated 
region within the CDKN2A locus with bone mineral content, bone area and areal bone mineral 
density in offspring from the Southampton Women’s Survey (SWS) cohort. As methylation of 
CDKN2A increases, bone mineral content, bone area and areal bone mineral density all decrease 
at both 4 and 6 years of age. The two cell cycle regulators p16INK4A and p14ARF are transcribed from 
this gene as well as the lncRNA ANRIL. 
    Various techniques were used to determine whether this differentially methylated region has a 
functional role in osteoblasts or whether it is just a potential marker for predicting bone mineral 
density. It was shown that there was specific binding in the osteoblast-like SaOS-2 cell line to this 
region and that methylation of these CpGs led to a decrease in transcription factor binding. 
Treatment of both SaOS-2 cells and primary osteoblasts with siRNAs against ANRIL caused a 
decrease in cell number, a decrease in cell proliferation, an increase in cells in G0/G1 phase of the 
cell cycle and, in SaOS-2 cells, caused an increase in the expression of bone differentiation 
markers RUNX2 and ALP. Knock down of ANRIL expression also caused a change in genes that 
have roles in osteoblast specific pathways as well as genes that were involved in molecular 
functions such as nuclear regulation and acetylation. Associations were found between CpG 
methylation in RXRA and offspring bone outcomes at birth in both the SWS and MAVIDOS 
cohorts. Daily maternal cholecalciferol supplementation was also shown to decrease the 
methylation of CpG loci within RXRA in offspring umbilical cord and further investigation showed 
that this effect of maternal supplementation was only seen in children born during the winter 
months. 
  Together, these findings suggest that the association between CDKN2A methylation at birth and 
later bone health could indicate a potential role for CDKN2A in bone development and function 
and raises the possibility that differential methylation of CDKN2A may allow the identification of 
individuals at increased risk of osteoporosis in later life.  Due to the effect of ANRIL knock down in 
primary osteoblasts, which could not be explained through normal cell cycle pathways, results 
suggest that ANRIL has potential trans-regulatory functions in these cells.  These findings suggest 
that ANRIL could potentially play a role in bone differentiation, cell proliferation and metabolism 
and that dysregulation of the expression of this lncRNA could have adverse effects on bone 
health, potentially increasing the risk of individuals developing osteoporosis in later life. 
II 
 
Table of Contents 
 
Abstract – I 
Table of contents – II 
List of figures – VII 
List of tables – X 
Declaration of authorship – XI 
Acknowledgements – XII 
Abbreviations – XIII 
 
  Page Number 
1.0 Introduction 1 
 1.1 Osteoporosis 3 
 1.1.1 Epidemiology of osteoporosis 3 
 1.1.1.1 Fracture 3 
 1.1.1.2 Morbidity 4 
 1.1.1.3 Mortality 5 
 1.1.1.4 Economic cost 6 
 1.2 Bone formation 6 
 1.2.1 Osteoblast differentiation 7 
 1.2.1.1 Transcription factors 9 
 1.2.1.2 Signalling pathways 10 
 1.2.1.3 Systemic regulation 16 
 1.2.2 Osteoclasts 17 
 1.2.3 Bone remodelling 18 
 1.2.4 Genome-wide association studies (GWASs) 19 
 1.2.5 Pathogenesis of osteoporosis 19 
 1.3 Developmental origins of health and disease (DOHaD) 21 
 1.3.1 Human studies 22 
 1.3.2 Animal studies 24 
 1.3.3 Evidence for the developmental origins of osteoporosis 25 
 1.3.3.1 Population studies 25 
 1.3.1.2 Physiological studies 26 
 1.3.3.3 Maternal lifestyle 27 
 1.3.3.4 Childhood growth 27 
 1.3.4 Vitamin D 28 
 1.4 Epigenetics 29 
 1.4.1 Epigenetic mechanisms 30 
 1.4.1.1 DNA methylation 30 
 1.4.1.2 Histone modifications 31 
 1.4.1.3 microRNAs (miRNAs) 31 
 1.4.1.4 Long non-coding RNAs (lncRNAs) 32 
 1.4.1.5 Evidence epigenetic processes mediate developmental 
origins of adult disease using animal models 33 
 1.4.1.6 Vitamin D and epigenetic mechanisms 33 
 1.4.2 Epigenetics and early life environment 34 
 1.4.3 Epigenetics and bone 36 
 1.5 Identification of potential predictive markers of offspring bone 
outcomes 38 
 1.5.1 Epigenetic biomarkers of later health 38 
 1.5.2 Epigenetic markers of later bone health 39 
III 
 
 1.5.2.1 RXRα 39 
 1.5.2.2 Endothelial nitric oxide synthase (eNOS) 40 
 1.5.2.3 CDKN2A 41 
 1.6 Aims and hypotheses 43 
   
2.0 Materials and Methods 45 
 2.1 Materials 47 
 2.2 Methods 50 
 2.2.1 Cell culture  50 
 2.2.1.1 Osteosarcoma SaOS-2 cell line 50 
 2.2.1.2 Human bone marrow stromal cells (hBMSCs) 50 
 2.2.2 Transfection of SaOS-2 with luciferase reporter constructs 52 
 2.2.2.1 ANRIL/p14ARF luciferase reporter constructs 52 
 2.2.2.2 Inoculation and minipreparation of plasmid DNA 52 
 2.2.2.3 Preparing plasmid DNA for transfection 53 
 2.2.2.4 Transfection of plasmid DNA 53 
 2.2.2.5 Preparation of cells for Dual-Luciferase assay 54 
 2.2.3 Isolation of nuclear extract 54 
 2.2.4 Analysis of transcription factor binding by electrophoretic 
mobility shift assays 54 
 2.2.4.1 Annealing oligonucleotides 54 
 2.2.4.2 Electrophoretic mobility shift assay (EMSA) 55 
 2.2.5 Transfection with siRNA against ANRIL 57 
 2.2.5.1 SaOS-2 57 
 2.2.5.2 hBMSCs and primary osteoblasts 59 
 2.2.6 Isolation of total RNA 59 
 2.2.6.1 TRI Reagent 59 
 2.2.6.2 RNeasy kit 60 
 2.2.7 Illumina Human H12 Gene Expression Array 60 
 2.2.8 DNase I treatment 60 
 2.2.9 cDNA synthesis 61 
 2.2.10 Real time quantitative polymerase chain reaction (RT-qPCR) 61 
 2.2.10.1 GeNorm assay 61 
 2.2.10.2 TaqMan assays 61 
 2.2.11 Fluorescence-activated cell sorting (FACS) 62 
 2.2.12 Measuring methylation levels of MAVIDOS umbilical cord 63 
 2.2.12.1 Isolation of genomic DNA from umbilical cord 63 
 2.2.12.2 Bisulfite conversion of genomic DNA 66 
 2.2.12.3 Polymerase chain reaction (PCR) 66 
 2.2.12.4 Pyrosequencing 68 
 2.2.13 Statistical analysis 68 
 2.2.13.1 Statistical analysis of siRNA transfected cells 68 
 2.2.13.2 Statistical analysis of MAVIDOS cohort 68 
   
3.0 Identification of CDKN2A as a predictive marker of bone mineral 
density 71 
 3.1 Introduction 73 
 3.1.1 CDKN2A gene locus 73 
 3.2 Aims 76 
 3.3 Results 77 
 3.3.1 Does the DMR control CDKN2A expression? 77 
IV 
 
 3.3.2 Is there specific binding to the CpGs within the CDKN2A DMR in 
bone cells? 
 
79 
 3.3.3 Does the methylation of CpGs -887 and -907 in the CDKN2A DMR 
alter the binding of transcription factors? 82 
 3.3.4 What transcription factors bind to CpGs -887 and -907? 85 
 3.4 Discussion 89 
 3.5 Summary 93 
 3.6 Future work 93 
   
4.0 Functional significance of ANRIL in SaOS-2, an osteoblast-like cell line 95 
 4.1 Introduction 97 
 4.2 Aims 99 
 4.3 Results 100 
 4.3.1 Is ANRIL expressed in bone-related cells? 100 
 4.3.2 Does ANRIL knock down affect SaOS-2 cell number? 103 
 4.3.3 Does knock down of ANRIL expression cause cell cycle arrest? 106 
 4.3.4 Does ANRIL knock down have an effect on osteoblast 
differentiation? 108 
 4.3.5 Does ANRIL knock down have an effect on mineralisation? 110 
 4.3.6 Does ANRIL mediate its affect through altered expression of the 
CDKN2A/B locus? 111 
 4.4 Discussion 113 
 4.5 Summary 118 
   
5.0 Characterisation of ANRIL in human bone marrow stromal cells and 
primary osteoblasts 121 
 5.1 Introduction 123 
 5.2 Aims 123 
 5.3 Results 124 
 5.3.1 ANRIL knock down causes a decrease in hBMSC and primary 
osteoblast cell number 124 
 5.3.2 ANRIL knock down does not have an effect on the viability of 
primary cells 129 
 5.3.3 Knock down of ANRIL expression causes a decrease in the 
proliferation of primary cells 131 
 5.3.4 Knock down of ANRIL expression causes cell cycle arrest in 
hBMSCs and primary osteoblasts 133 
 5.3.5 Does ANRIL mediate its affect through altered expression of the 
CDKN2A/B locus in primary cells? 135 
 5.3.6 hBMSCs and primary osteoblasts treated with siRNAs against 
ANRIL are not undergoing replicative senescence 138 
 5.4 Discussion 140 
 5.5 Summary 142 
 5.6 Future work 143 
   
6.0 Effects of ANRIL knock down on gene expression in human primary 
osteoblasts 145 
 6.1 Introduction 147 
 6.2 Aims 148 
 6.3 Results 149 
 6.3.1 Validation of Illumina Human H12 Gene Expression Array results 149 
V 
 
 6.3.2 ANRIL knock down in primary osteoblasts alters osteoblast-
specific pathways 
 
154 
 6.4 Discussion 163 
 6.5 Summary 166 
 6.6 Future work 167 
   
7.0 The association between the methylation status of CDKN2A, RXRA 
and NOS3 with bone outcomes at birth 169 
 7.1 Introduction 171 
 7.1.1 DNA methylation as a marker for a later phenotype 171 
 7.1.2 Maternal vitamin D and offspring bone health 171 
 7.1.3 Maternal Vitamin D Osteoporosis Study (MAVIDOS) 173 
 7.2 Aims 174 
 7.3 Results 175 
 7.3.1 Is the methylation of CDKN2A associated with offspring bone 
outcomes at birth? 175 
 7.3.1.1 SWS umbilical cord 175 
 7.3.1.2 MAVIDOS umbilical cord 178 
 7.3.2 Is the methylation of RXRA associated with offspring bone 
outcomes at birth? 180 
 7.3.2.1 SWS umbilical cord 180 
 7.3.2.2 MAVIDOS umbilical cord 183 
 7.3.3 Is the methylation of NOS3 associated with offspring bone 
outcomes at birth? 186 
 7.3.3.1 SWS umbilical cord 186 
 7.3.3.2 MAVIDOS umbilical cord 187 
 7.3.4 Is the methylation of CDKN2A, RXRA and NOS3 associated with 
birth weight? 188 
 7.3.4.1 CDKN2A 188 
 7.3.4.2 RXRA 189 
 7.3.4.3 NOS3 190 
 7.3.4.4 The association between birth weight and offspring bone 
outcomes at birth 191 
 7.3.5 Is the methylation of CDKN2A, RXRA and NOS3 measured in 
MAVIDOS umbilical cord tissue affected by maternal vitamin D 
supplementation? 194 
 7.3.5.1 CDKN2A 195 
 7.3.5.2 RXRA 196 
 7.3.5.3 NOS3 200 
 7.4 Discussion 201 
 7.4.1 CDKN2A CpG methylation in umbilical cord and offspring bone 
outcomes 201 
 7.4.2 RXRA CpG methylation in umbilical cord and offspring bone 
outcomes 201 
 7.4.3 NOS3 CpG methylation in umbilical cord and offspring bone 
outcomes 202 
 7.4.4 CDKN2A, RXRA and NOS3 methylation and birth weight 203 
 7.4.5 CDKN2A, RXRA and NOS3 methylation and maternal vitamin D 
supplementation 204 
 7.5 Summary 206 
 7.6 Further work 207 
VI 
 
8.0 Discussion 209 
 8.1 Summary of main findings 211 
 8.2 Discussion of main findings 212 
 8.3 Implication for human health 219 
   
9.0 Appendix 221 
 9.1 Appendix 223 
 9.1.1 Illumina Human H12 Gene Expression Array 223 
 9.1.2 Optimisation of primary cell siRNA transfection 226 
   
10.0 References 233 
 
 
  
VII 
 
List of Figures 
 Page Number 
Figure 1.1 – Osteoporotic fracture survival rates 5 
Figure 1.2 – Stages of osteoblast differentiation from mesenchymal stem cells 8 
Figure 1.3 – Bone morphogenic protein signalling in osteoblast differentiation 11 
Figure 1.4 – Wnt signalling in osteoblast differentiation 13 
Figure 1.5 – Indian hedgehog signalling in osteoblast differentiation 13 
Figure 1.6 – Notch signalling in osteoblast differentiation 15 
Figure 1.7 – Fibroblast growth factor signalling in osteoblast differentiation 15 
Figure 1.8 – Pathogenesis of osteoporosis 20 
Figure 1.9 – 5-methyl cytosine 30 
Figure 1.10 – Association between total bone mineral density and CpG9 
methylation at 4 and 6 years 42 
Figure 2.1 – Alkaline phosphatase staining of hBMSCs and primary osteoblasts 51 
Figure 2.2 – Transfection pGL-Basic plasmid constructs for ANRIL and p14ARF 52 
Figure 2.3 – Positions of ANRIL real time qPCR assays 62 
Figure 2.4 – Scheme of flow cytometry scan 63 
Figure 2.5 – Example of MAVIDOS umbilical cord DNA on an agarose gel 65 
Figure 2.6 – Example of pyrosequencing product on a 1.5% agarose gel 65 
Figure 3.1 – Layout of CDKN2A locus 74 
Figure 3.2 – Promoter activity of ANRIL/p14ARF upon CpG mutation 78 
Figure 3.3 – Location of EMSA probes on DMR sequence within CDKN2A locus 79 
Figure 3.4 – Testing the specificity of protein binding to liposarcoma and 
osteosarcoma cell lines 81 
Figure 3.5 – Testing the preference of binding to unmethylated and 
methylated radiolabelled CpGs -887 and -907 probe 83 
Figure 3.6 – Binding of unmethylated and methylated CpGs -887 and -907 
probe to similar size complex 84 
Figure 3.7 – Transcription factor competition with unmethylated CpGs -887 
and -907 probe 85 
Figure 3.8 – Competition of individual transcription factor consensus 
sequences with unmethylated CpGs -87 and -907 probe 88 
Figure 3.9 – The CDKN2A DMR with putative regulatory transcription factor 
binding sites 90 
Figure 4.1 – Position of ANRIL in relation to p14ARF and p15INK4B 98 
Figure 4.2 – Exons present in previously reported ANRIL isoforms 100 
Figure 4.3 – Expression of ANRIL exons 1-2, exons 5-6 and exons 18-19 in 
different cell lines 102 
Figure 4.4 – RT-qPCR confirmation of knockdown of ANRIL in transfected cells  104 
Figure 4.5 – Number of live SaOS-2 cells after 72hr incubation with siRNAs 
against ANRIL 105 
Figure 4.6 – Percentage of SaOS-2 cells in G0/G1 phase and apoptotic cells 107 
Figure 4.7 – Expression of RUNX2 and ALP compared to control in transfected 
SaOS-2 cells 109 
Figure 4.8 – Expression of BGLAP compared to control in transfected SaOS-2 
cells 110 
Figure 4.9 – Expression of p16INK4A, p15INK4B and p14ARF compared to control in 
transfected SaOS-2 cells 112 
Figure 4.10 – Exons present in 17 different ANRIL transcripts in PBMCs 113 
Figure 5.1 – RT-qPCR confirmation of knockdown of ANRIL in transfected 
hBMSCs 126 
VIII 
 
Figure 5.2 – RT-qPCR confirmation of knockdown of ANRIL in transfected 
primary osteoblasts 127 
Figure 5.3 – Number of live hBMSCs and primary osteoblasts after 72hr 
transfection with siRNAs against ANRIL 128 
Figure 5.4 – Relative luminescent signal from viable hBMSCs and primary 
osteoblasts compared to control 130 
Figure 5.5 – Relative absorbance of viable hBMSCs and primary osteoblasts 
compared to control 132 
Figure 5.6 – Percentage of hBMSCs and primary osteoblasts cells in G0/G1 
phase 134 
Figure 5.7 – Expression of p16INK4A and p15INK4B in hBMSCs after knock down of 
ANRIL expression 136 
Figure 5.8 – Expression of p16INK4A and p15INK4B in primary osteoblasts after 
knock down of ANRIL expression 137 
Figure 5.9 – Senescence-associated β-galactosidase activity of hBMSCs and 
primary osteoblasts after knock down of ANRIL expression 139 
Figure 6.1 – Validation of gene expression array results 151 
Figure 6.2 – Gene expression of HIF1A, IGF2, MAPK3, ETS1, CYR61 and TWSG1 
upon treatment of osteoblasts with Congrains E19 siRNA 153 
Figure 6.3 – Breakdown of biological functions and the number of genes with 
changed expression associated with those functions 155 
Figure 6.4 – The top two altered pathways under the molecular and cellular 
function subcategory that showed relation to osteoblast function 157 
Figure 6.5 – Tissue development pathways that involve genes altered by ANRIL 
knock down 158 
Figure 6.6 – Skeletal and muscular system development and function 
pathways that involve genes altered upon ANRIL knock down 159 
Figure 6.7 – The number of up and down regulated genes involved in protein 
transport and cellular processes in osteoblasts upon ANRIL knockdown 161 
Figure 6.8 – The number of up and downregulated genes involved In protein 
transport 161 
Figure 6.9 – Top five enriched functional categories upon ANRIL knock down in 
osteoblasts 162 
Figure 7.1 – Associations between CDKN2A methylation and offspring bone 
outcomes at birth in the SWS cohort 177 
Figure 7.2 – Associations between RXRA methylation and offspring bone 
outcomes at birth in the SWS cohort 182 
Figure 7.3 – Associations between RXRA methylation and offspring bone 
outcomes at birth in the MAVIDOS cohort 185 
Figure 7.4 – The association between birth weight and offspring total BMC at 
birth 191 
Figure 7.5 – The association between birth weight and offspring total BA at 
birth 192 
Figure 7.6 – The association between birth weight and offspring total BMD at 
birth 193 
Figure 7.7 – Comparison of maternal serum 25-hydroxyvitamin D 
concentration between placebo and supplementation groups at 14 and 34 
weeks gestation 194 
Figure 7.8 – Comparison of CDKN2A methylation in offspring umbilical cord 
between maternal treatment groups 195 
Figure 7.9 – Comparison of RXRA methylation in offspring umbilical cord  
IX 
 
between maternal treatment groups 197 
Figure 7.10 – Comparison of NOS3 methylation in offspring umbilical cord 
between maternal treatment groups 200 
Figure 8.1 – Methylation of specific CpG loci within the CDKN2A gene causes a 
decrease in ANRIL expression. 213 
Figure 8.2 – Decrease in ANRIL expression leads to an increase in 
differentiation markers and a decrease in cell number.   215 
Figure 8.3 – A potential mechanism by which CDKN2A methylation can cause 
dysregulation of bone homeostasis leading to an increased risk for 
osteoporosis 216 
Figure 9.1 – Optimisation of hBMSCs for transfection with siRNA against ANRIL 
using Lipofectamine RNAiMAX and 30,000 cell seeding density 227 
Figure 9.2 – Optimisation of primary osteoblasts for transfection with siRNA 
against ANRIL using Lipofectamine RNAiMAX and 30,000 cell seeding density 228 
Figure 9.3 – Optimisation of hBMSCs for transfection with siRNA against ANRIL 
using Lipofectamine RNAiMAX and 50,000 cell seeding density 230 
Figure 9.4 – Optimisation of primary osteoblasts for transfection with siRNA 
against ANRIL using Lipofectamine RNAiMAX and 50,000 cell seeding density 231 
  
X 
 
List of Tables 
 Page Number 
Table 2.1 – Reagents used in experiments 47 
Table 2.2 – Components used for 5% polyacrylamide gels in EMSAs 55 
Table 2.3 – EMSA oligonucleotide sequences 56 
Table 2.4 - Transfection master mix volumes for 24-well plate with 50,000 SaOS-
2 cells seeding density  58 
Table 2.5 - siRNAs used in transfections 58 
Table 2.6 – TaqMan assays used in RT-qPCR 62 
Table 2.7 – Components and conditions used for pyrosequencing PCR 66 
Table 2.8 – Forward and reverse primers for pyrosequencing PCR 67 
Table 2.9 – Sequencing primers for pyrosequencing 68 
Table 3.1 - The 9 CpGs in the differentially methylated region (DMR) of the 
CDKN2A locus 75 
Table 3.2 - List of transcription factor consensus sequences 86 
Table 3.3 – CpG -887 and -907 probe, GAS and Smad3/4 consensus sequences 87 
Table 6.1 – Twenty upregulated and twenty down regulated genes with highest 
fold change 149 
Table 7.1 – Associations between CDKN2A methylation in umbilical cord and 
offspring bone outcomes at birth in SWS cohort 176 
Table 7.2 – Associations between CDKN2A methylation in umbilical cord and 
offspring bone outcomes at birth in MAVIDOS cohort 179 
Table 7.3 – Associations between RXRA methylation in umbilical cord and 
offspring bone outcomes at birth in SWS cohort 181 
Table 7.4 – Associations between RXRA methylation in umbilical cord and 
offspring bone outcomes at birth in MAVIDOS cohort 184 
Table 7.5 – Associations between NOS3 methylation in umbilical cord and 
offspring bone outcomes at birth in SWS cohort 186 
Table 7.6 – Associations between NOS3 methylation in umbilical cord and 
offspring bone outcomes at birth in MAVIDOS cohort 187 
Table 7.7 – Associations between CDKN2A methylation in SWS and MAVIDOS 
umbilical cord tissue and birth weight 188 
Table 7.8 – Associations between RXRA methylation in SWS and MAVIDOS 
umbilical cord tissue and birth weight 189 
Table 7.9 – Associations between NOS3 methylation in SWS and MAVIDOS 
umbilical cord tissue and birth weight 190 
Table 7.10 – Associations between CDKN2A and RXRA CpG methylation in 
umbilical cord and offspring total BMC at birth in the SWS and MAVIDOS cohorts 191 
Table 7.11 – Associations between CDKN2A and RXRA CpG methylation in 
umbilical cord and offspring total BA at birth in the SWS and MAVIDOS cohorts 192 
Table 7.12 – Associations between CDKN2A and RXRA CpG methylation in 
umbilical cord and offspring total BMD at birth in the SWS and MAVIDOS cohort 193 
Table 7.13 – Independent t-test analysis of RXRA methylation in MAVIDOS 
offspring umbilical cord tissue between the two maternal treatment groups 196 
Table 7.14 – Associations between RXRA methylation in MAVIDOS offspring 
umbilical cord and maternal treatment group stratified by offspring season of 
birth 199 
Table 7.15 – Independent t-test analysis of NOS3 methylation in MAVIDOS 
offspring umbilical cord tissue between the two maternal treatment groups 200 
Table 9.1 – Table of all genes that showed differential expression on Illumina 
Human H12 Gene Expression array that passed FDR 223 
XI 
 
Academic Thesis: Declaration of Authorship 
 
I, ……………………………………………………………………………………………. [please print name] 
declare that this thesis and the work presented in it are my own and has been generated by me as 
the result of my own original research. 
[title of thesis] ……………………………………………………………………………………………………………….. 
…………………………………………………………………………………………………………………………………… 
 
 
 
 
I confirm that: 
 
1. This work was done wholly or mainly while in candidature for a research degree at this 
University; 
 
2. Where any part of this thesis has previously been submitted for a degree or any other 
qualification at this University or any other institution, this has been clearly stated; 
 
3. Where I have consulted the published work of others, this is always clearly attributed; 
 
4. Where I have quoted from the work of others, the source is always given. With the exception 
of such quotations, this thesis is entirely my own work; 
 
5. I have acknowledged all main sources of help; 
 
6. Where the thesis is based on work done by myself jointly with others, I have made clear 
exactly what was done by others and what I have contributed myself; 
 
7. Either none of this work has been published before submission, or parts of this work have 
been published as: [please list references below]: 
 
 
 
 
 
Signed: ………………………………………………………………………… 
Date: ………………………………………………………………………… 
XII 
 
Acknowledgements 
 
Firstly, I would like to thank my supervisors Professor Karen Lillycrop and Professor Nick Harvey 
for their guidance and support throughout my PhD.  I am truly grateful for the opportunity that 
you have provided me. 
 
To the BioNerds – Paula, Emma, Rob, Chaz, Len, Becky, Sam and Jordan (whether you’re still here 
or not).  Thanks for all the help you’ve given me over the years, whether it be assessing the 
quality of endless DNA gels or testing out my latest cake creation.  You’ve always been there 
offering good advice and I feel privileged to be able to call you my friends. 
 
To Swim Team: for keeping me sane.  There’s nothing like dancing it out at Jesters with an 
absolutely fabulous bunch of people or completing a rather challenging training set to calm you 
down after a stressful day at work.  Being around such an energetic group of people makes you 
realise that tomorrow’s another day and things are as never as bad as they may seem. 
 
To mum, dad and Liz: for always being there when I need you.  I’ve had some good days and bad 
throughout these four years, but I’ve always known who I could turn to when I felt like it was 
getting too much.  Thanks for putting up with all the science talk (I know it bores you half to 
death) and for always being on hand with words of encouragement. 
 
To Rob: for everything you do. You’ve been with me from the beginning, through the ups and the 
downs, the good times and the bad and we’re still going strong.  Thank you for always being there 
when I’ve needed a sounding board, even though you have no clue about molecular biology, or 
for when I just need to take my mind off things and recharge.  I couldn’t have done it without you.  
XIII 
 
Abbreviations 
Abbreviation Full Term 
%FM Percentage Fat Mass 
1,25VitD3 1 Alpha, 25-Dihydroxyvitamin D3 
5-mC 5-MethylCytosine 
aBMD Areal Bone Mineral Density 
ALP Alkaline Phosphatase 
ALSPAC Avon Longitudinal Study of Parents and 
Children 
ANRIL Antisense Non-Coding RNA in the INK4A Locus 
AP1 Activator Protein 1 
APS Ammonium Persulfate 
ATF4 Activating Transcription Factor 4 
BA Bone Area 
BATMAN Bayesian Tool for Methylation Analysis 
BGLAP Bone Gamma-Carboxyglutamate Protein 
BMC Bone Mineral Content 
BMD Bone Mineral Density 
BMI Body Mass Index 
BMP Bone Morphogenic Protein 
cAMP Cyclic AdNOS3ine Monophosphate 
CDK Cyclin Dependent Kinase 
cDNA Complementary Deoxyribose Nucleic Acid 
CpG Cytosine-Phosphate-Guanine 
CREB cAMP Responsive Element Binding Protein 
CVD Cardiovascular Disease 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMR Differentially Methylated Region 
DNA Deoxyribose Nucleic Acid 
DNMT DNA Methyltransferase 
dNTPs Deoxynucleotide Triphosphates 
DOHaD Developmental Origins of Health and Disease 
DXA Dual-Energy X-ray Absorptiometry 
EGR1 Early Growth Response Protein 1 
EMSA Electrophoretic Mobility Shift Assay 
eNOS Endothelial Nitric Oxide Synthase 
EZH2 Enhancer of Zeste 2 
FACS Fluorescence-Activated Cell Sorting 
FBS Fetal Bovine Serum 
FGF Fibroblast Growth Factor 
Fra1 FOS-Related Antigen 1 
GR Glucocorticoid Receptor 
GWAS Genome-Wide Association Study 
HDAC Histone Deacetylase 
hBMSC Human Bone Marrow Stromal Cell 
HPA Hypothalamic Pituitary-Adrenal 
IGF1 Insulin-like Growth Factor 1 
IGF2 Insulin-like Growth Factor 2 
IHH Indian Hedgehog 
JAG1 Jagged 1 
lncRNA Long Non-Coding RNA 
XIV 
 
LRP Low-Density Lipoprotein Receptor-Related 
Protein 
MAPK Mitogen Activated Protein Kinase 
MAVIDOS Maternal Vitamin D Osteoporosis Study 
MBD Methyl Binding Domain 
MDM2 Murine Double Minute 2 
MEG3 Maternally Expressed Gene 3 
miRNA microRNA 
MSCs Mesenchymal Stem Cells 
OPG Osteoprotegerin 
OSX Osterix 
P-32 Phosphorous 32 
PAH Princess Ann Hospital 
PBMC Peripheral Blood Mononuclear Cell 
PGC1α Peroxisome Proliferator Gamma Coactivator 1 
Alpha 
PGE2 Prostaglandin E2 
PI3K Phosphoinositide 3-Kinase 
PKCδ Protein Kinase C Delta 
PPARα Peroxisome Proliferator Activated Receptor 
Alpha 
PPARγ Peroxisome Proliferator Activated Receptor 
Gamma 
PRC Polycomb Repressive Complexes 
PTCH1 Patched Homologue 1 
PTH Parathyroid Hormone 
RAINE Western Australian Pregnancy Cohort Study 
RANKL Receptor Activator of Nuclear Factor Kappa-B 
Ligand 
Rb Retinoblastoma Protein 
RBPJκ Recombining Binding Protein Suppressor of 
Hairless Kappa 
RISC RNA-induced Silencing Complex 
RNA Ribose Nucleic Acid 
RPL13A 60S Ribosomal Protein L13a 
RT-qPCR Real Time Quantitative Polymerase Chain 
Reaction 
RUNX2 Runt-Related Transcription Factor 2 
RXR Retinoid X Receptor 
RXRA Retinoid X Receptor Alpha 
RXRβ Retinoid X Receptor Beta 
RXRγ Retinoid X Receptor Gamma 
SAM S-AdNOS3ylMethionine 
scBMC Size Corrected Bone Mineral Density 
Ser Serine 
siRNA Small Interfering RNA 
SNP Single Nucleotide Polymorphism 
SWS Southampton Women’s Survey 
T2D Type II Diabetes 
TBP TATA Box Binding Protein 
TEMED Tetramethylethylenediamine 
XV 
 
TGF-β Transforming Growth Factor Beta 
Thr Threonine 
Tyr Tyrosine 
VDR Vitamin D Receptor 
VDRE Vitamin D Responsive Element 
VSMC Vascular Smooth Muscle Cell 

1 
 
 
Chapter 1 
Introduction
2 
 
 
  
3 
 
1. Introduction 
1.1 Osteoporosis 
 Osteoporosis is a skeletal disease that is characterised by low bone mass and 
deterioration in the microarchitecture of bone which leads to an increased risk of fracture due to 
increased bone fragility (1).  Clinically, osteoporosis has been hard to define, although the World 
Health Organisation has now defined osteoporosis in terms of BMD and fracture.  Osteoporosis is 
diagnosed if bone mineral density (BMD) (measured by dual-energy X-ray absorptiometry (DXA)) 
is greater than 2.5 standard deviations below the young adult sex-matched mean, and if the 
patient also has a history of fragility fractures, the term ‘established osteoporosis’ is used (2).   
The three main outcomes of osteoporotic fracture are morbidity, mortality and economic cost 
(3,4), with the most common sites for fracture being the hip, spine and wrist.  As people now live 
longer, the percentage of the population that is made up of older individuals has increased and as 
a result osteoporotic fragility fractures are becoming a major financial burden on the healthcare 
system, with the annual cost of these fractures in the UK being estimated at £1.7 billion (5). 
 
1.1.1 Epidemiology of osteoporosis 
1.1.1.1 Fracture 
 Osteoporotic fractures most commonly occur in areas that have high trabecular bone 
content after a low or moderate trauma and the frequency of which have been shown to increase 
with age in both males and females (6,7).  Johnell et al have shown that lifetime risk of any 
osteoporotic fracture at 50 years of age is 40% in women and 13% in men (8).  Fracture incidence 
has been shown to vary geographically, even within countries, which suggests that environmental 
factors, such as vitamin D and diet, may be important in the pathogenesis of osteoporotic 
fracture.   
 Out of the three most common osteoporotic fractures, hip fractures usually have the 
worst outcomes as they require hospital admittance and cause excessive mortality and significant 
morbidity.  It has been estimated that around 90% of osteoporotic hip fractures occur after a fall 
from standing height (9) and their incidence increases exponentially with age.    In Western 
countries, women over 50 years of age are twice as more likely to suffer from a hip fracture than 
men of the same age and, overall, 98% of hip fractures occur in individuals that are over 35 years 
of ages, 80% of which occur in women (10).  Incidence rate appears to be seasonal, with a higher 
incidence occurring in winter, though this does not seem to be caused by slipping on icy 
pavements as most falls occur inside, suggesting that it could be due to an overall loss of balance 
or loss of neuromuscular function.  As mentioned above, geographical area also seems to have an 
influence on fracture incidence.  In Europe incidence rate varies seven-fold between countries 
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(11) and it seems to be those who live further away from the equator that have the higher 
incidence of hip fracture, with the highest rate being seen in Caucasians living in northern Europe, 
notably Scandinavia (12). 
 The epidemiology of vertebral fractures is less well established as many of these fractures 
do not get diagnosed.  It has been estimated that after 60 years of age, women in the US and 
Europe are 3 times more likely to suffer from a vertebral fracture than men (13).  In a study by 
Cooper et al on 341 residents of Rochester, Minnesota over a 5 year period, they showed that of 
all fractures, 14% occurred after severe trauma, 83% occurred following moderate or no trauma 
and 3% were caused by underlying pathological conditions, with those following moderate 
trauma occurring more frequently in women than men.  There is also evidence of geographical 
location having an influence on vertebral fracture incidence as it has been demonstrated that 
there is greater incidence of fracture in Sweden over other countries in Europe (6). 
 
1.1.1.2 Morbidity 
 All osteoporotic fractures have been shown to be associated with a significant increase in 
morbidity, which is defined as a loss in function.  Different studies have tried to determine the 
true morbidity of osteoporotic fractures by analysing the outcome of these fractures.  Johnell et al 
have demonstrated that the true morbidity caused by osteoporotic hip fracture is 6.07 times 
higher than that caused by hip fracture alone in women aged 50-54 years.  In men of the same 
age, the disability caused is 4.48 times higher when compared to that of hip fracture alone (8). 
Data in the US shows that a person’s pre-morbid status also has an effect on the outcome 
of an osteoporotic fracture.  Of those that were independent pre-fracture, 25% became partially 
dependent post-fracture, 50% of patients that were partially dependent before fracture were 
admitted into nursing homes after being released from hospital and those who were already in 
nursing homes remained there (10).  Sernbo et al found that only 50% of patients who have 
suffered from an osteoporotic hip fracture returned to their pre-fracture level of ability (14).  This 
was assessed by the ability of the patient to walk and the need for aids at home.  Similar findings 
have been presented by Miller where it was shown that out of 360 patients that had sustained a 
hip fracture, only 51% returned to pre-fracture ambulatory function (15).  This study also 
demonstrated that one year after injury 22% of these patients could no longer walk unaided. 
Morbidity due to osteoporotic vertebral fracture can be quite low from one fracture; 
however multiple fractures have been shown to have adverse outcomes on everyday function as 
they can lead to loss of height, severe back pain and kyphosis (16).  This can also exacerbate the 
underlying osteoporosis, which can lead to other fractures.  Those who suffer from wrist fractures 
are not usually completely disabled post-fracture, though 50% of patients have not regained full 
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function 6 months post-fracture.  Morbidity has also been shown to have psychological effects on 
patients due to loss-of-function, such as depression, anger, lowered self-esteem and anxiety (8). 
 
1.1.1.3 Mortality 
 Another outcome of osteoporotic fracture is excess mortality, which has mainly been 
associated with hip and vertebral fractures; however there is also evidence to suggest that there 
is slight increase in mortality in patients that suffered from a wrist fracture.  In a population-based 
study by Cooper et al of 335 patients from Rochester, Minnesota (79 men and 256 women), it was 
demonstrated that survival after hip or vertebral fracture differed significantly from what was 
expected (Figure 1.1) (17).  The patients were observed for 809 person-years and survival was 
shown to decline and diverge from what was expected.  For example, 5 years post vertebral 
fracture diagnosis the expected percentage survival was 76%, whereas the actual percentage 
survival was 61%.  This was comparable to what was seen with patients that suffered from hip 
fractures; however the excess mortality was greatest during the first 6 months post-fracture. 
 
 
Figure 1.1: Survival rates after diagnosis of vertebral, hip and wrist fractures compared to expected rates 
of patients in Rochester, Minnesota.  Reproduced from Cooper et al (17) 
  
Similar results were shown by Johnell et al on a cohort of 2,847 patients in Sweden.  Across a 5 
year follow up period mortality increased in patients with hip fracture from 22% to 59%, though 
the highest percentage mortality was seen in patients who had suffered a vertebral fracture 
where mortality increased from 28% at 1 year post-fracture to 72% 5 years after fracture (18).  
However, in this study there was some increased mortality with wrist fractures across the 5 year 
follow-up period, though at 5 years this had only increased to 26%. 
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1.1.1.4 Economic cost 
 Many studies have looked into the economic burden of osteoporotic fractures on 
healthcare and it has been estimated that in the US osteoporotic fractures cost the US healthcare 
system $20 billion per annum, with hip fractures accounting for a third of this total (10).  A study 
by Burge et al looked at predicting the incidence and cost of fracture in the US from 2005-2025.  
They estimated that in 2005 the number of total fractures in the US was more than 2 million with 
the total cost being close to $19 million.  They then split the cost by sex, age group, race and 
fracture type.  They found that women account for 75% of the costs and that the most costly 
fracture is that of the hip (72%) due to need for hospitalisation after and the fact that many 
patients end up needing assistance at home or are admitted into nursing homes (19).  This study 
also predicted that the cost of fractures will increase by 50% by 2025 due to an increase in the 
aging population. 
Research into prevention measures is ongoing and is now looking into ways of assessing 
patients for risk before a fracture occurs.  Research is also focusing on intervention methods to 
prevent fractures; however some of the drugs that are used are expensive and are not available 
worldwide.  There is now also evidence suggesting osteoporosis could have developmental origins 
depending on bone growth and formation in utero. 
 
1.2 Bone formation 
Bone formation is the process by which bone matrix replaces embryonic connective tissue 
to form the skeleton.  This process begins during the second month in in utero and occurs through 
two mechanisms: intramembranous ossification and endochondral ossification.  
Intramembranous ossification is responsible for the formation of the skull and clavicles and bone 
is formed on or within fibrous connective tissue membranes, which are made up of mesenchyme 
and collagen fibres (20).  Endochondral ossification occurs in all other bones of the skeleton and 
occurs through replacement of cartilage with bone matrix by osteoblasts (21).  In the 
endochondral ossification method, mesenchymal stem cells (MSC) condense and differentiate 
into chondrocytes (22).  The perichondrium is formed around the cartilage model and the 
chondrocytes then proliferate, which causes the cartilage model to grow.  They then become 
hypertrophic and secrete a cartilaginous matrix that attracts blood vessels, before undergoing 
apoptosis (20).  Osteogenic cells are then stimulated to differentiate into osteoblasts, which begin 
to deposit bone matrix and form the bone collar (a shell of compact bone around the cartilage 
model).  This bone collar prevents nutrients from reaching the cartilage and it begins to 
disintegrate.  Osteoblasts migrate to these areas through capillaries and use the cartilaginous 
matrix as a scaffold to deposit bone matrix (23).  This forms the primary ossification centre (24) 
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and after a few days the osteoblasts become osteocytes that promote the deposition of calcium 
salts to form trabeculae.  When these trabeculae fuse together they form trabecular bone, which 
then undergoes remodelling to form the medullary cavity.  This cavity forms at the core of the 
cartilage model and becomes filled with capillaries and red bone marrow.  Ossification then 
proceeds to form the diaphysis (the midsection of the bone), whilst the epiphyses (the ends of the 
bone) remain cartilaginous (20). 
 After birth blood vessels invade the cartilaginous epiphysis and a secondary ossification 
centre is formed (25).  In this case no medullary cavity is formed and, instead, ossification 
progresses outwards leaving the core of the epiphysis as spongy trabecular bone.  The last part of 
endochondral ossification involves the formation of articular cartilage and the formation of the 
epiphyseal plate.  The articular cartilage is a thin layer of cartilage formed from the hyaline 
cartilage that covers the end of the epiphyses to reduce friction in joints.  The epiphyseal plate is a 
layer of hyaline cartilage that remains between the diaphysis and the epiphyses that allows the 
long bones to length during growth in childhood (25). 
 
1.2.1 Osteoblast differentiation 
 Osteoblasts are mononuclear cells that are responsible for the deposition of osteoid, 
which is an uncalcified bone matrix that becomes bone tissue once calcified.  These bone forming 
cells secrete many different proteins that include alkaline phosphatase (ALP), type I collagen, 
proteoglycan, bone sialoprotein and osteopontin.  There is also evidence that demonstrates that 
they have a role in osteoclast differentiation, in that they synthesise receptor activator of nuclear 
factor kappa-B ligand (RANKL), which activates osteoclast differentiation, and osteoprotegerin 
(OPG), which negatively regulates osteoclast function. 
 Osteoblast differentiation is controlled through the interplay of different signalling 
pathways and the activation of different transcription factors at certain times during the 
differentiation process.  This process is shown in Figure 1.2. 
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1.2.1.1 Transcription factors 
 Many different transcription factors are needed for the successful differentiation of 
osteoblasts and the formation of mineralised bone.    
SOX9 is a transcription factor from the sex determining region Y (SRY)-related family of 
proteins that is expressed in chondrocytes and marks all mesenchymal progenitors that develop 
into osteoblasts (27); however its role in osteoblast differentiation is not fully understood.  
Akiyama et al demonstrated that when SOX9 is deleted in the mouse mesenchymal limb bud 
before MSC condensation, cartilage and bone are non-existent and Runx2 expression is 
eliminated (28).  There was also some evidence to suggest that SOX9 is needed to prevent the 
transition of proliferating chondrocytes into hypertrophic chondrocytes, which would inhibit the 
progression of endochondral ossification.  However, it is not clear that the lack of osteoblasts is 
due to the lack of cartilage or whether it has a direct role in the differentiation of osteoblasts. 
Runt-related transcription factor 2 (RUNX2) is a member of the RUNX family of 
transcription factors and contains a Runt DNA binding domain.  It is essential for the 
differentiation of osteoblasts in both intramembranous and endochondral ossification.  Both 
Komori et al and Otto et al have shown that mice that are homozygous for a mutation in the 
Cbfa1 (equivalent of human RUNX2) locus have a complete lack of ossification and die of 
respiratory failure shortly after birth (29,30).  Komori also found that there were some immature 
osteoblasts in the perichondral region that weakly expressed alkaline phosphatase but not 
osteopontin or osteocalcin, which are expressed later on in the differentiation pathway, and that 
there was not any vascular or mesenchymal stem cell invasion of the cartilage model (29).  This 
transcription factor is also needed in the function of mature osteoblasts, which includes the 
synthesis of bone matrix (31).  Other nuclear factors have been shown to interact with RUNX2 to 
promote osteoblast differentiation including MAF, Retinoblastoma protein (Rb), GLI2, DLX5 and 
MSX2. 
Osterix (OSX) is a transcription factor that acts downstream of RUNX2 in the proliferation 
step of differentiation and is induced in response to BMP signalling.  Nakashima et al 
demonstrated that bone formation does not occur in Osx-/- mice; however mesenchymal stem 
cells still condense and differentiate into chondrocytes (32).  This indicates that Osx-/- MSCs in 
mice still possess the ability to differentiate down the chondrocyte lineage.  They also showed 
that these cells did express Runx2 but Runx2-/- mice did not express OSX, which suggests that this 
transcription factor works downstream of RUNX2.  There is also evidence that OSX can be 
negatively regulated by the tumour suppressor transcription factor p53, as p53-/- mouse 
osteoblasts show a significant increase in the expression of Osx (33) 
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β-catenin is expressed via the activation of the Wnt signalling pathway and inactivation of 
this transcription factor in MSCs has been shown to completely block osteoblast differentiation, 
causing the MSCs to differentiate into chondrocytes instead (34,35).  Day et al showed that when 
β-catenin is inactivated in mesenchymal progenitor cells, these cells will still differentiate into 
chondrocytes even when they are subjected to an osteogenic promoting environment (34).  All 
three of these transcription factors work in conjunction with each other to cause the first stages 
of osteoblast differentiation.  RUNX2 has been shown to be expressed in β-catenin-/- MSCs, but 
not OSX, this would suggest that β-catenin is important for progression of osteoprogenitors into 
pre-osteoblasts (35,36).  Further to this, it has also been demonstrated by Gaur et al that β-
catenin can enhance RUNX2 expression (37), which suggests that RUNX2 acts to supress the 
differentiation of MSCs into adipocytes and chondrocytes so that β-catenin and OSX can then 
direct the osteoprogenitors to pre-osteoblasts. 
Other transcription factors are important for the proper function of mature osteoblasts, 
such as FOS-related antigen 1 (Fra1) and activating transcription factor 4 (ATF4).  Fra1 is a 
member of the activator protein 1 (AP1) family of transcription factors.  Its exact interactions with 
the previously described transcription factors are unknown, however when Fra1 was deleted in 
mouse embryos, Eferl et al found that the mice exhibited low bone mass, not unlike osteopenia in 
humans (38).  The bones in these mice also showed reduced levels of bone matrix proteins.  The 
reverse effect is seen in transgenic mice overexpressing Fra1, where there is an increase in bone 
mass which is due to an increase in the number of mature osteoblasts (39). 
More is known about the basic Leu zipper transcription factor ATF4, which has a role in 
mature osteoblasts.  It is believed that ATF4 exerts its function in osteoblasts by two potential 
mechanisms.  The first is that it has direct regulation over the expression of osteocalcin (bone 
matrix protein) and RANKL, which promotes osteoclast differentiation, and the second is that it 
ensures the transport of proteins into cells for the production of proteins by osteoblasts (40). 
 
1.2.1.2 Signalling pathways 
 There are five main signalling pathways that contribute to the differentiation of 
osteoblasts: Hedgehog signalling, Notch signalling, WNT signalling, BMP signalling and FGF 
signalling.  These pathways lead to the expression of transcription factors at particular points 
through the course of differentiation. The BMP, Wnt and Hedgehog signalling pathways all work 
to cause mesenchymal stem cells to differentiate into osteoprogenitor cells, which is the first step 
of the differentiation pathway. 
Bone morphogenic proteins (BMPs) are members of the transforming growth factor-β 
(TGF-β) superfamily of proteins that act by binding to heterotetramer membrane receptors made 
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up of type I and type II Ser/Thr kinase receptors.  This causes the activation of SMAD1, 5 or 8 
through site-specific phosphorylation and these phosphorylated SMADs then translocate to the 
nucleus, after forming a complex with SMAD4 (common to all SMADs), to regulate gene 
expression (Figure 1.3).  Knockout of BMP2 and BMP4 expression in mice have shown that a 
threshold level of these two BMPs is needed in order to cause progression of differentiation from 
chondrocytes to osteoprogenitor cells, though the exact mechanism was not elucidated (41).  This 
group also suggests that both BMP2 and BMP4 are needed to form mesenchymal condensations 
and that a loss of both these proteins causes osteogenesis to be severely impaired.  It has also 
been demonstrated by the same group that although bone development during embryogenesis 
can occur when BMP2 expression is knocked out, these mice demonstrated limb fractures at birth 
due to a lower bone mineral density when compared to wild type mice, which were not able to 
heal (42).  This suggests that BMP2 could be important in postnatal bone formation. 
 
 
 
Figure 1.3: Bone morphogenic protein (BMP) signalling in osteoblast differentiation.  BMP2 and 4 bind 
to bone morphogenic protein receptor (BMPR) I or II ( type I and type II Ser/Thr kinase receptors) to 
cause the activation of SMAD1, 5 and 8 through phosphorylation.  These bind to co-activator SMAD4 and 
translocate to the nucleus where they activate the transcription of genes to cause RUNX2+ to 
RUNX2
+
OSX
+
 cell transition 
 
There is also evidence to show that BMP signalling has a role in the functioning of mature 
osteoblasts as well as differentiation.  Devlin et al showed that when noggin, an inhibitor of BMP 
signalling, is overexpressed in mice there is an 23-29% decrease in bone mineral density, a 
decrease in the number of trabeculae and a decrease in bone formation rate; however number of 
osteoblasts was not significantly different from wild type mice (43).  This implicates BMP signalling 
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as having a role in the correct functioning of osteoblasts.  Tan et al also demonstrated that when 
Smad4 expression is disrupted in mature murine osteoblasts the proliferation and function of 
these cells were significantly decreased, with mice showing a decrease in bone mineral density, 
bone formation rate and numbers of osteoblasts (44). 
Wnt signalling works through both β-catenin dependent and independent pathways to 
promote osteoblast differentiation from RUNX2+ cells to RUNX2+OSX+ cells (Figure 1.4).  The β-
catenin dependent pathway is activated when WNT binds to Frizzled receptors and their co-
receptors low-density lipoprotein receptor-related protein (LRP) 5 and 6.  This leads to the 
stabilisation and translocation of cytosolic β-catenin to the nucleus where it interacts with various 
enhancers to regulate the expression of Wnt signalling target genes (45).  It has been shown in 
both humans and mice that loss-of-function mutations or deletion of LRP5 can have adverse 
effects on bone development.  In humans, a loss-of-function mutations in the LRP5 gene can lead 
to the onset of a form of juvenile osteoporosis called osteoporosis-pseudoglioma syndrome (46) 
and in mice, Lrp5 deletion leads to a postnatal reduced bone mass phenotype, which was 
demonstrated to be because of a decrease in osteoblast proliferation (47).  It has also been shown 
that β-catenin is required further down the differentiation pathway during the transition from 
pre-osteoblast to mature osteoblast, but convert to the chondrogenic lineage instead (48) and 
that deletion of this downstream signalling molecule in mesenchymal progenitors eliminates the 
generation of mature osteoblasts in mice (34).  β-catenin independent signalling has been 
implicated in promoting osteoblast differentiation by stimulating the progression of cells from the 
prechondrial cell stage to the osteoprogenitor stage (49).  This occurs when Wnt binds to a G-
coupled receptor and leads to the activation of protein kinase C δ (PKCδ), which leads to the 
regulation of target genes.  This group demonstrated that mice with homozygous mutant of PKCδ 
had decreased embryonic bone formation when compared to wild type mice.  It also promotes 
osteoblast differentiation as it prevents the expression of peroxisome proliferator activated 
receptor-γ (PPARγ), which is necessary for adipocyte differentiation (50). 
Indian hedgehog (IHH) signalling is stimulated by binding to Patched homologue 1 
(PTCH1) receptor, which then causes a signal transduction through the 7 transmembrane protein 
Smoothened (Figure 1.5). This causes the activation of GLI2 and repression of GLI3 transcription 
factors to regulate gene expression that leads to the generation of osteoprogenitor cells (45).   
GLI3 acts to inhibit this transition, whereas GLI2 acts to promote it (51,52).  St-Jacques et al have 
shown that, in IHH-null mice, there is a lack of osteoblast differentiation in endochondral bones as 
chondrocytes are unable to signal to cells to promote osteoblast differentiation (53) and  Long et 
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al have demonstrated that IHH signalling is essential for RUNX2 expression in mice as knockout of 
Smoothened leads to Cbfa1 expression becoming completely abolished (54). 
 
 
 
Figure 1.4: Wnt signalling in osteoblast differentiation.  Wnt binds to Frizzled receptors and their co-
receptors LRP5 and 6, which leads to the activation of either β-catenin dependent or independent 
pathways.  In the dependent pathway, β-catenin is stabilised and translocates to the nucleus where it 
interacts with enhancers to regulate gene expression.  In the independent pathway, PKCδ is activated and 
regulated Ant-activated genes.  Both of these pathways are induce the transition of RUNX2
+
 cells to 
RUNX2
+
OSX
+
 cells. Β-catenin dependent pathways also regulate the RUNX2
+
OSX
+
 to osteoblast cell 
transition. 
 
 
 
Figure 1.5: Indian Hedgehog signalling in osteoblast differentiation.  Indian hedgehog (IHH) binds to its 
receptor Patched homologue 1 (PTCH1), which causes signal transduction through Smoothened (SMO), a 
seven transmembrane protein.  This leads to the activation of transcription factor GLI2 and repression of 
transcription factor GLI3 to promote the generation of RUNX2
+
OSX
+
 cells. 
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Notch signalling functions at the same transition point as the previous signalling 
pathways; however it acts to suppress differentiation into osteoprogenitor cells rather than 
promote it (Figure 1.6).  There are 4 Notch receptors in mammals to which a range of different 
ligands can bind.  The main Notch receptor used to suppress osteoblast differentiation is Notch 1.  
After binding of a Jagged 1 (JAG1) to this receptor, its intracellular domain is cleaved and this 
interacts with recombining binding protein suppressor of hairless κ (RBPJκ) to translocate to the 
nucleus.  Here it activates the expression of the HEY and HES families of transcription factors, 
which act to inhibit RUNX2 activity by directly binding to this transcription factor (55,56).  Mouse 
studies have demonstrated that Notch signalling acts to suppress osteoblast differentiation.  A 
study by Hilton et al where Notch1 was disrupted showed that adolescent mice had significantly 
increased trabecular bone mass compared to wild type mice, and these mice went on to develop 
osteopenia in later life.  This increase in bone mass coincided with a decrease in the number of 
mesenchymal progenitors, suggesting that Notch signalling acts to suppress osteoblast lineage 
commitment and differentiation (56).  Long et al have also elucidated that Notch suppression 
occurs before the induction of OSX activation as when Notch signalling is suppressed in 
osteoprogenitor cells there is no increase in trabecular bone mass (45). 
Fibroblast growth factor (FGF) signalling is the final main signalling pathway that 
stimulates differentiation from pre-osteoblasts into mature osteoblasts (Figure 1.7).  There are 
two main FGF receptors that are involved in bone formation, FGFR1 and FGFR2, which belong to 
the Tyr kinase family of receptors.  When FGF proteins bind to these receptors, it causes the 
phosphorylation of signalling proteins that leads to the activation of signalling modules, which 
includes STAT1, PKC, mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K) (45).  It has been shown that FGF signalling has a role in both embryonic and postnatal 
stages of bone formation (57).  In this study they found that Fgf2-/- mice had decreased trabecular 
bone volume, bone formation rate and mineralisation when compared to the wild type.  FGFR1 
signalling during the embryonic stages of bone formation stimulates osteoblast differentiation 
without affecting RUNX2 expression, whereas in mature osteoblasts, FGFR1 signalling acts to 
inhibit mineralisation activity (58).  FGFR2 signalling on the other hand promotes both pre-
osteoblast proliferation and mature osteoblast function, as shown by Yu et al (59).  In this study, 
Fgfr2 inactivated mice showed a decrease in bone density, though the differentiation of 
mesenchymal stem cells into osteoblast was not affected.  Instead, the proliferation of pre-
osteoblasts and the ability to produce bone mineral matrix were severely decreased.  This could 
have an adverse effect on bone formation, which could lead to a decreased peak bone mass and 
increased fracture risk in later life. 
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Figure 1.6: Notch signalling in osteoblast differentiation.  When Jagged 1 (JAG1) binds to its receptor 
Notch 1, γ-secretase cleaves its intracellular domain (NICD), which interacts with recombining binding 
protein suppressor of hairless κ (RBPJκ).  This complex then translocates to the nucleus where it leads to 
the activation of HEY and HES transcription factors, which act to suppress the osteoblast differentiation 
by directly interacting with RUNX2 to inhibit its activity. 
 
 
 
Figure 1.7: Fibroblast growth factor (FGF) signalling in osteoblast differentiation.  The binding of FGF to 
the FGF receptor leads to the activation of various signalling pathways, which all have roles in regulating 
preosteoblast proliferation, osteoblast differentiation and osteoblast function. 
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1.2.1.3 Systemic regulation 
 As well as specific transcription factors and signalling pathways, bone formation is also 
regulated systemically.  There are four main systemic regulators that contribute to osteoblast 
differentiation and function: parathyroid hormone (PTH), insulin-like growth factor 1 (IGF1), 
prostaglandin E2 (PGE2) and 1α,25-dihydroxyvitamin D3. 
 PTH is crucial for the homeostasis of calcium in the body and has roles in regulating both 
bone formation and bone resorption.  It has been shown that intermittent PTH exposure 
stimulates the anabolic function of PTH, whereas continuous exposure causes an increase in the 
catabolic role (60).  PTH activates its signalling cascade by binding to the PTH receptor (a G-
protein coupled receptor), which leads to the activation of cyclic adenosine monophosphate 
(cAMP) and cAMP responsive element binding protein (CREB).  It has been shown by Isogai et al 
that PTH stimulates the progression of osteoprogenitor cells to pre-osteoblasts, whereas in 
mature osteoblasts it has an inhibitory effect on osteoblast function (61).  This stimulation of 
differentiation progression has also been seen by Yang et al, where it was elucidated that this 
progression occurs due to the activation of PKCδ by PTH (62).  At the pre-osteoblast stage, the 
main role of PTH is to increase pre-osteoblast proliferation rate through c-fos expression (63) and 
suppress apoptosis (64) in order to increase the number of bone matrix secreting cells.  Mouse 
studies have demonstrated that PTH function needs both IGF1 and FGF2 to carry out its role 
(65,66), as when these genes were knocked out in mice PTH signalling was suppressed.  
 IGF1 is the most abundant growth factor in the bone matrix and it has been shown to 
have an indispensable role to play in the differentiation of pre-osteoblasts into mature 
osteoblasts as demonstrated by Xian et al.  In this study, mice with knockout of Igf1 showed 
impaired osteoblast differentiation which resulted in lower bone mass and decreased mineral 
deposition when compared to wild type mice (67). When Igf1 receptor has been knocked out in 
mice osteoblasts, it has been shown that there is a significant decrease in osteocalcin expression, 
demonstrating the importance of IGF1 for correct bone matrix mineralisation (68). 
 Like PTH, PGE2 has been suggested to have roles in both bone resorption and formation 
(69).  It has been demonstrated that PGE2 has a role in the growth and differentiation in rat 
osteoblast-like cells by Yoshida et al.  When the PGE2 receptor is inhibited in these cells there is a 
significant decrease in the proliferation rate of the cells and a decrease in the number of mature 
osteoblasts (70), which both contribute to less bone formation as less bone forming cells are 
present.  PGE2 has also been shown to increase alkaline phosphatase expression and osteocalcin 
synthesis in these cells, which are both expressed by mature osteoblasts during the final stages of 
differentiation and bone matrix maturation (71). 
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 1α,25-dihydroxyvitamin D3 is the active form of vitamin D3 and is essential for the 
absorption and deposition of calcium in the bone mineral matrix (72).  Vitamin D3 is converted to 
its active form through the activity of 1α-hydroxylase, which is stimulated by the binding of PTH to 
the promoter of the gene that transcribes this enzyme (73,74).  Once in its active form, 1α,25-
dihydroxyvitamin D3 binds to a heterodimer that is made up of the vitamin D receptor (VDR) and 
the retinoid X receptor (RXR) (26,75).  This complex then translocates to the nucleus to bind to 
vitamin D responsive elements (VDREs) found in the promoters of various genes.  One of these 
genes encodes a calcium binding protein, which allows for the increase of active transport of Ca2+ 
into cells allowing for bone calcification.  The VDR has also been shown to stimulate the 
expression of osteocalcin (76,77) and osteopontin (78), which contribute to bone mineralisation.  
VDR overexpression studies in mature murine osteoblasts have shown an increase in bone 
formation and decrease in bone resorption (79), which could potentially be due to these 
osteoblasts having less of an ability to enhance osteoclast activity (80).  In relation to earlier 
stages of differentiation, treatment of rats with high doses of 1α,25-dihydroxyvitamin D3 has been 
shown to increase the proliferation rate of osteoprogenitors in bone marrow (81), which shows 
that vitamin D is important for the proper functioning of osteoblasts and proper bone formation. 
If the expression of any of these systemic factors is altered, it could lead to an imbalance 
in bone formation and the development of a suboptimal peak bone mass.  This could have a 
detrimental downstream effect on bone health in later life. 
 
1.2.2 Osteoclasts 
 Unlike osteoblasts, osteoclasts are multinuclear cells that are derived from macrophages 
and are the cells that break down extracellular bone matrix in the process of bone resorption (26).  
The differentiation process for these cells is stimulated through the binding of macrophage colony 
stimulating factor (MCSF) to its receptor c-fms.  This then causes an increase in the expression of 
RANK, which is the receptor for the osteoblast produced RANKL (82).  Signalling through these 
two receptors are the key drivers for osteoclast differentiation.  This leads to the expression of 
transcription factors such as nuclear factor κB (NF-κB) and AP1, which in turn bind to promoters 
and lead to the expression of osteoclast specific genes, such as cathespin K and matrix 
metalloproteinase 9 (MMP-9).  These osteoclast specific genes are essential for the final 
differentiation of osteoclasts as well as the fusion of their precursors to form multinucleated cells 
and their function (26). 
 In mature osteoclasts, continued signalling from c-fms and RANK receptors are also 
needed for osteoclast survival.  RANK signalling is also closely regulated by osteoblasts as they 
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produce OPG, which acts as a decoy to the RANK receptor, thus preventing osteoclast 
differentiation and survival.  One of the hallmarks of osteoporosis is increased bone resorption 
through increased osteoclast activity.  It has been shown that oestrogen deficiency can cause an 
increase in RANKL through the upregulation of IL-7 and the activation of T cells.  This in turn leads 
to the production of cytokines and reactive oxygen species, which results in an increase in RANKL 
and therefore osteoclast differentiation (83) 
 
1.2.3 Bone remodelling 
 Bone remodelling is the process through which mature bone tissue is resorbed from the 
skeleton and new bone tissue is formed through ossification (26) and occurs continuously 
throughout life.  These processes control the replacement of bone after the injuries such as 
fractures and also microdamage caused by everyday life and is moderated by the creation of the 
bone multicellular unit.  Bone lining cells form part of this unit and are quiescent cells formed 
from osteoblasts.  Although their exact functions are not completely understood, it has been 
suggested that one of their functions is to transmit the activation signal that initiates bone 
remodelling (84).  It has also been shown that bone lining cells can prevent direct interaction 
between osteoclasts and bone matrix when bone resorption should not be occurring (85).    The 
first process that occurs in bone remodelling is the resorption of mature bone matrix by 
osteoclasts.  When osteoclasts are activated to resorb bone matrix, they first become polarised 
and attach to the mineralised bone matrix, forming three distinct membrane domains: the sealing 
zone, the ruffled border and the functional secretory domain (86).  The ruffled border is essential 
in bone matrix resorption as it delivers the proteins that are involved in the resorption process, 
which acidify the area under the ruffled border and cause the break down of the bone mineral 
matrix beneath.  The resulting collagen fragments are then endocytosed by the osteoclast and 
transported through the cell to the functional secretory domain, where they are released into the 
bloodstream (87).  Once resorption has taken place, osteoblasts migrate to the site and secrete 
osteoid, which is the unmineralised bone matrix consisting of type I collagen and other proteins 
such as osteocalcin, osteopontin and bone sialoprotein.  Mineralisation then occurs through the 
localised release of phosphate from osteoblast derived vesicles containing phosphatases that are 
found within the osteoid.  This reacts with the calcium within the extracellular fluid to form 
hydroxyapatite.   
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1.2.4 Genome-wide association studies (GWASs) 
Bone mineral density has been shown to be influenced by hereditability (88,89) and is the 
most widely used predictor of fracture risk.  GWASs have identified 62 loci that are associated 
with BMD of either the lumbar spine or the femoral neck (90). Richards et al identified two single 
nucleotide polymorphisms (SNPs) that were negatively associated with BMD and increased 
osteoporotic fracture risk using samples from the TwinsUK cohort.  These results were then 
replicated in three independent cohorts (91).  Another study by Rivadeneira et al identified 
twenty loci associated with bone mineral density through meta-analysis of GWASs.  Thirteen of 
the identified loci were novel regions that included, for example, cytosine-phosphate-guanines 
(CpGs) associated with LRP4, SOX6, HDAC5 and FOXL1.  The meta-analysis confirmed that seven 
previously known BMD loci (including ESR1, LRP5 and SP7) still had significant associations at a 
genome-wide level (92).  By 2012 there had been 14 genome-wide analyses looking at the 
associations between SNPs and BMD, with the aim of trying to identify predictive markers of BMD 
and osteoporotic fracture risk, however most of the individuals who develop osteoporotic 
fractures have not been diagnosed with BMD-defined osteoporosis (90) and GWAS studies have 
only identified genes that account for 5% of the variance seen in BMD. 
Osteoporotic fractures also have heritable features, some of which are independent of 
BMD (93).  To date, the largest genome-wide meta-analysis looking at loci associated with 
fracture risk has been carried out by Estrada et al, with which they identified 56 loci associated 
with BMD by looking at associations in >80,000 subjects, 32 of which were novel associations.  
They then tested these loci for association with fracture in >130,000 cases and control, identifying 
14 loci that reached genome-wide significance (94).  Other groups have also shown significant 
association with fracture risk at a genome-wide level (92,95–97).  Some of these associations 
were replicated in the meta-analysis by Estrada et al, whereas others were not. 
1.2.5 Pathogenesis of osteoporosis 
 Osteoporosis is characterised by low bone mass and deterioration of bone 
microarchitecture.  This leads to increased bone fragility, which increases the risk of bone 
fracture.  Normal bone metabolism involves a balance between bone resorption and bone 
formation and it is when this system becomes unbalanced that bone deterioration occurs (98).  
Many factors are believed to contribute to the unbalancing of this system and development of 
osteoporosis (Figure 1.3). 
Osteoporosis occurs most commonly in the older population, with aging being one of the 
factors that contributes to the pathogenesis of the disease.  Studies have shown that the amount 
of bone produced with each remodelling cycle decreases with age in both men and women, 
20 
 
exhibited by the decrease in trabecular bone that occurs (99,100).  Evidence from both mouse 
and human studies have shown that there is less osteoblastogenesis in older subjects, suggesting 
a possible mechanistic explanation for the decrease in bone formation (101,102).  Both of these 
would lead to increased bone loss and a poorer bone quality. 
 Garnero et al have demonstrated that postmenopausal women have an increased rate of 
bone turnover that remains elevated for at least up to 40 years after menopause (103).  They 
found that during menopause there was a 79-97% increase in bone resorption with only a 37-52% 
increase in bone formation being observed and where bone formation rate decreased again after 
menopause, bone resorption remained elevated.  This leads to continuous bone loss which is a 
major determinant of osteoporosis.  Loss of oestrogen during menopause has also been linked to 
the pathogenesis of osteoporosis as fracture risk increases as oestrogen levels decrease in 
postmenopausal women (104,105).  It has been proposed that oestrogen may have three 
different sites of action in regulating bone turnover: (1) altering osteoblast production of RANKL 
and OPG, which upregulate osteoclast activity, (2) directly inhibiting osteoclast activity and (3) 
increasing osteoblast-mediated bone formation, which suggests that the action of oestrogen is 
both anti-catabolic and anabolic (106).  Studies have also demonstrated that the treatment of 
postmenopausal women with oestrogen decreases the rate of bone resorption (107,108). 
 
 
 
Figure 1.8: Pathogenesis of osteoporosis.  Diagram adapted from Lane (109). 
  
Other factors that contribute to increased bone loss are vitamin D and calcium deficiency, 
which in turn can lead to the development of secondary hyperparathyroidism as 1,25VitD3 exerts 
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an inhibitory effect on the synthesis of PTH.  Studies have demonstrated that, as well as 
contributing to increased bone loss in women, vitamin D deficiency and hyperparathyroidism is 
also associated with an increase in the rate of falls among the elderly (110,111).  Sambrook et al 
also demonstrated associations between PTH levels in the elderly and time of first fall are 
independent of circulating 25-hydoxyvitamin D levels and that those patients with increased PTH 
levels are likely to have a fall sooner than those with lower circulating levels of PTH.  Muscle 
biopsies from patients suffering with primary hyperparathyroidism have demonstrated atrophy of 
type II muscle fibres (112), which could suggest that increased levels of PTH are having a 
detrimental effect on the muscles of these patients, leading to decreased stability and increased 
likeliness to fall.  Clinical trials where the elderly were supplemented with vitamin D and calcium 
have shown decreased serum PTH levels, decreased bone loss and increased bone mineral density 
in the supplemented group versus the control group (113), suggesting that supplementing the 
diets of at risk individuals with these factors could be advantageous in treating osteoporosis. 
 As well as increased bone loss, low peak bone mass also contributes to the pathogenesis 
of osteoporosis and is major determinant of bone density in later life: if an individual has less 
bone to begin with, then age-related bone loss is going to affect those with a lower peak bone 
mass more severely than those with a higher one.  A person acquires most of their bone mass is 
attained by adolescence, even though the process starts in utero (109).  A study by Hansen et al 
demonstrated that over a 12 year period of 154 women, those who had a lower peak bone mass 
had a greater reduction in bone mass and density than those that had a higher peak bone mass.  
They also showed that using baseline measurements and an estimation of bone loss rate, they can 
identify those women that are at greater risk of developing osteoporosis post-menopause (114). 
 All of the above contribute to the development of low bone density which, along with 
poor bone quality due to changes in microarchitecture brought about by unbalance of bone 
homeostasis and increased likeliness of a fall, participates in the pathogenesis of osteoporosis by 
leading to the occurrence of fractures. 
 
1.3 Developmental origins of health and disease (DOHaD) 
During the 19th century health professionals in Hertfordshire began to keep records 
relating to weight, childhood illnesses, development and feeding method of children from birth 
up until 1 years of age and these records have since been used by the Medical Research Council 
for epidemiological studies.    Barker used this information to investigate the link between 
ischaemic heart disease in England and Wales and infant mortality.  Ischaemic heart disease had 
been associated with increasing levels of prosperity in the UK, but the mortality rates were 
highest in the least prosperous areas.  When the country was split into 212 regions, Barker et al 
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showed there was a strong correlation between ischaemic heart disease and both neonatal and 
postnatal mortality rates according to geographical location (115,116).  He used these findings to 
postulate that a poor diet during childhood increased susceptibility of an individual to developing 
cardiovascular disease in later life due to the effects of an affluent diet.     
 
1.3.1 Human studies 
 The research presented by Barker resulted in many other studies being undertaken to 
investigate the relationship between early life environment and its role in susceptibility to disease 
in later life (117–119).  Good record keeping on mothers and infants at the beginning of the 20th 
century allowed for investigation into the relationships between maternal pelvic size, fetal growth 
and death from stroke and coronary heart disease in a sample of 13,249 men across Hertfordshire 
and Sheffield born between 1907 and 1930 (120).  Mortality due to stroke was found to be 
associated with low birth weight and death from cardiovascular disease was shown to be 
associated with small head circumference, thinness and shortness of breath.  In adults born in 
Preston during 1935-43, strong relationships were shown between placental weight, birth weight 
and both diastolic and systolic blood pressure during adulthood (121).  An increase in birth weight 
was shown to be associated with an increase in blood pressure, though the relationships between 
placental weight and blood pressure and birth weight and blood pressure were independent of 
each other.  This meant that those with the highest blood pressure at age 45-54 were individuals 
that had had a lower birth weight and greater placental weight for both men and women.  These 
results showed for the first time that intrauterine growth has an important influence on blood 
pressure and hypertension in adults.  The limiting factors in these studies is the number of 
confounding variables that are available to include in analysis, meaning that direct comparisons 
cannot be made.  There is also a wide variety of differences in the environments across the 
studies, therefore the results cannot be generalised to the whole population.  However, as these 
are observational studies, and due to ethical reasons, relationships between infant phenotypes 
and later disease cannot be explored when there are severe environmental circumstances. 
 During the winter of 1944-45, the Netherlands suffered a severe reduction in food 
supplies due to German actions in the Second World War.  During this time calorific intake, which 
had been adequate before the war, fell below 1000kcal/day, which reduced even further to less 
than 500kcal/day by April 1945.  Food supplies where then returned to normal immediately 
following liberation in May of that year.  During this time it was ensured that children’s daily 
intake did not fall below 1000kcal/day (122).  Studies have gone on to characterise the effects of 
famine on birth weight and later disease risk, with focus on the effects of famine during different 
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stages of pregnancy (early, mid or late-gestation).  It was shown that mean birth weight dropped 
by 300g for babies born to mothers that were exposed to famine during late-gestation and that in 
296 individuals there was an increase in coronary heart disease in those that were exposed to 
famine during early gestation when compared to a non-exposed control group.  Babies born to 
this group were also shown to have smaller head circumferences and lower birth weights when 
compared to the non-exposure group (123).  Another study has shown that men and women 
exposed to famine during early gestation to have an increased BMI and low density lipoprotein-
high density lipoprotein ratio at 50 years of age, which lead to an increased risk of coronary heart 
disease in these individuals (124).  The findings from the Dutch Hunger Winter Famine emphasises 
the importance of timing of exposure to altered nutrition and that this can have an adverse effect 
on the offspring in later life, leading to increased risk for certain diseases. 
Non-communicable disease such as osteoporosis, cardiovascular disease and type 2 
diabetes, have also been linked to a poor early life environment.  Investigation into the 
relationship between growth in infancy and bone mass in later life using 189 women and 224 men 
between 63-73 years of age from the Hertfordshire cohort showed significant associations 
between weight at 1 year and bone mineral content (125).  Those individuals that weighed less at 
1 year were also the ones who had a lower bone mineral content in later life, suggesting that 
skeletal growth may be programmed in utero.  Using 297 women from the Hertfordshire cohort, 
relationships were revealed between birth weight and fasting plasma glucose concentrations, 
waist:hip ratio, systolic blood pressure and triglyceride concentrations in that increased birth 
weight led to a decrease in the above risk factors for cardiovascular disease in adulthood (126).  
This suggests that those babies that are small at birth are at greater risk of developing 
cardiovascular disease in later life, and those that become obese in adulthood are at greatest risk. 
Cohort studies have been invaluable in demonstrating the developmental origins of adult 
disease.  The Southampton Women’s Survey was established to measure the pre-pregnant 
characteristics of women aged 20-34 living in Southampton and to follow-up those that became 
pregnant (117).  This study focused on fetal development and post-natal growth and how they 
contributed to the child’s risk of developing chronic disease in later life.  Data has shown that 
babies who are smaller at birth have poorer lung function (127) and that poor maternal calcium 
and vitamin D status during pregnancy has been linked with impaired bone mineral accrual in the 
infant (128).  The Western Australian Pregnancy Cohort (RAINE) Study was set up in 1989 and 
recruited 2900 pregnant women with the aim to investigate the hypothesis that pregnancy 
complications may be prevented with frequent ultrasound scans, as well as to set up a long-term 
cohort to study the effects of early life environment on later health (129).  Data from this study 
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has revealed that maternal smoking during pregnancy and rapid childhood weight gain are 
associated with increased metabolic risk (130) and that infants with a smaller head circumference 
were at greater risk of neurodevelopment disorder (131). 
 Although human observational studies allow for identification of relationships between in 
utero, early life environment and the onset of disease in later life, they do not allow for the 
investigation of direct mechanisms that lead to the induction of certain phenotypes.  There are 
too many uncontrollable variables, such as socio-economic status and maternal and paternal 
background, therefore animal studies in a controlled environment where variables can be 
removed were used to determine alterations to specific pathways that could increase risk of 
disease in later life. 
 
1.3.2 Animal studies 
 Animal studies allow for the effect of altered nutrition on offspring phenotype to be 
investigated in a controlled setting and allows for the investigation of the mechanisms that may 
lead to an altered phenotype.  A low protein model has been used extensively in animal studies to 
demonstrate how restricted protein intake during pregnancy can have an adverse effect on 
offspring phenotype.  A study by Langley-Evans in 1994 showed that pups that were exposed to 
maternal low protein diet in utero were hypertensive at 4 weeks when compared to control pups 
(132).  This was shown to be due to the exposure during gestation as pups that were fed a low 
protein diet for 14 days did not exhibit the same increase in blood pressure, thus highlighting the 
importance of maternal diet in the development of offspring phenotype.  Langley-Evans et al also 
went on to show that maternal low protein diet altered the expression of maternally-derived 
glucocorticoids, which led to a loss in homeostatic control in the pups, and this in turn led to 
altered physiology and endocrine function (133).  Other studies using a restricted maternal 
protein diet have shown reduced cellular proliferation in embryos, smaller birth size of pups and 
rapid decline in glucose tolerance, which have led to altered metabolism in the offspring (134). 
 Intrauterine growth restriction (IUGR) has also been used to investigate the 
developmental origins of disease by causing restricted fetal growth.  This can be done via one of 
two methods, either by restricting maternal nutrition or by bilateral ligation of the uterine artery.  
Experiments have found that IUGR can cause obesity, type II diabetes and metabolic syndrome in 
the offspring.  Ozanne et al have demonstrated that IUGR causes a change in liver morphology, 
and therefore metabolism, as well as changes to glucose metabolism and insulin response in 
skeletal muscle and adipose tissue (135).  This demonstrates the influence that restricted fetal 
growth can have on the health the offspring from dams fed a nutrient restricted diet. 
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 In a study by Guberman et al, pups born to mothers that had been on a high fat diet (60% 
of calories from fat) throughout pregnancy had increased adiposity and hypertension when 
compared to control offspring (136).  This has also been demonstrated by Elahi et al where long-
term maternal high fat diet also led to hypertension in the offspring as well as fatty liver (137).  
However, in this study mothers had been on a high fat diet from weaning, not just during 
pregnancy.  Other studies have shown that a maternal high fat diet induces type II diabetes in 
offspring as well as increased birth weight and anxiety behaviours (138). 
 These various studies have demonstrated that both maternal undernutrition as well as 
over nutrition can both result in similar disease phenotypes; however, this is likely to be caused 
through different mechanisms.  The data from these studies shows that the environment the 
offspring is exposed to in utero via maternal diet has adverse effects on the health outcomes of 
the offspring and highlights the importance of elucidating the mechanisms involved to help us 
better understand the developmental origins of disease. 
     
1.3.3 Evidence for the developmental origins of osteoporosis 
 Fracture prevention has mainly been targeted at decreasing the rate of bone loss in the 
elderly through drug treatment, however it is now becoming evident that peak bone mass in 
adolescence is a major and important contributor to bone strength in later life.  Even though 
there is evidence to suggest that peak bone mass is inherited, this only accounts for a small 
fraction of the variation that is seen in bone mass and fracture risk across individuals (93).  
Environmental factors such as gender, diet, physical activity and smoking, have been shown to 
affect the accumulation of bone mineral throughout childhood and adolescence, however as 
there is a rapid accrual of bone mineral at the later stages of pregnancy, paired with skeletal 
development having a high level of plasticity in utero, there is the possibility that environmental 
stimuli could have an effect on the genome at this stage of life. 
Evidence for the developmental origins of osteoporosis comes from four main types of 
studies: 1) population studies, 2) physiological studies, 3) studies that characterised maternal 
nutrition and lifestyle and related these to bone mineral of their offspring and 4) studies that 
relate childhood growth to risk of hip fracture in later life (139). 
 
1.3.3.1 Population studies 
 Using a cohort of 153 women who were born in Bath between 1968-1971, Cooper et al 
demonstrated that there was a significant association between weight at 1 year and bone mineral 
content (BMC), which was not replicated between weight at 1 year and BMD (140).  This would 
suggest that there is some unbalance in the pathways that regulate skeletal growth and 
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mineralisation.  These results were replicated by Dennison et al and Cooper et al in the 
Hertfordshire cohort, though the associations with BMC were weaker (118,125).  These studies 
also demonstrated an association between weight at 1 year and bone area of the adult hip and 
spine.  Another study by Dennison et al found a significant association between VDR genotype 
and birth weight as factors that influence BMD (141).  Using 291 subjects from the Hertfordshire 
cohort (165 men, 126 women), they found that lumbar spinal BMD was higher in those that had 
the BB VDR genotype and were lighter at birth (p=0.01).  These observations are not significantly 
altered by changes in adult weight, which suggest that modifications occur in utero rather than in 
post-natal life to cause changes in BMD and BMC. 
 Twin studies have also been undertaken to determine if genetic factors determine bone 
mineral content, density and mass.  However, these studies have shown that only approximately 
20% of variance seen in BMC can be explained through genetics.  A study by Smith et al 
undertaken on 71 juvenile and 80 adult twin pairs showed that the variance in bone mass 
between juvenile monozygotic twins was 0.0013 g/cm2 compared to 0.0069 g/cm2 in adult 
monozygotic twins (88).  This suggests that although genetic factors have a role in determining 
bone mass, environmental factors may also have a role as there is greater variance in bone mass 
between the adult twin pairs.  Another study by Pocock et al has demonstrated that there is a 
higher level of correlation between BMD in monozygotic twins than dizygotic twins and that there 
is greater genetic contribution to BMD of the lumbar vertebrae and certain areas of the proximal 
femur (142).  This suggests that environmental factors have a greater influence on BMD of 
different areas of the skeleton. 
 
1.3.3.2 Physiological studies 
 In these types of studies groups have tried to identify the potential role of the 
hypothalamic-pituitary pathway osteoporosis but looking for associations between circulating 
growth hormone and cortisol levels with bone mineral density in both men and women.  It was 
shown that birth weight was predictive of basal growth hormone and cortisol during adulthood 
(143,144) and it has been suggested that these two hormones can be factors in determining the 
rate of bone loss.  Other studies have also shown that interactions between the genome and 
environmental stimuli can have an effect on the basal levels of growth hormone, which in turn 
can contribute to accelerated bone loss in later life (145).  In this study, Dennison et al showed 
that a SNP in the promoter region of the growth hormone gene had a significant association with 
lower basal concentrations of growth hormone and increased bone loss in later life.  This group 
also demonstrated significant associations between the SNP and weight at 1 year and rate of 
bone loss. 
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1.3.3.3 Maternal lifestyle 
Many animal studies have also demonstrated that restriction in maternal diets or dietary 
excess have a negative effect on skeletal bone development.  Fleeman et al showed that maternal 
nutrient restriction in pregnant rats caused a reduction in the levels of ossification in the  
offspring of dams on the lowest nutrient diet (146) and Lanham et al have demonstrated that low-
protein maternal diet leads to reduced strength and increased porosity in micro-swine offspring 
(147).   In contrast, Lanham et al have also shown that a maternal high fat diet can lead to the 
increase in deposition of fat in the distal femur of mouse offspring and female offspring also 
exhibited a change in trabecular structure (148).  Both these results show that alterations to the 
maternal diet, whether it be restriction or excess can lead to alterations in the development and 
structure of the offspring’s bones.  
Godfrey et al investigated the influence of maternal diet and lifestyle on intrauterine 
growth of 154 babies and they found that there were positive correlations between offspring 
bone mass and birth weight, length and placental weight (149).  They also demonstrated that 
maternal smoking and maternal energy intake at 18 weeks gestation had a negative association 
with BMC at birth as well as showing that the offspring of mothers who had a higher triceps skin 
fold thickness (a measure of fat stores) had higher BMC and BMD (p=0.02 and 0.007 respectively).  
This finding was replicated in a cohort of 216 9 year old children, where it was shown that lower 
fat stores at later stages of pregnancy was associated with lower BMC of children at 9 years of age 
(150).  This study by Javaid et al also showed associations between reduced BMC at 9 years with 
shorter maternal height, history of maternal smoking and lower maternal social class.  Of the 
subjects in this cohort, 77 of mothers also had below normal vitamin D status and both whole 
body and lumbar spine BMC of the offspring of these mothers was significantly reduced, 
(p=0.0088 and p=0.03 respectively).  These data suggest that maternal lifestyle and diet might 
influence intrauterine skeletal growth and studies have shown that these children could be at 
greater risk of developing osteoporosis in later life as offspring childhood growth, birth weight 
and bone mineral content relates to later bone health and risk of hip fracture (151,152). 
 
1.3.3.4 Childhood growth 
 7,000 men and women from a Finnish cohort were used to determine that childhood 
growth rate is directly linked to fracture risk (153).  This Finnish cohort linked hospital discharge 
reports for hip fracture with birth and childhood growth data and found that tall maternal height 
(p<0.001) and reduced rate of growth in both childhood height and weight (p=0.006 and p=0.01 
respectively) are factors that influence risk of hip fracture in later life.  This study also showed a 
significant positive association between increased fracture risk and babies that are born short.   
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 Javaid et al used 6,370 women from the same cohort to show that thinness in childhood is 
a risk factor for hip fracture in later life (151).  Out of these women there were 49 hip fractures 
over an 187,238 person year period and Javaid et al found that women in the lowest quarter of 
changes in body mass index (BMI) scores through childhood had an 8.2-fold increase in hip 
fracture risk when compared to those women in the highest quarter.  Data from both these 
studies show that poor growth in childhood has a direct effect on increasing hip fracture risk in 
later life. 
 
1.3.4 Vitamin D 
 Vitamin D belongs to a group of fat-soluble secosteroids (a subclass of steroids) and has 
an important role in regulating calcium uptake and bone homeostasis.  There are two forms of 
vitamin D: vitamin D3, which is synthesised in the skin from 7-dehydrocholesterol after exposure 
to sunlight (ultraviolet B radiation), and vitamin D2, which is acquired from food.  Vitamin D3 is 
hydrolysed into 25-hydroxyvitamin D3 in the liver by 25-hydrolase, which is then subsequently 
hydrolysed in the kidney into 1,25-dihydroxyvitamin D3 (the biologically active metabolite of 
vitamin D3) by 1-hydrolase (76).   In the circulatory system, the active metabolite of vitamin D3 is 
bound to the vitamin D receptor (VDR), which transports it into the nucleus of cells where it forms 
a heterodimer with members of the retinoid receptor family, namely RXR (154).  These complexes 
then bind to vitamin D responsive elements (VDREs) on target genes such as osteocalcin, calcium 
binding protein or 24-hydrolase.  In intestinal cells, transcription of the calcium binding protein 
allows for the increased transport of calcium into the blood, which allows for bone mineralisation 
to occur.  When there is a sufficient supply of 1,25-dihydroxyvitamin D3, it causes 25-
hydroxyvitamin D3 to be hydrolysed to 24,25-dihydroxyvitamin D3 by 24-hydroxylase in the kidney.  
This then goes on to be catabolised further. 
There have been many studies, in both humans and animals, which suggest that a 
deficiency in maternal vitamin D during pregnancy is a significant risk factor for severe adverse 
health outcomes in offspring during both fetal and childhood development.  In humans, it has 
been shown by a number of different groups in a variety of cohorts that maternal serum 25-
hydroxyvitamin D3 concentrations are positively associated with childhood BMC, BA and BMD.  
Using the SWS cohort, Harvey and colleagues have shown that across 278 pregnancies (136 
female offspring), female offspring of mothers that had a serum 25-hydroxyvitamin D3 lower than 
33 nmol/l had a mean whole body BA of 110cm2 compared to 119cm2 in offspring whose mothers 
had a serum 25-hydroxyvitamin D3 concentration above 33nmol/l.  This association reached 
significance, as did the positive association seen with whole body BMC (155). 
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Studies using the RAINE cohort and the Avon Longitudinal Study of Parents and Children 
(ALSPAC) have shown similar findings.     Recently, Hart and colleagues demonstrated that in 901 
mother-offspring pairs in the RAINE cohort, the offspring of the 37% of mothers which had a 25-
hydroxyvitamin D3 deficiency at 18 weeks of pregnancy (concentration less than 50nmol/l), had a 
lower peak bone mass at 20 years of age (156).  Using the same cohort, Zhu et al showed 
maternal serum 25-hydroxyvitamin D3 concentration to have a positive association with both 
offspring total body BMC and BMD at 20 years of age.  The offspring of mothers who had a serum 
concentration of 25-hydroxyvitamin D3 lower than 50nmol/l had a 2.7% lower total body BMC and 
1.7% lower total body BMD when compared to those whose mothers had a serum 25-
hydroxyvitamin D3 concentration greater than 50nmol/l (157).  A study by Sayers and colleagues 
using the ALSPAC cohort has also demonstrated that the exposure of a mother to UVB in the third 
trimester is also associated to the BMC of the child.  A total of 6995 boys and girls were assessed 
whose mothers’ exposure to UVB had been recorded and they found there to be a positive 
association between UVB exposure in the third trimester and childhood BMC, BA ad BMD, but not 
area adjusted BMC at 9 years of age (158).  This would suggest that maternal UVB exposure has 
an effect on the bone size of the offspring. 
There have also been some studies that have shown no associations between maternal 
serum 25-hydroxyvitamin D status and offspring BMC during childhood.  For example, using the 
ALSPAC cohort, which had previously been used to show that there was an association between 
maternal UVB exposure and childhood bone outcomes, Lawlor et al did not find any association 
between childhood bone outcomes and maternal 25-hydroxyvitamin D status.  Using 3960 
mother-offspring pairs, they were split into three groups according to maternal serum 25-
hydroxyvitamin D3 concentration: sufficient (>50nmol/l), insufficient (49.99-27.5nmol/l) and 
deficient (<27.5nmol/l) and relationship to childhood BMC was assessed.  This group did not find 
any differences in BMC at 9 years between the two lower concentrations and the sufficient group 
(159).  However, further investigation into this cohort have demonstrated that whilst there are no 
associations between maternal 25-hydroxyvitamin D2, there were positive relationships between 
child cortical bone density and thickness with maternal 25-hydroxyvitamin D3 (160).  This suggests 
that it is 25-hydroxyvitamin D3, which exerts beneficial effect to offspring cortical bone 
development in contrast to 25-hydroxyvitamin D2.  
 
1.4 Epigenetics 
As GWAS has only been able to explain 5% of variance seen in BMD, next generation 
sequencing should help to uncover much of the missing heritability, however, epigenetic 
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regulation may also have a role to play too.  Epigenetics is the study of the regulation of gene 
expression through modifications that do not alter the underlying DNA sequence (161,162).  
These modifications can be influenced by a variety of environmental factors, such as diet and 
smoking, especially in early life. 
 
1.4.1 Epigenetic mechanisms 
1.4.1.1 DNA methylation 
This is the process by which a methyl group is transferred from S-adNOS3ylmethionine 
(SAM) to carbon 5 of cytosines of CpG dinucleotides to form 5-methylcytosine (5-mC) (163), as 
shown in Figure 1.9.  Of all the CpG dinucleotides in the mammalian genome, it has been 
suggested that at least 80% of these are methylated (164).  The remaining 20% are unmethylated 
and are located in constitutively active or inducible gene promoters.  These clusters of CpGs are 
termed CpG islands and are defined as a region of <500 base pairs that has a CG content of more 
than 55% (165).  It is methylation of these CpGs that leads to a decrease in gene expression either 
due to the inability of the transcription factor of the gene to bind to the methylated sequence 
(166) or through the recruitment of transcriptional repressor complexes, some of which possess 
histone deacetylase (HDAC) activity (164).  Many CpG islands also have shores, which are slightly 
less dense regions of CpG dinucleotides near CpG islands and have been linked to tissue specific 
methylation (162). 
 
 
 
 
Figure 1.9: 5-methyl cytosine 
 
 
DNA methylation is regulated by three DNA methyltransferases (DNMTs): DNMT1, -3A 
and -3B.  DNMT1 is termed the ‘maintenance’ DNMT as it is specific for hemi-methylated DNA and 
is therefore responsible for passing on methylation patterns to the new strand of DNA.  DNMT3A 
and-3B are de novo methyltransferases and are therefore the methyltransferases that respond to 
environmental stimuli to transfer a new pattern of methylation onto the DNA (162).  Knockout 
studies have shown that deletion of any methyltransferase has a global effect on methylation 
(167).  The demethylation mechanism is not yet fully understood, though data from Metivier et al 
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suggests that this could be carried out by DNMT3A and -3B (168), however it has also been 
suggested that demethylation is a passive event (169).  There is now also increasing evidence to 
suggest that the TET family of enzymes can cause cytosine demethylation by converting 5-
methylcytosine to 5-hydroxymethylcytosine (170). 
 
1.4.1.2 Histone modifications 
Chromatin is made up of nucleosomes, which consist of 146bp of DNA wrapped 1.65 
times around a core of histone proteins.  This core is formed from an octamer of two copies each 
of H2A, H2B, H3 and H4.  A linker histone protein, H1, is also associated with the octamer core 
and binds at the entry and exit point of the DNA, thus locking it into place (164,171).  The N-
terminus tails of the histone proteins protrude past the DNA and make it ideal targets for post-
translational modifications, such as acetylation, methylation and phosphorylation.  Acetylation is 
a reversible modification where an acetyl group is transferred from acetyl CoA onto conserved 
lysine residues in H3 and H4 tails to form ε-N-acetyllysine.  This modification is associated with 
inducible gene expression and was originally thought to increase gene transcription by reducing 
the electrostatic interactions between the histone proteins and the DNA, thus making it more 
accessible (164).  This is now known not to be true, instead the acetyl group forms a 
bromodomain which allows for co-activators such as TATA box binding protein (TBP), TBP 
associated factors and RNA polymerase II to bind to DNA and promote gene expression (172).  
The removal of acetyl groups from lysine residues is associated with gene repression and gene 
silencing.  This process is carried out by HDACs, which are classed into four groups: I, II, III and IV 
(164).  It has been shown that the different classes of HDACs recognise different acetylation 
patterns and therefore repress different genes (173).  Lysine residues can also undergo 
methylation at H3K4 and H3K36. 
 
1.4.1.3 microRNAs (miRNAs) 
The first type of non-coding RNA that has a role in genome regulation are microRNAs 
(miRNAs).  These are small single stranded non-coding RNAs that are about 20 to 23 nucleotides 
in length that act as gene regulators in mammalian genomes (174).  They are transcribed from 
one of two places: 1) from intergenic regions of promoters (175) or 2) from an intronic part of a 
gene (176).  They are first formed into stem-loop structures, and are then exported out of the 
nucleus (177).  The stem loop is then removed by the enzyme Dicer, an RNase III enzyme, to form 
a duplex of the arms of the loop, one of which is then incorporated into RNA-induced silencing 
complex (RISC) through association with members of the Argonaute protein family (178,179).  The 
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RISC then either cleaves or suppresses translation of mRNA depending on the percentage of 
complementary base pairing between the miRNA and the target mRNA (180). 
 
1.4.1.4 Long non-coding RNAs (lncRNAs) 
 There is now evidence to suggest that another class of non-coding RNAs, long non-coding 
RNAs (lncRNAs), may have a role to play in epigenetic regulation.  lncRNAs are distinguished from 
short non-coding RNAs, such as miRNAs, as they are over 200bp in length.  The expression of 
lncRNAs has been shown to be developmentally regulated and it can be tissue or cell-type specific 
(181), though a significant proportion has been shown to be exclusively located in the nucleus of 
the cells (182). 
 There are no biochemical features or structural motifs that can be exclusively assigned to 
lncRNAs.  However, it is believed that the modifications that regulate and stabilise coding RNA 
structure may also regulate lncRNA function (183).  It has been shown that lncRNAs can fold into 
stable secondary and higher order structures and studies have shown that it is these higher order 
structures that can determine the function of lncRNA.  For example, Zhang et al have 
demonstrated that tumour suppressor function of Maternally expressed gene 3 (MEG3), a gene 
that causes growth suppression and the stabilisation of p53 when expressed in tumour cells, is 
determined by the secondary structure of the lncRNA transcribed from this gene, rather than the 
primary structure (184). 
There are three different functional domains that have been described in lncRNAs: RNA- 
(185), protein- (186)and DNA-binding domains (187), although there is little evidence that there 
are direct RNA-DNA interactions, though has been suggested that folding of the RNA can create 
DNA binding pockets (187).  The interactions of lncRNAs and their functions allow them to be 
separated into 3 groups: decoys, scaffolds and guides (188).  lncRNAs can belong to one or more 
of these groups.  The decoy class of lncRNAs are those that bind to regulatory proteins, such as 
transcription factors, and RNA that would otherwise bind to DNA and cause a change in gene 
expression (188).  Scaffold lncRNAs act as adaptors that allow complexes to form by bringing two 
or more proteins together (189) and the final group of lncRNAs is the guide group which allow for 
specific localisation of RNA:protein complexes (190).  There is also now evidence to suggest that 
some lncRNAs can act as transcriptional enhancers (191), though the mechanism for this is yet 
undiscovered. 
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1.4.1.5 Evidence epigenetic processes mediate developmental origins of adult disease using 
animal models 
There are many animal studies that show that the epigenome can be affected by early life 
environment, both during gestation and immediately after birth. Agouti viable yellow mice are 
useful in these studies as a change in methylation of the promoter of the Agouti gene produces 
easily observed results, i.e. when the promoter of this gene is hypomethylated, gene expression is 
increased and the rats have a yellow coat and are obese, however when the promoter is 
hypermethylated, gene expression decreases and the rats have a brown coat and have a normal 
weight (192).  Studies with these mice have shown that if the maternal diet is deficient of methyl 
donors and co-factors, the agouti promoter becomes hypomethylated and the resulting offspring 
have a high prevalence of obesity, cancer incidence and retain their yellow coats (193).  Lillycrop 
et al were the first to show that feeding pregnant rats a protein restricted diet can cause specific 
epigenetic changes in genes involved in the metabolic pathways of the offspring.  It was shown 
that protein restriction caused a decrease in methylation of the glucocorticoid receptor (GR) and 
peroxisomal proliferator-activated receptor alpha (PPARα) genes in the offspring that were 
persistent after weaning, however the methylation of PPARγ remain unaltered (194). 
It has also been shown that maternal behaviour can alter the epigenome.  A study on rats 
by Weaver et al has shown that methylation of the GR promoter can be altered in pups depending 
on the nursing behaviour of the mothers.  Those offspring that were exposed to a greater amount 
of nursing had a greater level of methylation in the GR promoter, lower GR expression and a 
modest hypothalamic-pituitary-adrenal axis (HPA) stress response when compared to those who 
were exposed to a lower amount of nursing.  These changes appeared within the first week of life 
and were persistent through adulthood, though the changes could be reversed through cross-
fostering, showing that it is the maternal behaviour that has an effect (195). 
 
1.4.1.6 Vitamin D and epigenetic mechanisms 
 There is evidence now suggesting that the active metabolite of vitamin D3, 1,25-
dihydroxyvitamin D3, can induce demethylation, however the exact mechanisms of how this 
occurs are not clear (196).  In most cases it is believed to be a passive process that occurs over 
multiple cell divisions, but some cases it is believed to be an active process as demethylation 
occurs within 1-4 hours (197). 
Various research groups have suggested that CpG methylation can be influenced by 
vitamin D status, in both cell lines and primary cells.  Tapp and colleagues have demonstrated that 
serum 25-hydroxyvitamin D3 concentrations are negatively associated with the methylation in the 
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promoter region of the tumour suppressor gene APC in human rectal mucosa (198) and a recent 
study on Canadian colorectal cancer patients demonstrated that high dietary intake of vitamin D 
is negatively associated with the promoter methylation of DKK1 and WNT5A, both of which are 
WNT antagonists and their expression is usually silenced through hypermethylation during the 
early stages of colorectal cancer (199). 
An EWAS comparing DNA methylation of 11 African American males aged 14-19 years 
with serum vitamin D levels 25nmol/l with age-matched controls revealed 79 novel CpGs that 
were differentially methylated between the two groups, only 2 of which remained significantly 
after multiple testing (200).  These were CpGs found within MAPRE2, a gene believed to be 
involved with controlling proliferation of cells, and DIO3, which encodes the enzyme thyroxine 5-
deiodinase.  It also showed significant difference in methylation of CpGs that had previously been 
identified through GWAS: DHCR7, CYP2R1 and CYP24A1, whose transcripts all have roles in the 
metabolism of vitamin D. 
 There is evidence in animal models that 1,25-dihydroxyvitamin D3 also influences 
histone acetylation.  In murine osteoblastic MC3T3-E1 and primary osteoblasts, Kim and 
colleagues demonstrated that when these cells are treated with 1,25-dihydroxyvitamin D3, it 
induces the rapid recruitment of co-activators, such as p300 and CREB binding protein (CBP), to 
the promoters of Cyp24 and Opn (201).  The recruitment of these co-regulators lead to the 
acetylation of histone 4 on Cyp24, but not Opn, suggesting a role for vitamin D in the regulation of 
histone acetylation.  Kim and colleagues have also demonstrated that 1,25-dihydroxyvitamin D3 
promotes the deacetylation of histones and the methylation of the CYP27B1 promoter (202).  This 
gene encodes for 1-hydroxylase, which converts 25-hydroxvitamin D3 into its biologically active 
metabolite 1,25-dihydroxyvitamin D3.  Both of these epigenetic processes lead to the 
suppression of CYP27B1 expression and is another example of how vitamin D can alter the 
epigenome. 
 
1.4.2 Epigenetics and early life environment  
The mechanism by which the fetus senses the environment and adapts its metabolism 
may involve the epigenetic regulation of genes.   A change in this epigenetic pattern can lead to 
dysregulation of the genes that control placental transfer of nutrients, which in turn can lead to 
abnormal energy allocation in the developing fetus (161). However this is probably secondary to 
environmental stimuli the blastocyst receives during the pre-implantation stage.  Watkins et al 
have shown that the offspring of mice fed on a low protein diet during pre-implantation stage of 
gestation are more susceptible to excess growth, cardiovascular and behavioural problems in 
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adulthood.  This effect was found to be independent of maternal diet in later stages of pregnancy 
and was shown that some of these effects could be mediated by the visceral yolk sac endoderm 
(203). 
 Evidence from animal models has shown that epigenetic mechanisms are influenced by 
the environment the offspring is subjected to in early life and studies have now shown that similar 
mechanism may occur in humans.  In a study by Heijmans et al they used the Dutch Hunger 
Winter cohort to determine if prenatal exposure to famine had an effect on the epigenome of the 
offspring.  They investigated the methylation levels of 5 CpG sites within the promoter region of 
the insulin-like growth factor 2 (IGF-2) gene in 60 individuals who were exposed to famine 
compared to their same-sex non-exposed siblings.  IGF-2 is a maternally imprinted gene that plays 
an important role in human growth and development.  When comparing those individuals that 
had been exposed to famine in utero to those that had not, it was found that the methylation 
levels of all the CpGs but one was significantly lower in the siblings that had been exposed to 
famine (p=5.9x10-5) (204).  They also looked at methylation of these CpGs in adults who had been 
exposed to famine during late gestation and found no significant differences when compared to 
their non-exposed same-sex siblings. 
 In a similar study by Tobi et al, the methylation status of 15 imprinted and non-imprinted 
genes that have been implicated in growth and metabolic disease were characterised using the 
same cohort.  Once again they looked at methylation levels of these 15 loci in 60 individuals that 
had been prenatally exposed to famine versus their non-exposed same-sex siblings and found that 
methylation of INSIGF was significantly lower in siblings that had been exposed to famine than 
those that had not (p=2x10-5), which agrees with the results previously shown by Heijmans et al.  
However, they also showed that methylation of IL10, LEP, ABCA1, GNASAS and MEG3 genes was 
significantly higher in exposed siblings than their non-exposed counterparts (all p<0.01).  The 
study also demonstrated the importance of timing of famine exposure as there was a difference 
in methylation of GNASAS in a sample of 62 individuals that were exposed to famine during the 
late stages of gestation. 
 Maternal vitamin D status has also been shown to have an effect on offspring 
development (150) and recently Harvey et al have demonstrated that maternal free 25(OH)-
vitamin D status is associated with the methylation of RXRA, the gene which encodes retinoid X 
receptor α (RXRα).  Using 230 SWS participants, this study showed that free maternal 25(OH)-
vitamin D index has a significant negative association with the methylation status of one CpG 
within the RXRα promoter (p=0.03) (205).  This further supports that early life environment can 
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alter the epigenome of the offspring and can cause alterations to genes that have been shown to 
have roles in growth and development. 
 
1.4.3 Epigenetics and bone 
Studies have demonstrated that many epigenetic mechanisms regulate the differentiation 
of osteoblasts, which can have a downstream effect on bone development and homeostasis.  
Huang et al have demonstrated that miR-22 in human adipose derived MSCs can affect the 
balance between adipogenesis and osteogenesis by leading to an increase in osteogenic 
differentiation.  When this miRNA is overexpressed in these cells, it causes an increase in ALP 
activity, matrix mineralisation and transcription of osteogenic specific genes whilst simultaneously 
causing repression of adipogenic transcription factors (206).  Further experiments showed that 
this promotion of osteogenesis was due to direct repression of HDAC6 via miR-22.  miR-17-5p and 
miR-106a have been shown to have to opposite effects by upregulating adipogenesis and 
suppressing osteogenesis.  In this study, these miRNAs were shown to inhibit BMP2, which caused 
downregulation of genes such as TAZ2, MSX2 and RUNX2, which are essential for osteoblast 
differentiation (207). 
Histone modifications have also been shown to have a role in regulating osteoblast 
differentiation.  A study from Hassan and colleagues has demonstrated that HOXA10 promotes 
osteoblastogenesis by directly regulating the activation of RUNX2.  It was also shown to 
upregulate other genes such as ALP, OCN and BGLAP, which are also essential for the progression 
of osteogenesis (208).  HOXA10 mediates chromosome hyperacetylation and H3K4 trimethylation 
of these genes, which allows for binding of transcription factor complexes and the activation of 
transcription.  Hemming et al have shown that EZH2 and KDMA6, a lysine demethylase, act as an 
epigenetic switch regulating H3K27 trimethylation to control lineage determination of MSCs.  
Overexpression of EZH2 caused an increase in adipogenesis and suppressed osteogenesis, 
whereas overexpression of KDMA6 had the opposite effect (209), demonstrating an important 
epigenetic switch centred around histone methylation that determines MSC differentiation. 
In rats, reduced CpG methylation has been associated with the transcriptional activation 
of bone-specific osteocalcin.  Villagra et al, using primary rat osteoblasts, demonstrated that 
during the differentiation process methylation levels of CpGs within the osteocalcin promoter was 
significantly reduced, which coincided with an increase in expression of bone-specific osteocalcin 
(210).  Delgado-Calle et al have demonstrated that DNA methylation has a role in regulating the 
expression of ALP and the RANKL-OPG pathway in human bone.  They found that across a variety 
of bone related cells the methylation of CpGs within the ALP promoter was inversely related to 
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the expression of alkaline phosphatase and when cells were treated with a demethylating agent, 
there was a 30-fold increase in the expression of this gene (211).  This group have also 
demonstrated that the demethylation of CpGs within the promoter of RANKL and OPG genes, two 
osteoblast-derived factors that are important in osteoclastogenesis, caused an upregulation in the 
expression of these two genes.  Treatment of HEK-293 cells with a demethylating agent led to a 
170-fold increase in RANKL expression and a 20-fold increase in OPG expression (212).  However, 
when looking at methylation across patients with osteoporotic fracture and those with 
osteoarthritis, there was no difference in methylation levels even though RANKL:OPG ratio was 
significantly higher in those patients with osteoporotic fracture.  This suggests that other 
mechanisms other than methylation could be at play to cause the increased ratios seen in 
patients with osteoporotic fractures. 
Research from independent groups has now demonstrated roles for specific lncRNAs in 
the osteogenic differentiation process.  A recent expression profile by Zuo et al has shown that 
there is differential expression of lncRNAs during the early differentiation of C3H10T1/2 
mesenchymal stem cells (murine mesenchymal stem cell line obtained from embryos) into 
osteoblasts (213).  Zuo and colleagues used an Arraystar lncRNA array to look at the expression of 
lncRNAs between control MSCs and those that had been treated with BMP2 to initiate osteoblast 
differentiation.  This expression array identified 116 lncRNAs that were differentially expressed 
between the two treatment groups – 59 upregulated and 57 downregulated in the BMP2 treated 
group.  Through bioinformatics analysis, this group also found potential regulatory mechanisms 
that allow lncRNAs to control osteoblast differentiation and identified 24 lncRNAs with nearby 
protein-coding gene pairs.  Zhu and colleagues have demonstrated that the lncRNA ANCR 
interacts with enhancer of zeste homolog 2 (EZH2), a subunit of PCR2, to repress RUNX2 
expression (214).  This was done through quantitative PCR and ChIP analyses, which 
demonstrated that it was the association of ANCR with EZH2 and their translocation to the 
promoter of the RUNX2 gene that caused this suppression.  When ANCR expression is knocked 
down via a siRNA in hFOB1.19 cells, a human fetal osteoblastic cell line, there is an increase in 
alkaline phosphatase and osteocalcin expression, differentiation and mineralisation markers 
respectively.  van de Peppel et al have shown that lncRNA H19 expression increases during 
osteogenic differentiation (215).  When expression of this lncRNA is knocked down by short 
hairpin RNAs (shRNAs) in human mesenchymal stromal cells, results showed a 70-90% decrease in 
ALP expression and an 80-95% decrease in matrix mineralisation.  This coincided with a decrease 
in the expression of RUNX2 and collagen type I, an extracellular matrix protein, which suggests 
that H19 may have a direct role in regulating osteoblastic differentiation.  This research does 
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suggest that there may be a role for lncRNAs in regulating the differentiation process of 
mesenchymal stem cells into osteoblasts. 
 
1.5 Identification of potential predictive markers of offspring bone outcomes 
1.5.1 Epigenetic biomarkers of later health 
 A biomarker is defined as ‘a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes or pharmacological responses to a therapeutic 
intervention’ (216).  If early life environment alters the epigenome as suggested from animal 
studies and if these marks are largely stably maintained, it may be possible to detect such marks 
in early life and use these to predict later metabolic capacity and future disease risk.  This would 
also allow for preventative therapies to be given to these individuals to increase the chances of a 
better health outcome. 
Both animal and human studies suggest that early life environment may alter the 
epigenome and that these altered marks then persist into adulthood (193), contributing to future 
metabolic health and risk.  It should be possible to detect such marks in early life and use these to 
predict later metabolic health; however, DNA methylation is tissue specific.  This suggests that it 
may not be possible to use methylation patterns in proxy tissue to predict methylation patterns in 
other, metabolically relevant cell types across the body.  However, rat studies have shown that 
the percentage methylation of the promoter of PPAR-α in umbilical cord is comparable to that in 
hepatic cells (217). 
Studies in humans also suggest that, at least for some CpG loci, methylation is correlated 
between different tissues, which strengthens the argument that methylation in one tissue can be 
representative of methylation in another tissue.  Woodfine et al demonstrated, through 
pyrosequencing assays, that methylation levels were stable in all germ-line differentially 
methylated regions (DMRs) associated with imprinted genes across all somatic tissues that were 
investigated (218).  Lu et al have identified five genes (N4BP2, EGFL8, CTRB1, TSPAN3 and 
ZNF690) that have consistent methylation levels across 13 different tissue types, which include 
brain, lung and colon cell lines (219). 
Supportive of epigenetic marks, even in proxy tissues, being used as biomarkers are 
various studies on human cohorts that shown associations between methylation in umbilical cord 
collected at birth and later childhood adiposity.  Godfrey et al showed that methylation of the 
RXRα promoter region had a strong positive association with a child’s adiposity at 9 years in two 
independent cohorts.  The results from the first cohort (Princess Ann Hospital (PAH) study, n=64) 
demonstrated that as percentage methylation of the RXRA promoter increased, so did the 
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percentage of whole body fat (p=0.009) and fat mass (p=0.023).  These associations were then 
replicated with both percentage whole body fat and fat mass (both p=0.002) using subjects from 
the Southampton Women’s Survey (SWS) cohort (n=239) (220).  These marks explain 25% of the 
variance in fat mass, and so supports the hypothesis that developmentally induced epigenetic 
markers significantly contribute to later phenotype. 
Potential biomarkers could also come from other tissues such as blood.  For example, 
Clarke-Harris et al have demonstrated that methylation levels in peroxisome proliferator-γ-co-
activator-1α (PGC1α) in blood at 5-7 years predicts adiposity in the child at 9 to 14 years of age 
(221).  Using 40 subjects from the EarlyBird cohort (20 boys and 20 girls) Clarke-Harris et al 
showed that the methylation levels of all 7 CpG loci of interest within the promoter region of 
PGC1α are stable from 5-7 years up to 14 years of age and that methylation of 4 of these CpGs 
was significantly associated with future adiposity, where 10% difference in methylation led to a 
12.5% change in body fat (p=0.002-0.03).  This demonstrates that stable methylation marks can 
be used to predict future risk. 
 
1.5.2 Epigenetic markers of later bone health 
1.5.2.1 RXRα 
RXRα, along with RXR and RXR form the retinoid X receptor family, which belongs to a 
superfamily of steroid hormone receptors (222).  RXRs were first shown to form heterodimers 
with retinoic acid receptors (RARs), but were subsequently shown to form dimers with other 
steroid hormone receptors, such as VDR, thyroid hormone receptor (223) and PPARs (224).  This 
demonstrates the versatile nature of RXRs as they mediate several different signalling pathways, 
exhibiting the potential of these receptors to influence different areas of development. 
In bone, RXRα has been shown to have a role in osteoclast differentiation and in postnatal 
bone remodelling as when RXR function is lost there is an increase in bone mass and the 
formation of non-resorbing osteoclasts.  Menéndez-Gutiérrez and colleagues discovered that this 
was because RXR forms a homodimer and binds to Mafbp promoter, which is a key regulator in 
osteoclast differentiation, proliferation and activity (225).  Through its formation of a heterodimer 
with VDR, RXRα also functions in osteoblasts by stimulating the expression of osteocalcin, an 
important protein in bone mineralisation (226) and by regulating osteoblast differentiation and 
proliferation (227). 
Godfrey and colleagues have previously identified significant positive associations 
between the methylation of a CpG within the promoter region of the RXRA gene and adiposity 
during childhood (220).  Methylation levels of 15 umbilical cord tissue DNA samples from the PAH 
cohort were examined using a NimbleGen promoter array.  This array identified 78 potential 
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differentially methylated genes, of which 5 were shown to have correlations with CpG 
methylation and adiposity at 9 years of age: RXRA, NOS3, SOD1, IL8 and PI3KCD.  Of the 14 CpGs 
within the DMR of RXRA, only 1 (chr9: 136355885) showed any associations with childhood 
adiposity.  This CpG showed a significant positive correlation with both fat mass (FM) and 
percentage fat mass (%FM) in both the PAH and SWS cohorts. 
As adipocytes and osteoblasts share a common lineage, it was reasoned that epigenetic 
marks associated with umbilical cord tissue DNA and fat mass might also be related to bone 
development. To this end, using the PAH and SWS cohorts, Harvey et al demonstrated 
associations between RXRA promoter methylation and size corrected bone mineral content.  
Using 230 children from the SWS cohort, they showed that an increase in the percentage 
methylation of the CpGs within the RXRα promoter at birth was significantly associated with a 
decrease in size corrected bone mineral content at 4 years (205). 
 
1.5.2.2 Endothelial nitric oxide synthase (eNOS) 
 eNOS is an enzyme that is encoded by the NOS3  gene found on chromosome 7 and is one 
of three isoforms that synthesise nitric oxide (NO), which is a small lipophilic molecule that has a 
role in a number of biological processes (228).  It is most well known for having a role in regulating 
vascular tone in the cardiovascular system by promoting vascular relaxation through its activation 
of guanylate cyclase and the subsequent production of cyclic guanosine monophosphate 
(229,230). 
 eNOS has also been shown to have mechanistic roles in osteoclasts, osteoblasts and 
osteocytes.  In osteoclasts NO has been shown to increase osteoclastogenesis, possibly through 
enhancing cellular fusion (231), whereas in osteoblasts, when the eNOS system is disrupted in 
mice, there is an increase in bone formation markers, such as serum alkaline phosphatase 
concentration and mineral deposition rate, as well as an increase in BMD (232).  In osteocytes 
Zaman and colleagues have demonstrated that increased mechanical strain on primary osteoclast 
cell culture leads to an increase in the expression of eNOS and in the production of NO (233).  
However, the other two isoforms of NOS were not expressed in osteoclasts or any other cells 
derived from the osteoblast/osteocyte lineage, suggesting that eNOS has a key role in osteocyte 
function. 
Godfrey and colleagues also found associations between a CpG (chr7: 150315553) within 
the NOS3 promoter and childhood adiposity.  In the PAH cohort, NOS3 methylation showed 
significant positive associations with childhood FM, %FM and ratio of truck to limb fat ratio at 9 
years of age. However, unlike RXRA, these findings were not replicated in the larger SWS cohort.  
41 
 
Harvey and colleagues have since gone on to demonstrate that in a cohort of 66 SWS children that 
there is a strong positive correlation between the methylation of a CpG within the NOS3 promoter 
and the child’s bone area (BA), BMC and areal bone mineral density (aBMD) at 9 years of age 
(234). 
 
1.5.2.3 CDKN2A   
CDKN2A is found on chromosome 9 and encodes for two cell cycle inhibitors, p16INK4A and 
p14ARF.  Both of these transcripts have been shown to have roles in senescence and mutations and 
deletions in this gene have been found in a wide variety of tumours (235).  In osteosarcoma it has 
been found that deletions in the CDKN2A gene and loss of p16INK4A expression occur in the types 
of osteosarcoma that also had retinoblastoma (Rb) protein inactivation.  This protein is involved in 
the downstream processes of the pathway that p16INK4A regulates. 
To identify potential perinatal epigenetic markers associated with later adiposity and 
bone outcomes, a methyl binding domain (MBD)-ChIP array (Agilent) was carried out on DNA 
from a 21 umbilical cord samples from the SWS cohort looking for differentially methylated 
regions across the samples in relation to offspring %FM, BA, BMC and aBMD.  Using the BATMAN 
algorithm, this identified 93 DMRs associated with %FM, one of which was a 300bp region within 
the CDKN2A gene locus that contains 9 CpGs.  Upon further analysis, Dr R Murray found that the 
methylation of this DMR has a negative association with fat mass, BA, BMC and aBMD 
(unpublished data).   
Preliminary analysis was carried out on a larger sample size of SWS subjects (n=292) that 
had DXA measurements at 4 and 6 years of age and this revealed that there were significant 
negative associations in offspring between all three and methylation with relation to CpG 9 at 
both 4 years and 6 years of age (Figure 1.10).  For every 1% change in methylation, bone mass 
decreased by 1.0g (p=0.005) and 1.8g (p=0.008) at 4 and 6 years respectively and it was 
determined that further investigation was warranted.  These relationships remained the same 
even after adjustments were made for maternal smoking, maternal parity and physical activity in 
later pregnancy, which have all previously been associated with childhood bone mass.  Negative 
associations were also seen with CpG 5 (data not shown). 
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Figure 1.10: Association between CpG 9 methylation and (A) bone area and bone mineral content at 4 
years, (B) bone area and bone mineral content at 6 years and (C) areal bone mineral density at 4 and 6 
years.  For both ages, methylation has a negative association with bone area, bone mineral content and 
areal bone mineral density.  Graphs reproduced with permission from Prof NC Harvey. 
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1.6 Aims and hypotheses 
 Osteoporosis is becoming a major burden on the healthcare system as the population is 
becoming more aged and fragility fractures are becoming more frequent.  One of the main 
contributors to the pathogenesis of the disease seems to be low bone mineral density brought 
about by increased bone loss, aging, menopause and other factors such as vitamin D deficiency 
and secondary hyperparathyroidism (109), though there is also evidence that early life 
environment can alter skeletal development, and therefore can also contribute to the 
pathogenesis of osteoporosis (118,149,153,236).  Bone homeostasis is maintained through the 
synergy brought about by the various signalling pathways and transcription factors that 
contribute to the regulation of bone formation.  It is when these systems become unbalanced 
that increased bone loss occurs and results in a lower bone density than is desirable for 
preventing fragility fractures in later life. 
Population studies, physiological studies, mother-offspring cohort studies and studies 
looking at childhood growth have all provided evidence for the developmental origins of 
osteoporosis through the affects environmental factors have on bone mineral accrual in utero, 
during childhood and during adolescence.  They have highlighted the importance of diet and 
lifestyle, both of the mother and the offspring in acquiring an optimal peak bone mass and density.  
However, these studies do not explain all the variance seen in BMD between individuals and 
genetic studies have only explained 5% of this variance.  
Epigenetic studies has provided some evidence in humans to suggest that DNA 
methylation of various genes associates with future BMD (205,234); however more evidence is 
needed to determine whether the relationship between regions of altered methylation in cord 
tissue and bone are simply markers or whether the differentially methylated genes are part of the 
causal pathway that leads to low bone mass and low bone mineral density.  Understanding which 
of the latter these marks represent is critically important for our understanding of bone 
development and the utility of such marks as biomarkers for later disease risk.  Both RXRA and 
CDKN2A are the markers most strongly associated with later bone health and there is evidence 
that they may have roles in bone development, but whether these regions of differential 
methylation influence their function is unknown. 
 
The aims of my project are to: 
 Identify whether the differentially methylated CpGs associated with later BMC are 
functionally important in the regulation of CDKN2A transcription. 
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 Determine whether perturbation in expression of the long non-coding RNA ANRIL, a 
product of the CDKN2A locus gene, affects bone cell proliferation, apoptosis or 
differentiation markers. 
 Determine whether ANRIL has any trans-functional effects in primary osteoblasts. 
 Determine whether a randomised controlled trial, which has seen changes in offspring 
BMC with maternal vitamin D treatment, causes changes in the methylation status of 
specific regions within CDKN2A, RXRA and NOS3.  
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2. Materials and Methods 
2.1 Materials 
Chemical/Reagent Details 
Ethanol 99%+ Fisher Scientific, #E/0600/05 
DNase and RNase free water, DEPC treated Fisher Scientific, #BPE561-1 
Human Liposarcoma SW-872 Cell Line Cell Lines Service, #SW 872 
Human Osteosarcoma SaOS-2 Cell Line Cell Lines Service, #36025 
Dulbecco’s Modified Eagle Medium (DMEM)/ 
Ham’s F-12 
Gibco, #11320-074 
Penicillin-Streptomycin Sigma-Aldrich, #P4333 
Fetal Bovine Serum PAA, #A15-151 
L-Glutamine Sigma-Aldrich, #G7513 
Trypsin EDTA PAA, #L11-004 
Phosphate Buffered Saline (PBS) Tablets Fisher Scientific, #12821680 
Trypan Blue Solution (0.4%) Sigma-Aldrich, #T8154 
FastRead Counting Slides Immune Systems Ltd, #BVS100 
4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic 
Acid (HEPES) 
Sigma-Aldrich, #H4034 
Potassium Chloride (KCl) Sigma-Aldrich, #P9541 
Ethylenediaminotetraacetic Acid Disodium Salt 
(EDTA) 
Sigma-Aldrich, #03690 
Dithiothreitol (DTT) Melford, #MB1015 
Sodium Chloride (NaCl) Sigma-Aldrich, #S3014 
Phenylmethanesulfonyl Fluoride (PMSF) Sigma-Aldrich, #P7626 
Leupeptin Hemisulfate Salt Sigma-Aldrich, #L5793 
Igepal CA-630 Sigma-Aldrich, #I8896 
BCA Protein Assay Kit Fisher Scientific, #23227 
Osteosarcoma SaOS-2 Nuclear Extract Active Motif, #36025 
40% Acrylamide Solution Fisher Scientific, # BPE1402-1  
10X Tris-Borate-EDTA Buffer (TBE) Fisher Scientific, # T/P050/15 
Ammonium Persulfate (APS) Fisher Scientific, #BPE179-25 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, #T7024 
ATP, [γ-32P] Perkin Elmer, #BLU002A250UC 
T4 Polynucleotide Kinase (100u) Promega UK, #M4101 
illustra™ MicroSpin™ G-50 Columns GE Healthcare, #27-5330-01 
Ficoll 400 Sigma-Aldrich, #F9378 
Tris(hydroxymethyl)aminomethane Sigma-Aldrich, #252859 
Poly(deoxyinosinic-deoxycytidylic) Acid Sodium 
Salt  (Poly DIDC) 
Sigma-Aldrich, #P4929 
Primers for electromobility shift assays Sigma-Aldrich 
Carestream® Kodak® autoradiography GBX 
developer/replenisher 
Sigma-Aldrich, #P7042 
Carestream® Kodak® processing chemicals for 
autoradiography films GBX fixer/replenisher 
Sigma-Aldrich, #P7167 
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CL-XPosure™ Film Thermo Scientific, #34088 
FuGENE 6 Transfection Reagent Promega, #E2691 
Dual-Luciferase® Reporter Assay System Promega, #E1910 
TRI Reagent Sigma-Aldrich, #T9424 
Chloroform, 99.8+%, Certified AR for analysis, 
stabilised with amylene 
Fisher Scientific, #10090120 
Lipofectamine® RNAiMAX Transfection Reagent Invitrogen, #13778 
Opti-MEM® I Reduced Serum Medium Invitrogen, #31985062 
Silencer Select siRNA against CDKN2B-AS 
(n272158) 
Ambion, #4390771 
Silencer® Negative Control #1 siRNA Ambion, #AM4611 
AllStars Hs Cell Death Control siRNA (5nmol) Qiagen, #1027298 
Custom Silencer Select siRNA against CDKN2B-
AS 
Life Technologies 
DNase I Amplification Grade Sigma-Aldrich, #AMPD1-1KT 
Random nonamers Sigma-Aldrich, #R7647 
Deoxynucleotide Triphosphates (dNTPs) Promega, #U1420 
M-MLV Reverse Transcriptase kit Promega, #M1701 
GeNorm 12 Kit (Human) Primer Design, #ge-SY-12 
TaqMan® Gene Expression Master Mix Applied Biosystems, #4369016 
RPL13A TaqMan® Gene Expression Assay Assay 
(Hs04194366_g1) 
Applied Biosciences, #4331182 
TaqMan® Non-Coding RNA Assay 
(Hs04259476_m1) 
Applied Biosciences, #4426961 
TaqMan® Non-Coding RNA Assay 
(Hs01390879_m1) 
Applied Biosciences, #4426961 
Dual hydrolysis RT-PCR primers and probes Eurofins 
CDKN2B TaqMan® Gene Expression Assay 
(Hs00793225_m1) 
Applied Biosciences, #4331182 
CDKN2A TaqMan® Gene Expression Assay 
(Hs02902543_mH) 
Applied Biosciences, #4331182 
CDKN2A TaqMan® Gene Expression Assay 
(Hs99999189_m1) 
Applied Biosciences, #4331182 
RUNX2 TaqMan® Gene Expression Assay 
(Hs00231692_m1) 
Applied Biosciences, #4331182 
Alkaline phosphatase, liver/bone/kidney 
TaqMan® assay (Hs01029144_m1) 
Applied Biosciences, #4331182 
BGLAP TaqMan® Gene Expression Assay 
(Hs01587814_g1) 
Applied Biosciences, #4331182 
HIF1A TaqMan®  Gene Expression Assay 
(Hs00153153_m1) 
Applied Biosciences, #4453320 
IGF2 TaqMan®  Gene Expression Assay 
(Hs04188276_m1) 
Applied Biosciences, #4448892 
MAPK3 TaqMan®  Gene Expression Assay 
(Hs00385075_m1) 
Applied Biosciences, #4453320 
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ETS1 TaqMan®  Gene Expression Assay 
(Hs00428293_m1) 
Applied Biosciences, #4448892 
CYR61 TaqMan®  Gene Expression Assay 
(Hs00998500_g1) 
Applied Biosciences, #4448892 
TWSG1 TaqMan®  Gene Expression Assay  
(Hs00221028_m1) 
Applied Biosciences, #4448892 
Propidium iodide Sigma-Aldrich, #P4170 
Ribonuclease A from bovine pancreas Sigma-Aldrich, #R6513 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Osteosarcoma SaOS-2 cell line 
Human osteosarcoma cells, SaOS-2 (Cell Lines Service) were grown to 70-80% confluence 
in 75cm2 tissue culture flasks in Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s F-12 
supplemented with 5% fetal bovine serum (FBS), 2mM L-glutamine and 1% 
penicillin/streptomycin in a humidified atmosphere at 37oC with 5% CO2 in air.  Cells were sub-
cultured twice a week using 0.05% trypsin/EDTA and used to re-seed flasks with a 1:3 split ratio or 
spun down to create a cell pellet for total RNA extraction. 
 
2.2.1.2 Human bone marrow stromal cells (hBMSCs) 
hBMSCs were isolated from human bone marrow by adding 5mL plain MEMα to a 50mL 
falcon tube containing bone marrow, after which it was shaken.  The bone marrow is obtained 
from patients undergoing hip replacement surgery at Southampton General Hospital who have 
given consent for the bone marrow to be used for research purposes.  The shaking process was 
repeated three times, with MEMα being transferred into separate 50mL falcon tube after each 
wash, to ensure maximum cell retrieval.  The cells were then pelleted at 1100rpm for 4 minutes, 
after which they are passed through a cell strainer and then transferred into a 175cm2 cell culture 
flask with complete MEMα (MEMα supplemented 10% FBS and 1% Penicillin/Streptomycin).  The 
hBMSCs were left to attach for a week in a humidified atmosphere (5% CO2; 37
oC) before media 
removed and replaced with fresh complete MEMα.  Sub-culturing occurred when cells reached 
70% confluence using 0.05% trypsin/EDTA, when they were split in a 1:2 ratio, with one flask of 
cells being differentiated into osteoblasts using osteogenic differentiation medium that consisted 
of complete MEMα supplemented with 2μL/mL ascorbic-2-phosphate and 1μL/mL 
dexamethasone.  Differentiation was detected through a positive alkaline phosphatase staining 
result (Figure 2.1). 
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Figure 2.1: Alkaline phosphatase staining of hBMSCs (top) and primary osteoblasts (bottom).  Alkaline 
phosphatase staining shows that there is no alkaline phosphatase activity in the hBMSCs, whereas the 
primary osteoblasts show a positive result for alkaline phosphatase activity (indicated by the red colour).  
This confirms that the hBMSCs have been successfully differentiated into osteoblasts. 
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2.2.2 Transfection of SaOS-2 cells with luciferase reporter constructs 
2.2.2.1 ANRIL/p14ARF luciferase reporter constructs 
 Luciferase reporter constructs contained the promoter region of ANRIL (-1281bp to +20bp 
relative to TSS) (Figure 2.2A) and the 5’ region of the p14ARF gene (-500bp to +1125bp relative to 
TSS) (Figure 2.2B), which were fused to the firefly luciferase reporter gene in the pGL3-Basic 
vector and were provided by Dr R Murray.  Ten copies of the construct were produced each for 
ANRIL and p14ARF through mutagenesis PCR - nine with one individual CpG mutated within the 
DMR and one where none of the CpGs were mutated within 300bp DMR to use as a control.  Each 
of these separate constructs were then transformed into JM109 cells. 
 
 
Figure 2.2: ANRIL (A) and p14
ARF
 (B) pGL Basic plasmid constructs used for Dual-Luciferase® Reporter Assays 
 
 
2.2.2.2 Inoculation and minipreparation of plasmid DNA 
 A sterile inoculation loop was used to distribute previously transformed JM109 cells over 
pre-warmed luria broth (LB) agar plates, containing 100μg/mL ampicillin, to allow for single 
colonies to be picked.  Plates were then incubated upside down for 16 hours at 37oC, after which 
they were stored at 4oC until colonies were picked. 
 Using a sterile tip, a single colony was picked from each plate and was added to 10mL of 
LB media that contained ampicillin (100μg/mL).  The bacterial cultures were then incubated for 16 
hours at 37oC with shaking (225rpm).  A negative culture that contained 10mL of LB medium but 
no cells was also incubated. 
Plasmid DNA was extracted from cells using the GeneJET Plasmid Miniprep Kit (Thermo 
Scientific) according to manufacturer’s instructions.  In brief, 1mL bacterial culture was 
centrifuged at 8000rpm for 2 minutes, after which supernatant was aspirated and any remaining 
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media removed.  Cells were then resuspended in 250μL Resuspension Solution and vortexed, 
after which 250μL Lysis solution added and samples mixed thoroughly by inverting 4-6 times.  
350μL Neutralisation Solution then added and samples inverted 4-6 times immediately after 
addition.  Samples then centrifuged for 5 minutes at 12,000rpm to pellet cell debris, after which 
supernatant was transferred to GeneJET spin column and spun at 12,000rpm for 1 minute to bind 
plasmid DNA to column.  Flow-through was discarded and 500μL Wash Solution added to the 
column.  Samples centrifuged at 12,000rpm for 30seconds and wash step repeated.  After an 
additional spin for 1 minute to ensure the removal of any remaining Wash Solution, DNA was 
eluted using 50μL RNase-free water by incubating for 2 minutes at room temperature and then 
spinning for 2 minutes at 12,000rpm. 
 
2.2.2.3 Preparing plasmid DNA for transfection 
 Plasmid DNA was sterilised by addition of 1/10th of the volume of sodium acetate (pH 
5.2), 2 volumes of ice cold 100% ethanol and incubating at -20oC overnight.  Plasmid DNA was the 
pelleted by centrifugation at 13,000rpm for 15 minutes, after which the supernatant was 
removed and the DNA was washed with 1mL 70% ethanol.  After the samples were centrifuged at 
13,000rpm for 5 minutes, the supernatant was carefully aspirated and the pellets were air dried 
for 5 minutes.  DNA was then resuspended in 200μL of sterile water and quantity and quality 
determined using the Nanodrop. 
2.2.2.4 Transfection of plasmid DNA 
SaOS-2 cells were seeded at 1x105 cells per well in a 24-well plate.  Six wells were plated 
for each separate transfection and cells then grown overnight in 1mL DMEM/Ham’s F-12 media 
supplemented with 5% FBS, 2mM L-glutamine and 1% penicillin/streptomycin at 37oC in a 
humidified atmosphere containing 5% CO2.  After 24 hours, cells were transfected with plasmid 
DNA using FuGENE 6 transfection reagent (Promega) as per manufacturer’s instructions.  FuGENE 
6 and Opti-MEM were left to reach room temperature before use and FuGENE 6 was vortexed 
immediately prior to use.  The Opti-MEM was added to each eppendorf to make the total volume 
up to 25μL per well, and 3μL FuGENE 6 added directly to media, before eppendorfs were 
vortexed, pulse spun and incubated for 5 minutes at room temperature.  After the incubation, 
3201ng of the reporter plasmids and 39ng Renilla CMV control plasmid DNA were added to the 
eppendorfs.  Samples were vortexed, pulse spun and then left to incubate at room temperature 
for 15 minutes, after which 25μL of transfection mix was added to the appropriate wells.  Media 
was carefully mixed by pipetting up and down, before incubating for another 48 hours at 37oC in a 
humidified atmosphere with 5% CO2. 
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2.2.2.5 Preparation of cells for Dual-Luciferase assay 
Media was removed 48 hours after transfection and SaOS-2 cells were rinsed with 100μL of 1x 
PBS. All traces of liquid was removed before the addition of 150μL 1x Passive Lysis Buffer 
(Promega) to each well and mixed by pipetting up and down before transferring plates to -80oC 
overnight.  Plates were then thawed and 30μL of the lysed cells from each well was transferred 
into an opaque 96-well plate in order to read the luciferase activity on the VarioSkan Flash 
Luminometer (Thermo Scientific). 
The luminometer was primed with 1500μL Luciferase Assay Reagent II and 1500μL Stop 
and Glo reagent (Promega).  100μL Luciferase Assay Reagent II was added to each well, followed 
by 100μL Stop and Glo reagent, with luciferase activity being read after each addition.  The level 
of firefly luciferase was then normalised to renilla luciferase. 
 
2.2.3 Isolation of nuclear extract 
Cell pellets from the liposarcoma cell line SW-872 were resuspended in 800µL of 
hypertonic buffer (10mM HEPES, 10mM KCl, 1mM EDTA, 1mM DTT, 0.5mM PMSF and 10ng/mL 
leupeptin) and incubated on ice for 10 minutes.  50µL of 10% NP-40 was added to the cell 
suspension, which was then vortexed and centrifuged at 12,000 rpm for 30 seconds.  Supernatant 
was discarded and pellet resuspended in 50µL of high salt buffer (0.4M NaCl, 20mM HEPES, 
10mM EDTA, 1mM DTT and 1mM PMSF).  Samples were incubated on ice for 30 minutes then 
centrifuged at 13,000 rpm for 5 minutes at 4oC.  The concentration of the nuclear extract (the 
supernatant) was determined using BCA protein assay kit (Pierce) according to manufacturer’s 
instructions and stored at -80oC.  SaOS-2 cell nuclear extract was purchased from ActiveMotif at 
2.5µg/µL. 
 
2.2.4 Analysis of transcription factor binding by electrophoretic mobility shift assay 
2.2.4.1 Annealing oligonucleotides 
 Complementary single stranded oligonucleotides (100µM) were mixed together in a 1:1 
ratio and were diluted down to the correct concentration in 1mL of annealing buffer (10mM Tris, 
1mM EDTA, 50mM NaCl) (pH 8.0).  Each of the unmethylated and methylated oligonucleotides 
shown in Table 2.3 were diluted down to 1pmol/μL and 5pmol/μL to be used as 100x and 500x 
competitor respectively in experiments.  Oligonucleotides were annealed by heating to 95oC for 5 
minutes and were then slowly cooled to room temperature overnight.  Annealed oligonucleotides 
were then stored at -20oC for use as competitors in electrophoretic mobility shift assays or to be 
end-labelled with phosphorous-32 (P-32). 
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2.2.4.2 Electrophoretic mobility shift assay (EMSA) 
All unmethylated oligonucleotides shown in Table 2.3 were end-labelled with P-32 using 
T4 polynucleotide kinase.  The probe was prepared by mixing 2μL of 1pmol/μL competitor stock, 
5μL 5x Polynucleotide kinase buffer (Promega), 1μL polynucleotide kinase, 2μL P-32 and 40μL 
water in and eppendorf tube.  Reaction mixture was then incubated for 30 minutes at 37oC, after 
which another 50μL of water was added to tube and all of reaction mixture was spun through 
illustra™ MicroSpin™ G-50 Columns (GE Healthcare) for 5 minutes.  2μL of probe (theoretical final 
concentration of 20fmol/μL) was then checked using Geiger counter to ensure oligonucleotide 
had been successfully labelled and that labelled oligonucleotide was at 200 counts or above. 
5% polyacrylamide gels were prepared using the components shown in Table 2.2 and 
allowed to set in glass plates cleaned with 70% ethanol for 30 minutes.  Gels were pre-run with 1x 
Tris-Borate-EDTA (TBE) buffer for 1 hour on ice.  This allows the temperature to equalise across 
the gel.  Whilst the gels were pre-running, the binding reactions were set up.  For each binding 
reaction, 5µg of liposarcoma or osteosarcoma nuclear extract, 10µL of 10x Parker buffer and 1µL 
of Poly dIdC were incubated at 4oC for 10 minutes before the addition of 2µL of labelled probe 
(final concentration of 2fmol/μL).  Samples were then incubated for a further 10 minutes at room 
temperature before being loaded into a pre-run 5% polyacrylamide gel.  Gel was run for 45 
minutes at 100V, when the gels were removed from the gel tank and dried down using a gel dryer 
for 45 minutes.  Two CL-XPosure™ films were then exposed to the gels in light tight cassettes at -
80oC overnight.  The films were then developed using Carestream® Kodak® GBX developer and 
then fixed using Carestream® Kodak® GBX fixer. 
 
 
 Component Volume (mL)  
 40% acrylamide 3.125  
 10x Tris-Borate-EDTA (TBE) 1.250  
 Ultrapure water 20.600  
 MIX  
 10% ammonium persulfate (APS) 0.250  
 MIX  
 TEMED 0.025  
 TOTAL 25.00  
 
Table 2.2: Components for 5% polyacrylamide gels used in electrophoretic mobility shift assays. 
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2.2.5 Transfection with siRNA against ANRIL 
2.2.5.1 SaOS-2 
 SaOS-2 cells were plated out at 50,000 cells per well in 24-well culture plates, left for 
24hrs and then transfected with siRNA using Lipofectamine RNAiMax (Life Technologies) 
according to manufacturer’s instructions.  In brief, 23.5μL Opti-MEM and 1.5μL Lipofectamine 
RNAiMAX per well were added to an eppendorf and mixed by pipetting up and down.  Then 
23.5μL Opti-MEM and 0.5μL of 20μM siRNA per well were added (final concentration 10μM in 
well) and samples mixed by pipetting (master mix volumes shown in Table 2.4).  Eppendorfs were 
pulse spun to collect liquid and left to incubate at room temperature for 5 minutes.  50μL of 
transfection mixture then added to appropriate wells and cells left to incubate at 37oC in a 
humidified atmosphere with 5% CO2 for a further 72hrs. 
Cells were transfected with three siRNAs against different exons of ANRIL (n=12 for each 
siRNA; Table 2.5), a negative ‘scrambled’ control (n=12) and a positive cell death control (n=6) at 
10nM.  Some wells were also left untreated as a control (n=12).  After 72hrs untreated cells and 
cells treated with negative ‘scrambled’ control, positive control and ANRIL siRNAs were 
trypsinised and counted (n=6 for each treatment).  The remaining untreated, negative control and 
ANRIL siRNA wells (n=6 for each) were treated with TRI Reagent (Sigma-Aldrich) and RNA was 
extracted for RT-qPCR. 
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 Component Volume (μL)  
 Opti-MEM 23.50  
 Lipofectamine RNAiMAX 1.50  
 siRNA (10nM) 0.50  
 Opti-MEM (10nM) 24.50  
 TOTAL 50.00  
 
Table 2.4: Transfection master mix volumes for 24-well plate with 50,000 SaOS-2 cells seeding density.  
Volumes of siRNA added to master mix based on 20μM stock concentration. 
 
 Sequence (5’-3’) Target exon Designation 
Silencer Select against CDKN2B-
AS (n272158; #4390771) 
GAAAACAAGCGAAAUUAAAtt ANRIL exon 1 Ambion E1 
Custom Silencer Select designed 
by Congrains et al (237) 
GAAUGUCAGUUUUGAACUAtt ANRIL exon 1 
Congrains 
E1 
Custom Silencer Select designed 
by Congrains et al (237) 
GAACCAGGACUGGAACCUAtt ANRIL exon 19 
Congrains 
E19 
 
Table 2.5: siRNAs used in SaOS-2 transfections 
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2.2.5.2 hBMSCs and primary osteoblasts 
The siRNA transfection protocol was re-optimised in primary cells to ensure a high level of 
efficiency of transfection as both seeding density and treatment time have been shown to affect 
this.  These experiments determined that 30,000 seeding density for both hBMSCs and primary 
osteoblasts with a 6 hour treatment of siRNA were the optimal conditions to use (see Appendix, 
Section 9.1.1 for full summary of optimisation experiments). 
Before plating, media was removed from flasks and primary cells treated with 2% 
Collagenase Type IV (100mg Collagenase Type IV dissolved in 5mL plain MEMα supplemented 
with 25μL 1M CaCl2) for 30 minutes before trypsinisation with 0.05% trypsin/EDTA.  Primary cells 
then plated out in 24-well plates at 30,000 cells/well in either basal or osteogenic medium, 
incubated for 24hrs and then transfected with siRNA using Lipofectamine RNAiMAX as described 
in section 2.2.3.1).  Cells were treated with two siRNAs against ANRIL (Congrains E1 and Congrains 
E19; shown in Table 2.2; n=6 for each siRNA) as well as a negative ‘scrambled’ control (n=6) and a 
positive cell death control (n=2) at 10nM.  As with SaOS-2 transfections, some wells were also left 
untreated (n=2).  Master mix volumes were the same as shown in Table 2.4. 
Plates were incubated with siRNAs for 6hrs, after which media was replaced with fresh 
basal or osteogenic medium and then left to incubate for a further 66hrs in a humidified 
atmosphere at 37oC with 5% CO2.  Two wells of each treatment were then trypsinised, cells 
counted and then fixed for FACS analysis (described in Section 2.2.8), whereas the remaining 4 
wells for ‘scrambled’ control, Congrains E1 and Congrains E19 were treated with TRI Reagent and 
RNA extracted for RT-qPCR. 
 
2.2.6 Isolation of total RNA 
2.2.6.1 TRI Reagent 
Cells were trypsinised and pelleted before being homogenised with TRI Reagent (Sigma-
Aldrich) and incubated at room temperature for 5 minutes.  The homogenate was collected and 
200µL of chloroform added to each sample per 1mL of TRI Reagent used.  The samples were 
shaken for 15 seconds and incubated at room temperature for a further 10 minutes before 
centrifugation at 11,200 rpm for 15 minutes at 4oC.  This separated out the RNA from the DNA 
and protein fractions, and the top aqueous layer (containing RNA) was transferred to a clean tube.  
500µL of isopropanol per 1 mL TRI Reagent used was added to each sample and vortexed for 10 
seconds to precipitate out RNA before being transferred to -80oC overnight.  Samples were then 
incubated at room temperature for 10 minutes and then centrifuged at 11,200 rpm for 8 minutes 
at 4oC after which supernatant was removed and 1mL of 75% ethanol added per mL of TRI 
60 
 
Reagent.  Samples were centrifuged again for 5 minutes, then the ethanol removed and RNA 
pellets left to air dry for 10 minutes.  Pellets were then resuspended in 30-50µL of RNase-free 
water and heated to 55oC for 10 minutes. 
 
2.2.6.2 RNeasy kit 
 RNA was extracted from primary cells using RNeasy Micro Kit (Qiagen) as per 
manufacturer’s instructions.  In brief, media was aspirated from cells and cells lysed directly with 
350μL Buffer RLT (lysis buffer).  Lysate then homogenised by vortexing for 1 minute, after which 
an equal volume of 70% ethanol was added and samples mixed by pipetting.  Samples were 
transferred to RNeasy MinElute spin column and centrifuged for 15 seconds at 10,000rpm.  Flow-
through was discarded and 700μL of Buffer RW1 added to column to bind total RNA.  Column 
centrifuged for 15 seconds at 10,000rpm and flow-through discarded.  500μL Buffer RPE (wash 
buffer) added to the samples and then centrifuged once again for 15 seconds at 10,000rpm.  
Samples then centrifuged for 2 minutes at 10,000rpm after the addition of 500μL of 80% ethanol, 
after which, samples were dried by centrifuging for a further 5 minutes at 13,000rpm with lids 
open.  RNA was then eluted into 14μL of RNase-free water at 13,000rpm for 1 minute and 
quantified using the Nanodrop. 
 
2.2.7 Illumina Human H12 Gene Expression Array 
Osteoblast cRNA was normalised and hybridised onto Illumnia Human H12v4 expression 
beadChip arrays by a service provider Genome Centre, Barts and the London School of Medicine 
and Dentistry. Signal extraction was performed by the Genome Centre within GenomeStudioTM 
and AVG_Signal and Detection_Pvalue values were obtained for each of the 47,229 protests on 
the array. Only the 14,757 probes that achieved detection p_value <0.05 in all ten samples were 
retained for analysis. Paired t-tests were performed on AVG_Signal values to determine the 
probes varying by treatment within each cell line pair. 274 probes (mapping to 260 unique genes) 
were significantly differentially expressed with respect to treatment after multiple testing 
correction (FDR corrected pvalue < 0.05). HT12 arrays do not contain probes specific to ANRIL 
expression but do include probes within the CDKN2B locus, which also are predicted to hybridise 
to ANRIL (ILMN_1723198 and ILMN_2376723). Signal at these probes decreased in all cell lines 
after treatment. 
2.2.8 DNase I treatment 
DNase treatment was performed using a kit as per manufacturer’s instructions (Sigma-
Aldrich).  In brief, 1µg of RNA in 8µL of water is incubated with 1 µL of 10x Reaction buffer and 
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1µL of Amplification grade DNase I at room temperature for 15 minutes.  After this 1µL of Stop 
Solution was added to bind calcium ions and the solution then heated to 70oC for 10 minutes to 
denature the DNase I.   The RNA samples were then chilled on ice before reverse transcription. 
 
2.2.9 cDNA synthesis 
After DNase I treatment, 1µg RNA was incubated with 1µL 10mM dNTP mix and 1µL 
random nonamers (5μM), briefly centrifuged and incubated at 70oC for 10 minutes.  Eppendorfs 
were then placed on ice and 4µL 10x M-MLV Reverse Transcription buffer, 1µL M-MLV Reverse 
Transcriptase and 5µL RNase-free water (Promega) are then added to each sample.  After this, 
samples were incubated at room temperature for 10 minutes, then at 37oC for 50 minutes.  
Samples were then incubated at 95oC for 10 minutes to denature the enzyme.  cDNA was then 
diluted to 25ng/µL and stored at -20oC. 
 
2.2.10 Real time quantitative polymerase chain reaction (RT-qPCR) 
2.2.10.1 GeNorm assay 
 To determine the best housekeeping gene to use for RT-qPCR analysis we used a GeNorm 
assay kit (Primer Design).  In brief, RT-qPCR assays for 13 of the most commonly used 
housekeeping genes were run on 10 samples each of SaOS-2, hBMSC and primary osteoblast 
cDNA.  The housekeeping genes that were analysed were 18S, ACTB, ATP5B, B2M, CYC1, EIF4A2, 
GAPDH, RPL13A, SDHA, TOP1, UBC, YWHAZ and PPIA.  For each 10μL reaction, 0.5μL primers 
(working concentration of 300μM), 5μL SYBR Green master mix, 0.5μL RNase free water and 25ng 
cDNA were added to 384-well plates and went through 50 cycles of 95oC for 10 minutes, 95oC for 
15 seconds and 60oC for 60 seconds, at which point data was collected.  Melt curve was also run 
to determine if any primer dimers were present.  Analysis of RT-qPCR results identified 60S 
ribosomal protein L13a (RPL13A) as the best candidate to use as a housekeeping gene for each of 
the three different cell types.  
 
2.2.10.2 TaqMan assays 
Expression levels of ANRIL were determined through use of TaqMan assays from Applied 
Biosystems (Life Technologies Ltd).  The two assays contained primers for ANRIL transcripts 
containing exons 1 and 2 (Hs04259476_m1) and exons 5 and 6 (Hs01390879_m1).  Primers and 
probe for exons 18 and 19 were taken from Burd et al (238) and were supplied by Eurofins.  The 
primers and probe for exons 18 and 19 were diluted to 100µM upon arrival and stored at -20oC.  
Positions for each RT-qPCR assay relative to ANRIL transcript exons are shown in Figure 2.3 and 
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RT-qPCR primer and probe information for custom exon 18-19 assay is shown in Table 2.6.  
Remainder of TaqMan assays used are shown in Materials. 
 
 
 
 
Figure 2.3: Diagram of positions of (A) exon 1-2 RT-qPCR assay, (B) exon 5-6 RT-qPCR assay and (C) exon 18-
19 RT-qPCR assay in relation to exons of ANRIL transcript. Diagram not to scale. 
 
 
For each sample 100ng cDNA, 1µL 20x TaqMan Gene Expression Assay, 10µL 2x TaqMan 
Gene Expression Master Mix and 5µL RNase-free water was used, giving a reaction volume of 
20µL for each set up. Primers and probes from Eurofins were diluted to 18μM and 5μM 
respectively and 1μL used per reaction.  Each sample was measured in triplicate on a 96-well plate 
using the Step One Plus PCR machine (Applied Biosystems), with three negative template controls 
(NTCs) on each plate, where the cDNA was replaced with RNase free water.   
Cycling conditions were: UNG incubation step of 50oC for 2 minutes, polymerase 
activation step of 95oC for 10 mins then 40 cycles of 95oC for 15 seconds and annealing/extension 
at 60oC for 1 minute.  For each assay the standard curve method (100ng-0.78ng) was used to 
measure gene expression.  All assays were normalised to RPL13A.  All real time assays had 
previously been optimised either experimentally or commercially. 
 
Primer Name Primer Sequence (5’ → 3’) Location 
ANRIL 18F AATGAGGCTGAGAGCATGGGAGATAC ANRIL Exon 18 (238) 
ANRIL 19R GAGATATAGGTTCCAGTCCTGGTTCTG ANRIL Exon 19 (238) 
ANRIL 18/19 probe 
/5HEX/TGTGTGTTTCCTTGTGAGCTACTGCA/
3BHQ_2/ 
ANRIL 18/19 exon 
boundary (238) 
Table 2.6: Custom real-time PCR primer and probe sequences 
 
2.2.11 Fluorescence-activated cell sorting (FACS) 
At 72hrs after transfection SaOS-2 cells were harvested for FACS analysis.  Medium was 
aspirated into a FACS tube and cells were washed once with 1x PBS.  This was then also aspirated 
in to the FACS tube and 0.25% trypsin EDTA added to each well.  SaOS-2 cells were incubated at 
37oC until cells had detached from plate when FBS added to each well to inactive the trypsin 
EDTA.  Cells were collected into the FACS tube and all tubes spun at 1000rpm for 5 minutes.  
Media then poured off, cells resuspended in 1mL 1x PBS and pelleted again at 1000rpm for 5 
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minutes.  After 1x PBS poured off the SaOS-2 cells were resuspended in 300μL ice cold 1x PBS and 
then fixed by drop pipetting 700μL 100% ice cold ethanol into the FACS tube whilst vortexing.  
Cells were then stored at 4oC for at least 2hrs, after which they were resuspended and spun for 5 
minutes at 1000rpm.  Ethanol was then aspirated and cell pellet resuspended in 1mL 1x PBS 
before being spun at 1000rpm for 5 minutes.  200μL propidium iodide staining mixture was made 
up for each sample containing 189μL 1x PBS, 10μL 20x propidium iodide and 1μL 200x RNase A.  
Once the PBS wash has been aspirated, cells were resuspended in 200μL of the propidium staining 
mixture and incubated at 37oC in the dark for 30 minutes.  After the incubation, tubes were 
placed on ice and then analysed on the flow cytometer. 
5000 events were measured for forward and side scatter on FACScalibur® flow cytometer 
(Applied Biosystems) with the FL2 channel (258nm λ) and analysed using Cellquest™ software 
(Applied Biosystems).  The number of cells in each stage of the cell cycle was analysed by selecting 
for live and dead cells and by setting markers to outline each stage of the cell cycle.  The 
percentage of gated cells in each phase was then plotted on a graph.  Figure 2.4 shows the 
different areas that were measured for each phase of the cell cycle. 
 
 
Figure 2.4: Scheme of flow cytometry scan showing the different areas measured for each phase of the cell 
cycle, which are then converted into graph form 
 
 
2.2.12 Measuring methylation levels of MAVIDOS umbilical cord 
2.2.12.2 Isolation of genomic DNA from umbilical cord tissue 
 DNA was isolated from umbilical cords which were collected as part of the MAVIDOS 
study.  Umbilical cords were frozen within 24hrs of collection and stored at -80oC long term.  
Samples were crushed, in the presence of liquid nitrogen, using metal pestle and mortar that had 
been cooled, and were not allowed to thaw during the crushing process. 
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500mg of crushed umbilical was measured into a gentleMACSTM homogenisation tube 
(Miltenyi Biotec) and 500μL of hyaluronidase solution (0.0125mg/mL) was added to the sample.  
Samples were centrifuged to 1000 rpm to ensure all tissue was fully immersed in hyaluronidase 
solution and then incubated for 30 minutes at 37oC with shaking (150rpm).  After incubation, 
500μL of TNES (50mM Tris, 400mM NaCl, 100mM EDTA, 0.5% SDS) was added to each sample and 
tapped to ensure mixing before homogenisation for 30 seconds on Xiril Dispomix Homogeniser.  
Samples were then pulse spun before the addition of 5μL of Proteinase K (20mg/mL), after which 
the umbilical cord was incubated overnight at 55oC. 
 After complete digestion of umbilical cord tissue, lysate was transferred into tubes, 500μL 
of 2.6M NaCl was added and samples were shaken vigorously for 15 seconds before being spun at 
12,000 rpm for 20 minutes at room temperature.  After centrifugation, the supernatant was 
transferred to a new tube and equal volume of ice cold 100% ethanol then added to each sample.  
Tubes were inverted to precipitate out DNA, which was then spooled, using a glass pipette, into 
500μL of sterile water containing 5μL RNase A (10mg/mL).  Care was taken to ensure excess 
ethanol was not transferred with the DNA.  Samples were incubated at 37oC for at least 1 hour to 
ensure DNA had gone into solution, after which 500μL phenol/chloroform (50:50) was added to 
each sample.  Samples were shaken and then centrifuged at 12,000 rpm for 5 minutes at room 
temperature.  Supernatant (~400μL) was then transferred into a new tube and 400μL 
phenol/chloroform was added.  Tubes were once again shaken and spun for 5 minutes at 12,000 
rpm, after which supernatant (~300μL) was transferred into a fresh tube.  Two volumes of ice cold 
100% ethanol (600μL) and 30μL NaAc (3M, pH5.2) were then added to supernatant, tubes 
inverted to precipitate DNA and DNA then spooled into DNAse and RNAse free water.  DNA was 
then quantified on Nanodrop 1000 and 250ng of DNA run on 0.8% agarose gel to check quality of 
extracted genomic DNA (Figure 2.5).  All samples had a 260/280 ratio between 1.4 and 1.8 and all 
samples had yields between 10μg and 124μg.  Any samples less than 40ng/μL were concentrated 
to allow for 1μg of DNA to be bisulphite converted.  All samples were stored at -20oC. 
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Figure 2.5:  Example of MAVIDOS umbilical cord DNA run out on an agarose gel.  250ng of seven random 
MAVIDOS umbilical cord DNA samples run on a 0.8% agarose gel at 120V for 30 minutes.  Samples were run 
to determine if DNA was of a good enough quality for bisulphite conversion. 
 
 
 
Figure 2.6: Example of pyrosequencing PCR product run on a 1.5% agarose gel at 120V for 20 minutes.  
5μL of each sample was run on the gel. Seven random MAVIDOS umbilical cord PCR samples were run 
alongside the five control samples (Promega 1-3, 0% methylated DNA and 100% methylated DNA).  Both 
NTCs were run to confirm that they hadn’t been contaminated with DNA, and therefore the bands that are 
seen in the sample lanes are due to the amplification of the samples of interest, not foreign DNA. 
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2.2.12.3 Bisulphite conversion of genomic DNA 
 1μg of genomic DNA was bisulphite converted using the EZ DNA Methylation-GoldTM kit 
(Cambridge Biosciences) according to manufacturer’s instructions.  In brief, Each sample was 
eluted in 30μL of DNase and RNase free water.  Each plate of MAVIDOS samples also contained 
controls to allow for inter and intra plate validation.  Controls included unmethylated DNA 
(Qiagen), 100% methylated DNA (Merck Millipore), human genomic DNA (Promega) that was run 
in triplicate and no template controls run in duplicate, where DNA was replaced with 20μL water. 
 
2.2.12.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction was used to amplify MAVIDOS bisulphite converted DNA for 
each of the regions of interest within different genes.  The forward and reverse primers used for 
each PCR are shown in Table 2.7.  4μL of bisulphite converted DNA was added to a master mix 
containing the components shown in Table 2.6 to make up a 50μL reaction.  Samples were then 
amplified using the conditions detailed in Table 2.7.  The specific temperatures used for the PCR 
reaction for each gene are shown in Table 2.8.  To confirm the product size and DNA 
amplification, 5μL of each of the controls and a random selection of seven MAVIDOS samples 
were run on a 1.5% agarose gel at 120V for 20 minutes (Figure 2.6). 
 
 
Component Volume (μL)  
95oC 5 minutes 
95oC 30 seconds 
45-60oC 30 seconds 
72oC 1 minute 
72oC 10 minutes 
4oC ‎∞ 
45 cycles 
 
10x Qiagen Buffer 5.00  
dNTPs (10mM) 1.00  
Forward Primer (10μM) 1.00  
Reverse Primer (10μM) 1.00  
Qiagen HotStar Taq (5ng/μL) 0.25  
RNase-free water 37.75  
DNA (50ng total) 4.00  
TOTAL 50.00  
 
Table 2.7: Components and conditions used for pyrosequencing PCR 
 
 
 
 
67 
 
 
 
 
P
ro
d
u
ct
 s
iz
e 
(b
p
) 
1
5
4
 
2
3
6
 
1
3
9
 
1
9
4
 
2
7
4
 
1
7
6
 
Ta
b
le
 2
.8
: 
P
C
R
 f
o
rw
ar
d
 a
n
d
 r
ev
er
se
 p
ri
m
er
s 
fo
r 
p
yr
o
se
q
u
en
ci
n
g 
A
n
n
ea
lin
g 
 
Te
m
p
er
at
u
re
 
o
C
 
5
7
.6
 
5
7
.6
 
6
0
.0
 
6
0
.0
 
6
0
.0
 
6
0
.0
 
B
io
ti
n
 t
ag
? 
R
ev
er
se
 
R
ev
er
se
 
R
ev
er
se
 
Fo
rw
ar
d
 
R
ev
er
se
 
Fo
rw
ar
d
 
R
e
ve
rs
e
 P
ri
m
e
r 
(3
’-
5
’)
 
TA
TC
TC
A
C
C
A
A
TC
C
TC
C
A
C
TC
TC
C
TA
A
A
 
A
A
A
A
A
C
C
C
A
TT
TC
C
C
TA
TT
A
A
C
TA
C
A
 
A
A
C
A
C
A
A
A
A
A
C
TA
A
A
TA
TA
A
A
C
C
C
A
A
A
TC
T 
C
C
C
A
C
TA
TT
A
A
A
A
A
A
TA
A
C
C
TC
A
A
A
C
A
C
TT
 
C
C
A
A
C
C
A
A
A
A
A
A
C
TC
A
A
A
C
A
A
C
TT
 
A
C
A
A
A
C
C
C
C
TA
C
C
A
C
TA
C
C
A
A
A
A
T 
Fo
rw
ar
d
 P
ri
m
e
r 
(5
’-
3
’)
 
A
G
TA
G
G
A
A
A
G
G
TG
TA
TT
TT
A
A
G
TA
TA
TT
T 
TG
G
G
G
A
G
A
A
TT
A
TT
G
TT
A
A
TT
A
TT
TA
A
G
TT
 
TG
G
G
A
A
G
G
TT
G
A
A
G
G
TT
TT
A
G
A
A
 
TG
G
G
A
TT
A
TT
G
G
TT
TT
TG
A
G
TT
A
G
G
T 
TT
TT
A
G
G
G
A
TA
A
G
G
A
G
TG
A
G
A
TG
G
 
G
G
G
A
G
TT
TT
TT
A
G
TT
G
G
G
G
A
G
TA
G
 
A
ss
ay
 N
am
e 
C
D
K
N
2
A
 
C
p
G
 -
7
69
 t
o
 -
7
96
 
C
D
K
N
2
A
 
C
p
G
 -
8
3
6
 t
o
 -
9
07
 
R
X
R
A
 
C
p
G
 -
2
68
6
 t
o
 -
26
42
 
R
X
R
A
 
C
p
G
 -
2
40
6
 t
o
 -
23
57
 
R
X
R
A
 
C
p
G
 -
2
35
7
 t
o
 -
23
46
 
N
O
S3
 
C
p
G
 -
3
43
4
 
68 
 
2.2.12.5 Pyrosequencing 
The methylation of individual CpG sites was determined by pyrosequencing.  10μL of each 
PCR product was aliquoted into a fresh 96-well plate and immobilised using a binding master mix 
containing 38μL binding buffer (Qiagen), 2μL sepharose streptavidin beads (Fisher Scientific) and 
30μL ultrapure water per sample.  Plates were sealed and after 5 minutes on a plate shaker, 
samples were washed, denatured and released into annealing buffer (Qiagen) containing the 
appropriate sequencing primer at 10μM (Table 2.9).  Pyrosequencing was carried out using 
PyroMark Gold Q96 Reagents (Qiagen) on a PyroMark Q96 MD Pyrosequencer (Qiagen).  The 
percentage methylation was calculated using PyroMark CpG software 1.0.11 (Qiagen). 
 
Assay Name Sequencing Primer (5’-3’) Direction 
Sample 
Pass Rate 
CDKN2A 
CpG -769 to -796 
AGAATTATTGTTAATTATTTAAGTT Forward 87% 
CDKN2A 
CpG -836 to -861 
TAGGAGAGTGGAGGA Forward 81% 
CDKN2A 
CpG -887 to -907 
GTAGGTAGAGATTTTTTGAAATGT Forward 92% 
RXRA 
CpG -2686 to -2673 
GTTATTTTTTGTTTTAGAGAT Forward 81% 
RXRA 
CpG -2649 and -2642 
AGAAGGGTTTTTTGTTTTTAA Forward 99% 
RXRA 
CpG -2406 to -2385 
CCCAACCTTCCCACC Reverse 99% 
RXRA 
CpG -2357 
CCTACTACTCCTTCTCT Reverse 99% 
RXRA 
CpG -2357 to -2346 
GTTGTTTTTTTTTTTTGTAG Forward 65% 
NOS3 
CpG -3434 
ATCTTAAATTTCCAAATCAC Reverse 99% 
Table 2.9:  Sequencing primers for pyrosequencing 
 
2.2.13 Statistical analysis 
2.2.13.1 Statistical analysis of siRNA transfected cells 
 Statistical analyses were performed using IBM SPSS Statistics version 22.0.  An 
independent t-test was used to determine if there were statistically significant differences 
between the means of each of the siRNA transfected cells and the ‘scrambled’ control. 
 
2.2.13.2 Statistical analysis of MAVIDOS cohort 
Statistical analyses were performed using IBM SPSS Statistics version 22.0.  Where 
appropriate, the data was transformed when the methylation or phenotypic outcomes were not 
normally distributed.  The methylation of each CpG loci was the independent variable and the 
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phenotypic outcome was the dependent variable when determining the association between 
methylation of each CpG and total BMC, total BA, total BMD and total prentice BMC at birth.  The 
statistical model was corrected for gestational age, sex and age at time of DXA when using linear 
regression. 
 When determining if there were statistically significant differences between the mean 
methylation of the placebo and vitamin D supplemented groups, a Mann-Whitney U test was 
used in the case of CDKN2A as all methylation measurements were not normally distributed.  In 
the case of RXRA, where appropriate, methylation data was transformed so that it was normally 
distributed and an in independent t-test was used to determine if there were statistical 
differences between the mean methylation across the two groups. 
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Chapter 3 
Identification of CDKN2A as a Predictive 
Marker of Bone Mineral Density
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3.1 Introduction 
Recent methylation association studies by Harvey et al (205,234) have shown that 
methylation of specific CpG loci in umbilical cord DNA at birth is predictive of BMC outcomes in 
later childhood.  They found that percentage methylation of 2 CpGs in the NOS3 promoter in 
umbilical cord had a significant positive association with offspring whole-body BA, BMC and aBMD 
at nine years of age (234), while there was a significant negative association between the 
methylation of 4 CpG sites within the promoter of RXRA in umbilical cord and bone mineral 
content at 4 years of age (205). 
To identify further methylation differences at birth which are associated with bone 
outcomes in childhood, a discovery MDB-array was performed on umbilical cord DNA samples 
from 21 subjects from the SWS cohort, who were selected as they represented a range of bone 
mineral contents at 6 years of age (Garratt, unpublished data). This identified a significant 
association between the methylation of a 300bp region within the CDKN2A gene locus at birth 
and offspring bone outcomes at 6 years (Section 1.5).  These associations were then validated by 
pyrosequencing in a larger subset of SWS subjects (n=292), where a significant negative 
association was observed between the methylation of the nine CpG loci within the 300bp 
differentially methylated region (DMR) of CDKN2A at birth and offspring BA, BMC and aBMD at 
both 4 and 6 years of age, consistent with the findings from the MBD array. 
 
3.1.1 CDKN2A gene locus 
This CDKN2A gene locus, which covers 35kb, is found on chromosome 9p21 and encodes 
for two cell cycle inhibitors – p16INK4A and p14ARF, both of which have been shown to have a role in 
cellular senescence (239). CDKN2A also produces an anti-sense transcript, a long non-coding RNA 
called ANRIL (antisense non-coding RNA in the INK4 locus), the function of which has not been 
fully elucidated.  p16INK4A binds to CDK4 and 6 and blocks cell cycle progression by preventing the 
phosphorylation of Rb, causing G1 arrest (240).  p14
ARF, which shares the same exon 3 as p16INK4A, 
binds to murine double minute-2 (MDM2) protein to inactivate it (241).  MDM2 is a p53 negative 
regulator encoded by p53-responsive gene and this inactivation triggers a p53-dependent 
programme that can lead to either G1 phase arrest or apoptosis.  Inactivation of this protein also 
prevents p53 turnover as E3 ubiquitinase activity of MDM2 is also inhibited.  Downstream to the 
CDKN2A locus is CDKN2B, which encodes for p15INK4B, a cyclin dependent kinase (CDK) inhibitor 
that prevents cell cycle progression by binding to CDK 4 and 6.  ANRIL has been shown to suppress 
both p16INK4A and p15INK4B expression by either acting as a scaffold for the recruitment of 
Polycomb repressive complexes (PRC) 1 and 2 (242,243) or by functioning as an antisense 
transcript repressing p15INK2B expression.  Figure 3.1 shows a diagrammatic representation of the 
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CDKN2A/B locus and the 300bp DMR containing the 9 CpGs in yellow, with Table 3.1 showing the 
position of each CpG relative to the CDKN2A transcription start site (TSS). 
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Table 3.1: The 9 CpGs in the differentially methylated region (DMR) of the CDKN2A locus and their positions 
relative to the ANRIL transcription start site (TSS). 
 
The CDKN2A locus, and its products p16INK4A and p14ARF, play a key role in cellular 
senescence and aging (244).  p16INK4A expression significantly increases in many tissues with aging.  
This observation was first noted by Sherr and colleagues in 1997 (245) and was later confirmed by 
several independent groups (245–247).  It has since led to the proposal by Krishnamurthy et al 
that expression of p16INK4A could be used as a biomarker for aging (239).  There have been various 
animal studies looking at the decline in replicative potential of self-renewing cells that show both 
an age-related increase in p16INK4A expression and that cell proliferation seems to be CDK4/6 
dependent (246,248,249).  These studies suggest that p16INK4A promotes aging by decreasing 
proliferation potential and self-renewal, causing the cells to become senescent.  However, 
p16INK4A deficiency only partially diminished the age-induced decrease in proliferation but did not 
completely remove the effects of aging suggesting that other proteins may also have a role in 
cellular aging and senescence. 
Recent GWAS have demonstrated that the CDKN2A/B locus is a hotspot for disease-
associated polymorphisms, with the majority of the SNPs locating to the gene that encodes ANRIL, 
CDKN2B-AS.  SNPs within this gene have been linked to frailty (250), T2D (251), Alzheimer’s 
disease (252) and CVD, with the SNP associated with CVD being highlighted as the strongest 
susceptibility locus for this disease (251). 
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3.2 Aims 
Given the associations between CDKN2A DMR methylation at birth and measures of bone 
mineral content and density in later childhood, the aim of this chapter was to investigate the 
functional relevance of differential DMR methylation within the CDKN2A locus by i) determining 
the effect of mutagenesis of each of the CpG sites within the DMR on ANRIL and p14ARF expression 
through luciferase reporter constructs, ii) determining, through the use of electrophoretic 
mobility shift assays, if proteins bind to this region within an osteoblast-like cell line, iii) 
establishing whether CpG methylation alters protein binding to specific loci within the DMR and 
iv) elucidating what proteins bind to this region. 
77 
 
3.3 Results 
3.3.1 Does the DMR control CDKN2A expression? 
 As the DMR identified within the CDKN2A gene is located 922bp upstream of the ANRIL 
transcription start site and within the first intron of p14ARF, the role that the CpG sequences within 
the DMR play in the regulation of ANRIL and p14ARF expression was investigated.  The role of these 
CpGs on p16INK2A was not investigated, as the CDKN2A DMR is located >16,000bp upstream from 
the transcription start site of this trasnscript.  To test this, the promoter region of ANRIL (-1281bp 
to +20bp relative to TSS) and the 5’ region of the p14ARF gene (-500bp to +1125bp relative to TSS) 
were fused to the firefly luciferase reporter gene in the pGL3-Basic vector, and each of the 
individual CpG sites within the DMR were mutated, before co-transfection into the human 
osteosarcoma cell line, SaOS-2 cells.  Mutated plasmids were transfected along with a control pGL 
CMV Renilla plasmid.  The level of firefly luciferase activity was normalised to the Renilla 
luciferase activity to remove any variability between samples caused by pipetting error, 
differences in transfection efficiencies and difference in cell number. 
The mutation of the individual CpG sites led to a decrease in ANRIL promoter activity 
(p<0.022 for all CpGs), apart from CpGs -769 and -907, where no significant change in the ANRIL 
promoter activity was seen (Figure 3.2A).  With regards to p14ARF promoter activity, mutation of 
CpGs -793, -796 and -845 caused a significant decrease in activity (p<0.0072 for all) when 
compared to the control, whereas mutation of CpG sites -852, -861, -887 and -907 led to increase 
in promoter activity (p<0.035 for all) (Figure 3.2B).  The mutation of CpGs -769 and -836 did not 
cause a significant change in p14ARF promoter activity when compared to control. 
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Figure 3.2: Promoter activity of ANRIL (A) and p14
ARF
 (B) relative to normal promoter activity when 
individual CpG sites within the DMR are mutated. (A) Mutation of all CpG sites, apart from CpGs -769 and -
907 cause a significant decrease in ANRIL promoter activity when compared to control. (B) p14
ARF
 promoter 
activity significantly decreases when CpGs -793, -796 and -845 are mutated and increases when CpGs -852 
to -907 are mutated within the DMR. Mutation of CpGs -769 and -836 do not cause a significant change in 
p14
ARF
 promoter activity. (****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05) (n=2) 
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3.3.2 Is there specific binding to the CpGs within the CDKN2A DMR in bone cells? 
 Having shown that a number of the CpG sites within the DMR are important in the 
regulation of ANRIL and/or p14ARF promoter activity, electrophoretic mobility shift assays (EMSAs) 
were then used to determine what transcription factors bound to this sequence in SaOS-2 cells 
and whether this binding was affected by methylation.  Moreover, in order to look at tissue 
specific differences in binding across the DMR, we also compared protein binding in the 
liposarcoma cell line SW-872, an adipose derived cell line.  Nuclear extracts from SaOS-2 cells 
were incubated with five P-32 radiolabelled double-stranded oligonucleotide probes.  The five 
probes, approximately 40bp in length, covered CpG -769, CpGs -793 and -796, CpGs -836 to -861, 
CpGs -887 and -907 and CpG -907 respectively (see Figure 3.3 for sequences covered by individual 
probes).  Binding to this region was analysed across five probes as binding to larger DNA 
fragments makes the identification of individual protein complexes much harder to detect and 
distinguish.  Results described below were consistent across three independent experiments. 
 
 
 
 
Figure 3.3: Location of EMSA probes on DMR sequence within CDKN2A locus.  Probe sequences are 
underlined.  Sequence that has a double underline is where the probes containing CpGs -887 and -907 
and CpG -907 only overlap. 
 
 Specific protein binding was observed to two of the five of the oligonucleotide probes in 
SaOS-2 cells.  There were three protein complexes bound to the oligonucleotide probe containing 
CpG -769 (Figure 3.3A), which were bound out by the addition of a 500-fold excess of an 
unlabelled specific competitor probe.  Complex 1 and 4 bound very strongly, while complex 3 
showed much weaker binding.  One protein complex was also observed binding to the 
oligonucleotide probe containing CpGs -887 and -907 (Figure 3.3D), which was competed out by 
the addition of an excess of specific competitor.  Protein binding to the oligonucleotide probes 
containing CpGs -793 to -796 (Figure 3.3B), CpGs -836 to -861 (Figure 3.3C) and CpG -907 (Figure 
3.3E) was also observed, although this binding was not competed out by a 500-fold excess of 
specific competitor, suggesting that the binding is non-specific. 
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 There were also cell type specific differences in the binding across the different probes in 
the osteosarcoma cell line compared to SW872, a liposarcoma cell line.  Three protein complexes 
were seen binding to the probe containing CpG -769 in both SaOS-2 and SW-872 cells, however 
although the 2 fastest migrating complexes were common to SaOS-2 and SW-872 cells, the 
slowest migrating complexes were unique to the specific cell type (Figure 3.3A). 
 One protein complex specific to liposarcoma cells was seen binding across CpGs -793 to -
796, which was competed out by an excess of specific competitor.  A faster migrating protein 
complex was seen in both SaOS-2 and SW-872 cells but this was not competed out by the addition 
of a specific competitor in either cell type (Figure 3.3B).  Three specific protein complexes bound 
to the probe containing CpGs -836 to -861 in liposarcoma cells (Figure 3.3C), whereas no bands of 
equivalent mobility were seen in SaOS-2 cells.  A lower band was observed in both SaOS-2 and 
SW-872 cells but a specific competitor in either cell line did not compete this band out.  In 
contrast, a similar size complex was seen binding to the probes containing CpGs -887 and -907, or 
CpG -907 alone (Figures 3.3D and E respectively), in both liposarcoma and osteosarcoma cells, 
although binding to the probe containing just CpG -907 was extremely weak suggesting a weaker 
interaction between the probe and the protein complex when the CpG site -887 is absent. 
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3.3.3 Does the methylation of CpGs -887 and -907 in the CDKN2A DMR alter the binding of 
transcription factors? 
 As strong binding to CpGs -887 and -907 was observed and these CpGs were previously 
shown to be strongly associated with bone mineral content (unpublished data), EMSAs were then 
used to determine whether differential methylation of these CpGs altered transcription factor 
binding to this sequence within SaOS-2 cells. 
Firstly, the unmethylated radiolabelled probe was incubated with osteosarcoma nuclear 
extract along with 100-, 250- or 500-fold excess of either the unmethylated or methylated 
unlabelled specific competitor, where both cytosines within the CpGs at -887 and -907 were 
methylated.  Binding to the unmethylated radiolabelled probe was reduced in the presence of 
both 250-fold and 500-fold excess of unlabelled unmethylated specific competitor (Figure 3.4A) 
but not in the presence of 100-fold excess unmethylated specific competitor.  In contrast, binding 
to the radiolabelled probe was not reduced in the presence of 100- or 250-fold excess of 
unlabelled methylated specific competitor, binding was only effectively competed out with a 500-
fold excess of unlabelled methylated competitor. 
 Reciprocal EMSAs were also run using radiolabelled methylated probe to confirm whether 
there is preferential binding to unmethylated DNA over methylated DNA.  Consistent with the 
previous results, binding to the methylated sequence was effectively competed out in the 
presence of 250- and 500-fold excess of unmethylated specific competitor, however, with 
methylated specific competitor, only 500-fold excess of unlabelled probe was able to reduce 
binding (Figure 3.4B). 
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Figure 3.5: Testing the preference of protein binding to unmethylated and methylated radiolabelled CpG -
887 and -907 (n=3).  Osteosarcoma nuclear extract was incubated with unmethylated (A) or methylated (B) 
radiolabelled probe specific for CpGs -887 and -907 and three different concentrations of unmethylated and 
methylated specific competitor.  The retarded DNA-protein complexes and the remaining free probe are 
indicated by the arrows.  This complex (lane 2) was then competed out by unlabelled unmethylated probe 
at 100x (lane 3), 250x (lane 4) and 500x excess (lane 5) and methylated competitor also at 100x (lane 6), 
250x (lane 7) and 500x excess (lane 8).  Radiolabelled probe was also run on its own to confirm probe was 
not contaminated with protein, i.e. no band present (lane 1). 
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To confirm that both unmethylated and methylated sequences were binding the same protein 
complex, EMSAs containing the methylated and unmethylated probes were run alongside each 
other.  Results demonstrate that upon incubation of osteosarcoma extract with methylated and 
unmethylated radiolabelled probe (Figure 3.5) a retarded DNA-protein complex of similar mobility 
was seen.   
 
Figure 3.6: Both the unmethylated and the methylated radiolabelled CpGs -887 and -907 probes bind 
to the same protein complex (n=3). Osteosarcoma nuclear extract was incubated with an unmethylated 
(lane 2) or a methylated (lane 3) radiolabelled probe specific for CpGs -887 and -907. The retarded DNA-
protein complexes and the remaining free probe are indicated by the arrows.  Radiolabelled probe was 
also run on its own to confirm probe was not contaminated with protein (lane 1). 
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3.3.4 What transcription factors bind to CpGs -887 and -907? 
 Multiplexed competitor EMSAs (253) were used to investigate what transcription factors 
bind across CpGs -887 and -907 within the CDKN2A DMR in the osteosarcoma cell line SaOS-2.  
SaOS-2 nuclear extract was incubated with the unmethylated probe containing CpGs -887 and -
907 along with a 500-fold excess of eight ‘cocktails’, each of which contained ten or eleven 
unlabelled oligonucleotides for different transcription factor binding site consensus sequences. 
Figure 3.6 shows that binding to the unmethylated radiolabelled probe containing CpGs -
887 and -907 is reduced in the presence of three of the transcription factor cocktails, namely 
cocktails 2, 5 and 8. This was consistent across three independent experiments. 
Table 3.2 lists the transcription factor consensus sequences in each of these three 
cocktails. 
 
 
 
Figure 3.7: Transcription factor competition with radiolabelled unmethylated CpGs -887 and -907 
probe (n=3).  Cocktails containing 500-fold excess of different transcription factor consensus sequences 
were incubated with CpG -887 and -907 probe and SaOS-2 extract. 
86 
 
  
  
TRANSCRIPTION FACTOR COCKTAILS 
Cocktail 1 Cocktail 2 Cocktail 3 Cocktail 4 
AP1 E2F1 HIF1a NFATc 
AP2a Egr Sox2 NFkB 
AR ER HNF4 NR5A2 
Brn3 Ets IRF1 OCT1 
CBP Ets1 MEF1 p53 
CDP FAST1 MEF2 Pax5 
CEBP GAS MIBP1 Pbx1 
cMyb GATA MycMax Pit1 
CREB Gfi1 NF1 PPAR 
CTCF GR NFE2 PR 
Cocktail 5 Cocktail 6 Cocktail 7 Cocktail 8 
RAR Stat4 VDR NRF1 
RXR Stat5 YY1 PAX3 
SIE Stat5/6 ZEB Mash1 
Smad Tbet HNF1 Maf 
Smad3/4 TFE3 ARP1 MyoD 
Smuc TFEB NFY Oct4 
Sp1 TFIID HNF3 GABPA 
SRE TGIF BARP NR4a2 
Stat1 TR SREBP1 TCF4 
Stat3 USF1 HSF1 Zic 
   Sox2 
Table 3.2: List of transcription factor consensus sequences that are present in their respective cocktail. 
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To determine which specific transcription factor may be binding to the CpG -887 and -907 
unmethylated probe, osteosarcoma extract was incubated with 500-fold excess of each of the 
individual transcription factor consensus sequences from cocktails 2, 5 and 8.  As shown in Figure 
3.7 addition of a 500-fold excess of the gamma activated site (GAS) and Smad3/4 consensus 
binding sequence effectively reduced binding to this sequence. 
Consensus sequences for the gamma activated site (GAS) and the binding site of the 
Smad3/4 complex are shown in Table 3.3.  There are some similarities between the CpG -887 and 
-907 containing probe and both the consensus sequences. 
 
 
  
 
 
  
Sequence 5’-3’ 
CpG -887 and -907 probe CTAACAAGGATCGTAGGATCAGTTACTGCTGCGAG 
GAS AAGTACTTTCAGTTTCATATTACTCTA 
CpG -887 and -907 probe CTAACAAGGATCGTAGGATCAGTTACTGCTGCGAG 
Smad3/4 TCGAGAGCCAGACAAAAAGCCAGACATTTAGCCAGACAC 
Table 3.3: CpG -887 and -907 probe, GAS and Smad3/4 consensus sequences. CpG sites are 
highlighted in red and bold.  Core binding sequences for GAS and Smad3/4 complex are 
underlined.  The sequence similarities between the CpG -887 and -907 probe and GAS consensus 
sequence are highlighted in blue and the sequence similarities between the CpG -887 and -907 
probe and Smad3/4 consensus sequence are highlighted in purple. 
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3.4 Discussion 
 As the DMR associated with the CDKN2A gene locus was found within intron 1 of p14ARF 
and 922bp upstream of the ANRIL transcription start site, we investigated whether the CpGs 
within this 300bp region were important for the regulation of p14ARF and/or ANRIL expression in 
the osteosarcoma cell line SaOS-2.  Interestingly mutagenesis of the individual CpGs within the 
DMR had different effects on ANRIL and p14ARF promoter activity.  Mutation of CpGs -793 to -887 
within the ANRIL construct led to a decrease in promoter activity, however, mutation of CpG -763 
and -907 had no effect, suggesting that the CpG sites within the DMR may be differentially 
regulated but that seven of the nine CpG sites within the DMR are important in regulating the 
level of ANRIL promoter activity.  Mutation of the CpGs within the p14ARF construct had a range of 
effects; when CpGs -793, -796 and -845 are mutated within this region this caused a decrease in 
p14ARF promoter activity, whereas the mutation of CpGs -852, -861, -887 and -907 caused a 
significant increase is promoter activity.    The different effect of CpG mutagenesis on p14ARF and 
ANRIL promoter activity might reflect the different genomic context of the DMR with regards to 
the TSS of ANRIL and p14ARF, as the DMR lies within the promoter of ANRIL but within the first 
intron of p14ARF.  The finding that CpG mutagenesis within the DMR which lies downstream of the 
TSS of p14ARF affects the level of p14ARF promoter activity suggests that this region may be part of 
a downstream enhancer or part of an alternative promoter, however to date no functional role of 
this region has been described. 
 Although it should be noted that mutagenesis of the CpG sites does not test whether 
differential methylation of these sequences would affect ANRIL or p14ARF expression, but does 
show that these sequences are potentially important for ANRIL and p14ARF expression.  
Unfortunately, methods to directly test whether specific CpG sites are methylated in vivo are 
technically difficult (254) and limited studies have reported the use of patch promoter 
methylation to measure the effect of the methylation of a single CpG site within a promoter on 
gene activity (255–257).  However, the ligation of the modified DNA into plasmids is not always 
100% efficient (258) and this makes comparison between the unmethylated and methylated 
plasmids difficult. An alternative approach would be to clone the promoter region of ANRIL and 
p14ARF into a CpG free luciferase vector and then methylate the promoter region in vitro; however, 
this would induce methylation across the whole promoter region, making it impossible to 
determine the contribution of the CpGs in question. 
To determine whether transcription factors bind across the DMR and whether 
methylation of the CpGs had an effect on this binding, EMSAs were carried out.  This revealed 
strong protein binding across CpGs -769 and CpGs -887 and -907 in SaOS-2 cells.  Interestingly, 
binding was cell type specific and differences in the protein complexes bound across the CpGs 
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were seen between SaOS-2 and SW-872.  This may suggest that this region is subject to tissue 
specific regulation.   There are many putative transcription binding sites across this region, one of 
which belongs to PPARγ that spans CpGs -793 and -796 and this gene has a well-documented role 
as an activator of adipogenesis (259–261).  Using MATInspector, we determined that there are 
potential putative binding sites that span CpGs -887 and -907, which has shown preferential 
binding in osteosarcoma cells over liposarcoma cells, for transcription factors that have been 
shown to have a role in bone metabolism (Figure 3.9). 
 
 
Figure 3.9: THE CDKN2A DMR with putative regulatory transcription factor binding sites. Putative 
transcription factor binding sites were determined using MATInspector and are shown by blue brackets.  
Each CpG site is numbered according to the distance from the TSS of ANRIL and shown in red.  HNF1B 
Hepatocyte Nuclear Factor-1-Beta; CTCF CCCTC-binding Factor; EKLF Erythroid Kruppel-Like Factor; PPAR 
Peroxisome Proliferator-Activated Receptor; AHR/ARNT Aryl Hydrocarbon Receptor/AHR Nuclear 
Translocator; bHLH Basic Helix-Loop-Helix; MAFB V-maf Musculoaponeurotic Fibrosarcoma Oncogene 
Homolog B; Oct Octamer Binding Transcription Factor 
 
To determine whether methylation affects binding to this region, the effect of 
methylation of CpGs -887 and -907 on transcription factor binding was investigated.  The findings 
show that in osteosarcoma cells, there was specific binding of a complex to CpGs -887 and -907, 
but when the cytosine of CpGs -887 and -907 were methylated, protein binding was reduced.   
This is consistent with the findings from many studies which show that transcription factor 
binding is generally reduced by methylation (262).  EMSAs showed that a protein of similar 
molecular weight binding to both the unmethylated and methylated CpG -887 and -907 
containing probes, with the protein binding more strongly to the unmethylated probe, suggesting 
that proteins forming this complex preferentially bind to unmethylated DNA.  This further 
suggests that the binding between the unmethylated CpG -887 and -907 containing probe and 
proteins in SaOS-2 cells is stronger than the binding of protein to the methylated probe and that 
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transcription factors in the osteosarcoma extract preferentially bind to this particular region of 
the CDKN2A DMR when it is unmethylated.  As methylation of CpGs -887 and -907 within this 
region have a negative association with offspring bone outcomes during childhood, this could be 
due to reduced transcription factor binding due to increased methylation.  This could prevent 
correct regulation of bone development and could put the child at risk for adverse bone outcomes 
during later life. 
Identification of the complexes that signal through this region will be important in 
understanding factors that regulate ANRIL/p14ARF and how perhaps perturbation in early life 
environment may influence methylation at this locus.  To identify transcription factors that may 
bind to this region, multiplexed competitor EMSAs were carried out.  The excess addition of the 
consensus binding sequences for both GAS and Smad3/4 effectively competed out binding across 
CpGs -887 and -907. 
Interferon (IFN) gamma-activated site (GAS) elements are found in the promoters of IFNγ 
inducible genes as they were originally defined as a requirement for the induction of IFNγ 
signalling, however they have now been shown to be present in IL-6, growth factor, 
hematopoietic growth factor and growth hormone inducible genes in various species (263). The 
most common core binding sequence of these short stretches of DNA consists of AAG(N2-4)CTT, 
where ‘N’ is any base. There is almost an exact match between the core consensus sequence and 
the CpG -887 and -907 containing probe, in that the only part that does not match is the first T in 
the GAS consensus sequence is replaced by a G in the probe sequence, though in some cases, this 
T has been replaced by other bases (263).  This binding site would then lie directly over CpG -887.  
Various transcription factors that have a role in IFNγ signalling have been shown to bind to these 
sequences but the most common is STAT1 (263). IFNγ has been shown to have a role in both 
osteoblastogenesis and osteoclastogenesis. Using microarray expression analysis, Duque and 
colleagues demonstrated that various IFNγ-inducible genes were upregulated during the early 
phases of hMSC differentiation into osteoblasts and when IFNγ expression was knocked down by 
siRNA, RUNX2 expression also decreased, suggesting IFNγ is important for this process (264).   The 
same group also went on to show that IFNγ knock out mice display a reduction in bone mineral 
density when compared to their wild-type littermates and that treatment of ovariectomised mice 
with doses of IFNγ can rescue them from osteoporosis by causing an increase in bone mass and a 
improves the balance between bone formation and resorption (265).  There are conflicting 
reports on the role of IFNγ in osteoclastogenesis as there is evidence to support that IFNγ both 
inhibits and promotes osteoclastogenesis.  Takayanagi et al demonstrated that IFNγ inhibits 
osteoclastogenesis by interfering with the RANK-RANKL signalling pathway (266), which is the 
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major pathway regulating this process, whereas Gao et al have shown that IFNγ stimulates the 
production of RANKL, promoting osteoclast activation and bone resorption (267). 
Binding to CpGs -887 and -907 was also competed out by the addition of the consensus 
sequence for the SMAD3/4 complex.  The SMAD3/4 complex is part of the SMAD family of 
proteins, which are important in the signal transduction pathway by which BMPs on binding to 
their receptors activate gene expression, as well as signal transduction in the TGF-β pathway, also 
for the activation of gene transcription.  SMAD proteins are separated into three subgroups: 
receptor-regulated SMADS (SMAD1, 2, 3, 5 and 8), common-mediator SMAD (SMAD4) and 
inhibitory SMADs (SMAD 6 and 7) (268).  There is much research that demonstrates the 
importance of the SMAD3/4 complex in the transduction of TGF-β signalling to allow for correct 
osteoblast differentiation and function.  Feng et al have demonstrated that this complex can 
cooperate with Sp1, a zinc finger transcription factor where SNPs within the recognition site of 
this protein have been associated with reduced bone density and increased risk of osteoporotic 
fracture, to induce p15INK4B expression, causing cell cycle arrest (269). The SMAD3/4 complex has 
also been shown to repress the expression of osteoblast differentiation transcription factors.  
Kang et al demonstrated that Runx2 function was repressed in murine osteoblasts, leading to the 
decrease in expression of osteocalcin (270).  Furthermore, they showed that SMAD3/4 formed a 
complex with Runx2 at its DNA binding sites to recruit HDACs to these areas, thereby repressing 
the expression of Runx2 activated genes.  Alliston et al have also independently demonstrated 
that Smad3 can repress the expression and function of CBFA1 (murine RUNX2), which leads to the 
inhibition of Cbfa1 and osteocalcin genes (271).  There is no evidence in the literature to suggest 
that these transcription factors work in synergy.  Altering the binding potential transcription 
factors to either of these two sites through methylation could have consequences on bone 
structure and risk of fracture in later life by altering bone mineral content and bone mineral 
density. 
STAT1 is a transducer of IFNγ pathway whereas the SMAD3/4 complex is a signal 
transducer for the TGF-β pathway and there is evidence to suggest that there is a mechanism for 
transmodulation between these two signal transduction pathways (272).   Given that in 
osteoblasts these two pathways have been shown to regulate RUNX2 function but in opposite 
directions, this could suggest that the signal received from the environment determines which of 
these two transcription factors bind to these CpGs in CDKN2A to regulate ANRIL expression and 
whether this leads to an upregulation or downregulation of downstream effector molecules. 
However, MATInspector and PROMO searches did not reveal any known putative binding 
sites for these transcription factor complexes across the probe containing CpGs -887 and -907, 
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though this could be because the probe sequence is not an exact match for either transcription 
factor binding consensus sequence, though there are similarities between the both the consensus 
sequences and the CpG -887 and -907 probe sequence.  This could suggest that the CpG -887 and 
-907 containing probe includes previously unknown binding sites for the Smad3/4 complex and 
that there are potentially many transcription factors that could be binding to the GAS consensus 
sequence, or the highly similar sequence within the CpG -887 and -907 containing probe. 
 
3.5 Summary 
We sought to establish whether the differentially methylated region identified in the 
CDKN2A gene locus may have a causal role in the pathway that could lead to differences in bone 
mineral content or whether it is simply a marker of bone development.  These data suggest that 
the DMR region may have a role in regulating the expression of the lncRNA ANRIL and p14ARF.  
Although, because of the difficulty in obtaining tissues from infants, the relevance of altered 
methylation of this region in cord tissue or its relation to the methylation patterns seen in bone is 
unknown, as methylation patterns have been shown to be tissue specific, though others have 
been shown to be consistent across different tissue types (219,273) . 
We also sought to demonstrate that differential methylation of CpGs -887 and -907 alters 
transcription factor binding to this region of the CDKNA gene, a DMR negatively associated with 
total bone mineral content and density.  These data show that methylation decreases protein 
binding and that this region is bound by SMAD and STAT transcription factors, which have been 
shown to have effects on osteogenesis and bone metabolism.  Together these data suggests that 
differential methylation of this region may influence the transcription of both ANRIL and p14ARF 
though further work will be required to determine what factors bind and how this impacts ANRIL 
or p14ARF expression.   However, even if methylation does affect ANRIL, and/or p14ARF expression, 
whether differential methylation of this region is causally involved in the adverse bone 
development remains to be determined.  Perturbations in ANRIL or p14ARF expression however 
could address, at least in cell lines, whether ANRIL in particular is important for bone function and 
development. 
 
3.6 Future work 
In order to determine whether members of the GAS family of transcription factors and 
the SMAD3/4 complex are binding to this region within the DMR, EMSAs would be repeated using 
antibodies against the GAS transcription factors and the SMAD3/4 complex.  If these proteins are 
binding to the unmethylated CpG -887 and -907 probe, the antibody would bind to the protein 
and retard the complex, causing a super shift on the EMSA. EMSAs using the methylated CpG -887 
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and -907 probe could also determine whether the binding of these two consensus sequences is 
affected by methylation of this region in the CDKN2A DMR. 
If it is indeed SMAD3/4 that is binding to this region and the GAS element has 
transcription factors binding to it, we could co-transfect expression vectors containing this 
transcription factor or this consensus sequence and the ANRIL/p14ARF promoter constructs to 
determine whether overexpression of these proteins leads to a change in activity of the ANRIL 
and/or p14ARF promoters. 
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Chapter 4 
Functional Significance of ANRIL in 
SaOS-2, an Osteoblast-like Cell Line 
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4.1 Introduction 
 Previous research has demonstrated that CDKN2A methylation at birth is associated with 
BMC, BA and aBMD at 4 and 6 years of age, suggesting that altered CDKN2A methylation maybe a 
valuable marker of later bone health but whether it is directly involved in bone development or 
simply a marker of later bone outcomes is unknown.  Methylation patterns have been shown to 
be tissue specific; however, there is now also research demonstrating inter tissue correlation of 
methylation patterns.  Byun et al have demonstrated inter tissue correlation of methylation 
patterns between 11 different tissues (274) and Lokk and colleagues have shown that methylation 
patterns were well conserved across 17 different somatic tissues (275), whether the methylation 
pattern observed in cord tissue reflects methylation changes in bone cells in these individuals is 
unknown. The CDKN2A locus encodes for p16INK4A, p14ARF and the lncRNA ANRIL and in the 
previous chapter, we found that site directed mutagenesis of the CpG sequences within the DMR 
of CDKN2A are important for ANRIL and p14ARF expression. P14ARF has a well-defined role in cell 
cycle progression and this has been characterised in a wide range of cell types.  Such studies 
would suggest that perturbation of p14ARF expression during development might impact on 
osteoblast cell number, differentiation potential or turnover.  We have also shown that the DMR 
can influence ANRIL expression, however the function of this lncRNA is relatively poorly defined 
with no research to date as to its role in bone cell development or function although SNPs within 
ANRIL have been associated with frailty.  Much of the previous research on ANRIL has investigated 
its role in vasculature because of the link between SNPs within ANRIL and CVD risk (237,276).  
Here siRNAs directed against ANRIL have been shown to cause a decrease in vascular smooth 
muscle cells (VSMCs) number and rate of proliferation. However, there are conflicting reports as 
to whether ANRIL acts through p16INK4A and/or p15INK4B, which is encoded for by CDKN2B, a gene 
that is upstream of CDKN2A, or through a trans mechanism independent of p16INK4A/p15INK4B 
(237,276,277). 
ANRIL is a long non-coding RNA (lncRNA), which are a group of RNAs that are defined and 
distinguished from short non-coding RNAs as those which have a length of more than 200 base 
pairs (278).  Very little is known about the function of lncRNAs, though there is evidence to 
suggest that they can act as scaffolds, where they act as platforms for the assembly of molecular 
complexes (279,280), either in cis or in trans.  The first ANRIL transcript was discovered by 
Pasmant et al in 2007 (281) and the gene encoding this RNA contained 19 exons spanning a region 
of 126.3kb; a more recent study however by Holdt et al have also now shown the existence of 
transcripts that contain a novel exon 20 (282).  ANRIL is transcribed by RNA polymerase II (283) 
into 3834bp mRNA in the antisense direction of the CDKN2B gene locus.  The first exon of this 
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ANRIL transcript is approximately 14,850bp downstream from p15INK4B TSS and approximately 
300bp upstream of the TSS for p14ARF (277). 
 
 
Figure 4.1: Position of ANRIL in relation to p14
ARF
 and p15
INK4B
. The TSS of ANRIL is located 
approximately 14,850bp downstream of the p15
INK4B 
TSS, encoded for by the CDKN2B gene, and 300bp 
upstream of the p14
ARF
 TSS, encoded for by the CDKN2A gene.  ANRIL is transcribed from the CDKN2A 
gene locus in the antisense direction to p15
INK4B
. 
  
Since 2007 it has been shown that there are many different linear isoforms of ANRIL 
created from alternate splicing (238,284), Burd et al have also shown that circular isoforms also 
exist, and these are predominantly formed from the less abundant central exons 4-12 (238).  The 
expression of the circular isoforms has been shown to be associated with CVD-risk alleles; 
however their functions have yet to be clarified.  It has been shown that some splice variants are 
tissue specific, which further suggests that ANRIL has a physiological relevance, though the 
characterisation of the isoforms in different tissues and cell lines are still incomplete (285).  
Various isoforms have been shown to have a range of diverse functions that include gene 
regulation, epigenetic regulation, cell cycle control and cell differentiation, which are mediated by 
RNA-RNA, RNA-DNA or RNA-protein interactions (reviewed by Lee (286)). 
 Recent GWAS have demonstrated that the CDKN2A/B locus is a hotspot for disease-
associated polymorphisms.  Two SNPs within this gene locus have been linked to frailty (250).  In 
this study Melzer et al showed that the rare allele (G) of two SNPs located 3.5kb proximally to the 
CDKN2A/B locus (rs2811712 and rs3218005) are associated with increased physical function in 
older people.  Of the 2673 subjects that were common homozygous, 15% of them had severely 
impaired physical function compared to the 7% of subjects that were genotyped as rare 
homozygous (250), suggesting that those with the rare homozygous genotype are less at risk of 
suffering from severe physical impairment later in life.  Other SNPs within this gene locus have 
been linked to T2D (251), Alzheimer’s disease (252) and CVD (251).  Studies have also shown that 
these disease-associated SNPs are frequently located within exons of ANRIL and, in most cases, 
associated with a change in ANRIL expression.  ANRIL exons 1-2 expression seems to be the most 
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commonly affected (285), though some SNPs have been shown to alter the expression of exons 
15-16 and 17-18 as well (276,287).  Some of the SNPs within ANRIL are associated with a specific 
disease while others are associated with a range of ageing associated diseases, demonstrating the 
potential of different ANRIL splice variants having roles in different tissues. 
 Studies have shown that a knockdown in ANRIL expression leads to a decrease in cellular 
proliferation, characterised by significant decreases in both VSMCs and peripheral blood 
mononuclear cell (PBMC) number (276,282), which is potentially due to the cis functional effects 
of ANRIL.  This lncRNA has been shown to act in cis by down regulating the expression of p15INK4B 
and p16INK4A (both cell cycle inhibitors) from the CDKN2A/B locus by recruiting PRCs to the 
promoters of both these genes and causing trimethylation of lysine 27 of histone 3 (243,283).  
This prevents the binding of transcriptional machinery and so suppresses p16INK4A and p15INK4B 
expression, thus preventing cell cycle progression.  ANRIL also regulates p15INK4B through an 
antisense mechanism where it binds directing to its complementary sequence in the CDKN2B 
locus and prevents the transcription of this gene (288). 
 Recent studies have however also suggested that ANRIL may act in trans by binding to Alu 
elements (277,282,289).  Using a genome-wide mRNA expression array carried out on cell lines 
overexpressing ANRIL transcripts, Holdt et al found that there were significant changes in gene 
expression distributed across the genome.  They then went on to show that these trans functional 
effects were due to binding of PRC proteins, recruited by ANRIL binding, to Alu binding elements 
in the promoters of ANRIL regulated genes (282).  Sato et al have demonstrated the role of a 
novel splice form of ANRIL to be involved in the regulation of the nucleus (277).  They 
overexpressed this isoform in HeLa cells and found, using gene ontology enrichment analysis, that 
expression of 38 genes involved in nucleus regulation were altered – 36 genes were down 
regulated and 2 genes were upregulated.  However, what role, if any, ANRIL plays in the function 
of bone-derived cells is unknown. 
 
4.2 Aims 
 To determine whether i) the long non-coding RNA ANRIL is expressed in bone-related 
cells, such as primary osteoblasts and human mesenchymal stem cells, ii) to explore the role of 
ANRIL in osteoblast cell proliferation, differentiation and mineralisation and iii) to determine 
whether these effects are dependent or independent of p16INK4A expression. 
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4.3 Results 
 4.3.1 Is ANRIL expressed in bone-related cells? 
The expression of ANRIL in different tissue types has not been well documented, 
therefore to determine whether ANRIL is expressed in bone-related cells, RT-qPCR was used.  
Three RT-qPCR assays were used that spanned the exon 1-2, exon 5-6 and exon 18-19 boundaries 
of ANRIL.  These exons were chosen as the major ANRIL isoforms in other cell types (some of 
which are shown in Figure 4.2) have been shown to contain these exons more frequently than 
others. 
 
 
 
Figure 4.2: Figure showing the exons present in previously reported ANRIL isoforms.  Figure taken from 
Burd et al (238). 
 
 
Using these assays ANRIL expression was investigated in bone-related cells, which 
included: primary osteoblasts, human bone marrow stromal cells (hBMSCs) and SaOS-2, an 
osteoblast-like osteosarcoma cell line.  As very little is known about ANRIL expression in other cell 
types, cDNA from different cells and tissues were run alongside the bone-related cells, which 
included SW-872 (an adipocyte derived cell line), HepG2 (liver cancer cell line), Hs578T (breast 
cancer cell line) and HMT-3522 (breast epithelial cell line). 
RT-PCR analysis showed that ANRIL expression was detectable across a wide range of 
tissues and cell types, although there were differences in the relative expression of the amplicons 
across the different tissues (Figure 4.3).  The pattern of expression was very similar for assays 
measuring transcripts containing exons 1-2 and exons 5-6, with transcripts containing exons 18-19 
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being quite distinct.  ANRIL expression in all three RT-PCR assays was highest in the bone-related 
cells (hBMSCs, primary osteoblasts and SaOS-2 cells).  hBMSCs had the highest expression of 
transcripts containing exon 1-2 and 5-6.  Interestingly expression of ANRIL transcripts containing 
exons 1-2 or 5-6 is lower in primary osteoblasts and osteoblast-like SaOS-2 cells when compared 
to the expression of these exons in hBMSCs, however there was no significant change in 
expression of ANRIL transcripts containing exon 18-19 between hBMSCs and primary osteoblasts 
or SaOS-2 cells.  Relatively high expression was also observed in the liposarcoma cell line SW-872 
and breast cancer cell lines.  HepG2 cells showed the lowest expression of ANRIL exons 1-2 and 
exons 5-6. 
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Figure 4.3: Expression ANRIL exons 1-2 (A), exons 5-6 (B) and exons 18-19 (C) in different cell lines 
relative to normalised ddCT.  Comparisons were made between each of the bone-related cell types 
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4.3.2 Does ANRIL knock down affect SaOS-2 cell number? 
 Having shown that ANRIL is expressed in hBMSCs, primary osteoblasts and the osteoblast-
like cell line SaOS-2, the function of ANRIL in the osteosarcoma cell line SaOS-2 was then 
examined.   SaOS-2 cells were transfected with 10nM of 3 siRNAs directed against different exons 
of ANRIL using Lipofectamine RNAiMAX.  Of the three siRNAs used, one siRNA targeted exon 1 of 
ANRIL (Ambion E1 siRNA), while the other two matched the ANRIL siRNAs used successfully by 
Congrains et al to knock down expression of ANRIL in VSMCs (237).  Of the latter two siRNAs, one 
targeted exon 1 of ANRIL (Congrains E1 siRNA), but a different sequence to the siRNA from 
Ambion, and the other siRNA targeted exon 19 (Congrains E19 siRNA).  All three of these siRNAs 
have been commercially or experimentally shown to successfully knock down ANRIL expression.  
After optimisation of transfection conditions with a control ‘cell death’ siRNA, cells were 
transfected with the three ANRIL siRNAs, and cells incubated at 37oC for 72hrs, after which they 
were either, trypsinised and counted, or RNA extracted for expression analysis. 
 To confirm that the siRNAs effectively knocked down ANRIL expression in SaOS-2, RT-
qPCR assays were run using primers across ANRIL exons 1-2, 5-6 and 18-19.  Results showed that 
each of the three ANRIL siRNAs significantly knocked down ANRIL exon 1-2, 5-6 and 18-19 
expression (Figure 4.4).  However, there were significant differences in the effectiveness of the 
siRNAs in knocking down ANRIL expression.  ANRIL exon 1-2 transcripts were knocked down 2.4-
fold by Ambion E1 siRNA, 5.9-fold by Congrains E1 and 1.4-fold by Congrains E19.  ANRIL exon 5-6 
transcript expression was knocked down 2.2-fold by Ambion E1 siRNA, 6.4-fold by Congrains E1 
siRNA and 1.5-fold by Congrains E19 siRNA.  ANRIL exon 18-19 transcripts were knocked down 
1.4-fold by Ambion E1 siRNA, 2.7-fold by Congrains E1 siRNA and by 2.9-fold by Congrains E19 
siRNA. 
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Figure 4.4:  Results from RT-qPCR confirming knockdown of ANRIL exons 1-2 (A), exons 5-6 (B) and exons 
18-19 (C) in transfected SaOS-2 cells.  Graphs represent results from three independent transfections (n=3).  
Results shown as mean ±SEM * denote comparisons to control (****p<0.0001; ***p≤ 0.001; **p≤0.01). 
Letters denote comparisons between the three ANRIL siRNAs. 
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To determine the effect of a reduction in ANRIL expression, cell number was assessed in 
the SaOS-2 cells transfected with each of the three ANRIL siRNAs, a positive cell death siRNA and a 
negative scrambled siRNA.  Results from three independent experiments (Figure 4.5) showed that 
there was a significant decrease in the number of live cells in cells treated with the positive ‘cell 
death’ siRNA control when compared to the ‘scrambled’ control.  There was also a significant 
decrease in cell number upon treatment with the three ANRIL siRNAs (p<0.0001 for each siRNA 
treatment).  The decrease in cell number induced in SaOS-2 cells transfected with the ANRIL 
siRNAs was similar for all three siRNAs used.  These results suggest that ANRIL knock down leads 
to a decrease in cell number. 
 
 
Figure 4.5: Number of live SaOS-2 cells after 72hr incubation with 10nM ‘scrambled’, ‘cell death’ and 
three siRNAs against ANRIL. Graph summarises data from three independent transfections (n=3).  
Results shown as mean ±SEM  ****p<0.0001 
106 
 
4.3.3 Does knock down of ANRIL expression cause cell cycle arrest? 
 A decrease in cell number may be due to either a decrease in cell proliferation or an 
increase in cell death, therefore to determine what process a decrease in ANRIL expression may 
perturb, FACS analysis was used.  ANRIL siRNA treated SaOS-2 cells, together with SaOS-2 cells 
transfected with the scrambled siRNA control were fixed in 70% ethanol and then stained with 
propidium iodide and analysed by FACS to assess cell cycle progression by measuring the amount 
of DNA within 5000 cells.  
 In cells transfected with the ANRIL siRNAs, there were significant changes in the 
percentage of cells undergoing apoptosis and those held in G0/G1 phase.  However, the different 
ANRIL siRNAs cause different effects.  Ambion E1 siRNA caused a significant increase (p<0.0001) in 
the percentage of cells being held in G0/G1, whereas there was no significant change seen with the 
Congrains E1 or Congrains E19 siRNAs (Figure 4.6A).  However, significant increases in the 
percentage of cells undergoing apoptosis were seen when the cells were treated with Congrains 
E1 and Congrains E19 siRNAs (p=0.0006 and p<0.0001 respectively) (Figure 4.6B) but not with cells 
treated with Ambion E1 siRNA.  These results suggest that a reduction in ANRIL transcripts can 
affect cell cycle progression and apoptosis of the osteosarcoma cells. 
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Figure 4.6: Percentage of SaOS-2 cells in G0/G1 phase (A) and apoptotic cells (B) after treatment with 
10nM siRNA for 72hrs.  Graphs represent results of three independent transfections (n=3). Results shown 
as mean ±SEM ****p≤0.0001; ***p≤0.001 
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4.3.4 Does ANRIL knock down have an effect on RUNX2 and ALP expression? 
 To determine whether knock down of ANRIL expression caused a change in the 
differentiation potential of SaOS-2 cells, cells were transfected with the three ANRIL siRNAs, as 
previously described, and RT-qPCR used to look at the expression of two differentiation markers: 
RUNX2 and ALP.  RUNX2 is expressed during the early stages of differentiation, whereas ALP is 
expressed at the later stages of differentiation.  Both of these genes have been shown to be 
expressed by SaOS-2 cells (290) 
 When ANRIL expression was knocked down in SaOS-2 cells, there was a significant 
increase in RUNX2 expression, though Ambion E1 and Congrains E19 caused a greater increase 
(2.5-fold and 1.9-fold respectively; p<0.0001 for both) in RUNX2 expression than Congrains E1 
siRNA (1.4-fold increase; p=0.0018) (Figure 4.7A).  A significant increase in ALP expression was 
seen compared to control when SaOS-2 cells were treated with the Ambion E1 and Congrains E19 
siRNAs (p=0.0059 and p=0.012 respectively; Figure 4.7B), whereas there was no statistical 
difference in ALP expression when cells were treated with Congrains E1 siRNA. 
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Figure 4.7:  Expression of (A) RUNX2 and (B) ALP in SaOS-2 cells compared to control when ANRIL 
expression has been knocked down.  All three siRNAs cause a significant increase in RUNX2 expression but 
only Ambion E1 and Congrains E19 siRNAs cause an increase in ALP expression. Graphs represent three 
independent transfections (n=3).  Results shown as mean ±SEM ****p≤0.0001; ***p≤0.001; **p≤0.01; 
*p≤0.05 
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4.3.5 Does ANRIL knock down have an effect on expression of BGLAP? 
 To determine whether knock down in ANRIL expression leads to a change in the ability of 
the SaOS-2 cells to mineralise extracellular matrix, RT-qPCR was used to determine the expression 
levels of bone gamma-carboxyglutamate protein (BGLAP).  BGLAP, also known as osteocalcin, is a 
marker for bone mineralisation and its expression has been characterised in the SaOS-2 cell line 
(290).  ANRIL knock down had no significant effect on osteocalcin expression (Figure 4.8). 
 
 
 
 
 
 
Figure 4.8: Expression of BGLAP in SaOS-2 cells compared to control when ANRIL expression has been 
knocked down.  ANRIL knockdown by any of the three siRNAs does not cause a significant change in BGLAP 
expression.  Graphs represent three independent transfections (n=3).  Results shown as mean ±SEM 
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4.3.6 Does ANRIL mediate its effect through altered expression of the CDKN2A/B locus? 
 As ANRIL has been shown to negatively regulate p16INK4A and p15INK4B, RT-qPCR was used 
to determine if the knockdown of ANRIL expression also induced a change in expression of these 
transcripts.  Following transfection of cells with Ambion E1 siRNA, there was a significant increase 
in p16INK4A expression (p=0.0018), however there was no change in p16INK4A expression in cells 
transfected with either Congrains E1 or E19 siRNAs (Figure 4.9A).  Interestingly, p15INK4B 
expression was significantly decreased in cells transfected with each of the three ANRIL siRNAs 
(p=0.0045, p<0.0001 and p<0.0001), though Ambion E1 siRNA caused a smaller decrease in 
expression compared to either Congrains E1 and Congrains E19 siRNAs (statistical differences in 
expression between the three siRNAs denoted by letters in Figure 4.9B). 
Expression of p14ARF, a third product of the CDKN2A/B locus was also investigated, though 
there is no evidence to suggest that this transcript is regulated by ANRIL.  Results showed that 
when ANRIL expression is knocked down, there was a significant decrease in p14ARF expression 
when SaOS-2 cells were treated with the Congrains E1 and Congrains E19 siRNAs (p=0.0029 and 
p<0.0001 respectively) (Figure 4.9C). 
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Figure 4.9: Expression of p16
INK4A
 (A), p15
INK4B
 (B) and p14
ARF
 (C) in SaOS-2 cells compared to control when 
ANRIL expression has been knocked down.  Graphs represent three independent transfections (n=3).  
Results shown as mean ±SEM * denote comparisons to control (****p≤0.0001; ***p≤0.001; **p≤0.01; 
*p≤0.05) Letters denote comparisons between the three siRNA treatments.  
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4.4 Discussion 
 In this chapter the role of ANRIL was investigated in the osteoblast derived cell line SaOS-
2 cells.  Previously, very little was known about the expression of ANRIL, which cell types it is 
expressed in and what its precise function is.  The results in this chapter show that ANRIL is highly 
expressed in the osteoblast-like derived cell line SaOS-2 and primary osteoblasts, as well as 
human bone marrow stromal cells (hBMSCs).  Transcripts containing exon 1-2, 5-6 and 18-19 were 
all detected.  Moreover, ANRIL expression was also detected in a liposarcoma cell line (SW-872), 
breast cancer cell line (Hs578T) and liver cell line (HepG2), suggesting tissue wide expression 
patterns.  Although interestingly, the relative abundance of the transcripts containing exons 1-2 
and 5-6 in SW-872 cells compared to SaOS-2 cells was similar, whereas transcripts containing 
exons 18-19 were relatively low. 
  
Our results show that expression of ANRIL transcripts containing exons 1-2 or 5-6 is higher in 
hBMSCs than those that have been differentiated into primary osteoblasts, whereas there was no 
significant difference in exons 18-19 expression.  As ANRIL has been shown to repress p16INK4A and 
p15INK4B, cell cycle inhibitors, high levels of ANRIL expression in hBMSCs would be consistent with 
the higher self-renewal capacity of these stem cells.  It has been shown across different cell types 
that differentiation is co-ordinated with cell cycle exit (291).  In the case of ANRIL, you would 
potentially expect to see decreased expression in cells that are undergoing differentiation as cells 
exit the cell cycle in order to differentiate, which would allow for an increase in p16INK4A levels. 
These results do suggest that different cell types express different levels of ANRIL, which agrees 
with results from other research groups (238,281,284,292).  Figure 4.10 shows exons present in 
different known ANRIL transcripts and this figure shows that exons 5 and 6 are more abundant in 
 
 
 
 
Figure 4.10:  Exons present in 17 different ANRIL transcripts in PBMCs.  Transcripts identified using RACE 
and PCR amplification.  Figure replicated from Holdt et al (282). 
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ANRIL transcripts when compared to exons 18 and 19.  Even though exon 1 is present in the 
majority of the transcripts shown in these figures, exon 2 is present in only a few of the 
transcripts shown.  This agrees with our RT-qPCR results as we found that transcripts containing 
exons 5-6 were the most highly expressed and transcripts containing exons 18-19 had the lowest 
expression.  However, even though different isoforms have been shown to be expressed in VSMCs, 
HeLa and PBMCs, the specific isoforms that are expressed in bone are not known. 
Further work would need to be done in order to determine which specific ANRIL 
transcripts are expressed in bone.  This could be done by rapid amplification of cDNA ends (RACE), 
where reverse transcription of RNA and PCR amplification are used to determine the sequence of 
unknown transcripts, which can then be mapped back to its unique genomic region.   An 
alternative method would be to use PCR, with forward and reverse primers mapping to sequences 
within the exons of known ANRIL transcripts. 
To determine what phenotypic and functional effects ANRIL has on bone development, 
siRNAs were used to knock down ANRIL expression in the osteoblast-like cell line SaOS-2.  Three 
siRNAs were used to knock down ANRIL expression, and the results show that ANRIL was 
successfully knocked down by all three siRNAs.  The effectiveness of knockdown was different for 
the three siRNAs depending on the transcript examined.  For example, as Congrains E19 siRNA is 
less effective in knocking down transcripts containing exons 1-2 compared to Congrains E1 or 
Ambion E1, this suggests that not every ANRIL transcript that contains exon 1 also contains exon 
19.  Although, as exons 18-19 expression is knocked down to the same level when cells are 
treated with both Congrains E1 and Congrains E19, this may additionally suggest that the majority 
of ANRIL transcripts that do contain exon 19 also contain exon 1. To fully understand the 
significance of these results, the next step would be to map the ANRIL isoforms present in these 
cells.  Interestingly the Ambion E1 siRNA did not knock down ANRIL expression to the same extent 
as Congrains E1 siRNA, which suggests there is a difference between the effectiveness of the 
siRNAs directed against exon 1 of ANRIL, potentially due to the different sequence that is targeted 
within exon 1 or a difference in secondary structure of the region. 
 The results show that when ANRIL expression is successfully knocked down by all three 
siRNAs, SaOS-2 cell number decreases.  This decrease could be due to different mechanisms 
which include cell cycle arrest, an increase in apoptosis or potentially both of these mechanisms 
working together.  To determine if the cells were being held in G0/G1 phase or whether an 
increase in cell death is the cause of the decrease in cell number, samples were stained using 
propidium iodide and analysed using FACS.  Ambion E1 siRNA induced a significant increase in the 
number of cells in the G0/G1 phase of the cell cycle, but no effect on G0/G1 cell number was seen 
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with the other ANRIL siRNAs. Congrains E1 and E19 transfection lead to a significantly higher 
number of cells undergoing apoptosis compared to the ‘scrambled control’.  This difference is 
interesting especially between the two siRNAs directed against exon 1.  Ambion E1 siRNA was less 
effective at knocking down exons 1-2 and exons 5-6 expression than Congrains E1 siRNA and less 
effective at knocking down ANRIL exons 18-19 expression than either Congrains E1 or E19 siRNAs.  
Even though there are 6 known variants of exon 1 across the 17 sequenced ANRIL transcripts, 
both Ambion E1 and Congrains E1 siRNAs map to all 6 different exon 1 sequences, so this does not 
explain the difference seen in knock down efficiency.  Whether this difference in response is then 
due to the severity of the knock down is not clear, however it could probably be tested by 
transfecting SaOS-2 cells with an increasing concentration range of ANRIL Ambion E1 siRNA.  
However, another possibility is that the secondary structure of the sequence of mRNA maybe be 
different, therefore this could affect the effectiveness of siRNA binding and its knock down 
efficiency.   
As the Ambion E1 siRNA from Life Technologies caused an increase in the number of cells 
being held in G0/G1 phase, this points to ANRIL working in cis to prevent cell cycle arrest.  
Consistent with this, treatment with Ambion E1 siRNA did lead to an increase in p16INK4A 
expression, while the others did not. As ANRIL negatively regulates p16INK4A, expression of this 
transcript should increase when ANRIL expression decreases.  This would lead to cell cycle arrest 
and prevention of cell cycle progression into S phase.  The results shown here agree with what 
have previously been demonstrated in other cell types (237,243,293) and agrees with all the 
theories that low expression of ANRIL leads to an increase in the expression of p16INK4A and, 
consequently, an increase in the number of cells held in the Go/G1 phase of the cell cycle. 
A decrease in ANRIL expression and increase in p16INK4A expression, in relation to bone 
development, could lead to premature cell cycle exit and differentiation.  This could lead to an 
imbalance in bone formation as it has been shown in mice that premature osteoblast 
differentiation can lead to deregulated bone formation (294) and there is also evidence to suggest 
that premature cell cycle exit and early differentiation can lead to mislocalised transcription 
factors (295).  An increase in p16INK4A expression has also been linked to replicative senescence 
(239), which is when cells no longer undergo proliferation (296), and this could potentially be 
another ‘state’ that the cells adopt upon ANRIL knockdown.   
There is now also evidence from mouse models demonstrating that premature 
senescence can lead to impaired osteogenic differentiation potential, with bone marrow stromal 
cells from 3 different mouse strains favouring adipogenic differentiation (297–299).  These mice 
showed lower trabeculae number, decreased bone strength and reduced bone mineral density 
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from a young age, further highlighting the need for proper regulation of osteogenesis. If 
osteoblasts became prematurely senescent, this could cause an imbalance in bone cell turnover 
which favoured osteoclasts and bone degradation.  This would potentially lead to a lower peak 
bone mass and greater risk of fracture and osteoporosis in later life (114). 
ANRIL siRNAs Congrains E1 and E19 induced apoptosis in the SaOS-2 cells, though no 
effect was seen upon treatment with Ambion E1 siRNA.  There is evidence to suggest that ANRIL 
has a role in apoptosis pathways, though the evidence is contradictory.  Holdt et al have 
demonstrated a pro-apoptotic effect of ANRIL knockdown in PBMCs and MonoMac cells (a 
monocytic cell line), shown by a significant increase in Annexin V+ cells (282), whereas Congrains 
et al have demonstrated an anti-apoptotic effect when VSMC are treated with an siRNA against 
exon 19 of ANRIL (237).  This demonstrates the potential of ANRIL having cell type specific trans 
functions and if, as my results suggest, ANRIL has an anti-apoptotic function in osteoblasts, this 
could have adverse effects on bone development by decreasing bone formation and potentially 
leading to a lower peak bone mass (64,300,301). 
Interestingly, our results show that p16INK4A expression is not changed upon knock down 
of ANRIL with Congrains E1 and E19 siRNAs, which suggests that the cells are not undergoing 
premature senescence or cell cycle arrest via p16INK4A.  This agrees with results previously shown 
by other groups (282), though others have shown that when ANRIL expression is knocked down 
p16INK4A expression increases and cells become senescent (243).  In this study ANRIL knock down 
did induce a decrease in p15INK4B expression when ANRIL expression is knocked down.  As ANRIL is 
the antisense RNA to the CDKN2B gene, one would expect an increase in p15INK4B expression as 
previously demonstrated by independent groups (276,289).  However, these experiments were 
not carried out in bone cells; therefore this may not be the case for SaOS-2 cells.  As ANRIL acts as 
a scaffold lncRNA to recruit PRC complexes to the p15INK4B gene locus, if ANRIL expression is 
knocked down, this could allow for other repressive complexes to bind to this region instead, 
potentially acting as a compensatory mechanism due to the importance of the cell cycle pathway.  
Dysregulation of cell cycle control regulators may induce apoptosis or ANRIL may do this through 
an independent mechanism, through which it could alter other regulatory factors that would 
otherwise cause the upregulation of p15INK4B. 
The Ambion E1 siRNA also induced a decrease in p14ARF expression. Though there is 
evidence to suggest that p14ARF can induce apoptosis in cells by stabilising p53, which leads to the 
induction of Bax expression (302), this is unlikely to be the case with SaOS-2 cells as this cell line is 
p53-null.  However, there is evidence to suggest that a p53 homologue, p73, can induce apoptosis 
independently of p14ARF expression (303), and its expression has been demonstrated in SaOS-2 
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cells (304).  Interestingly, our results show that upon knock down of ANRIL expression with 
Congrains E1 and E19 siRNAs there is a decrease in the expression of p14ARF, though there is no 
evidence in the literature to suggest that ANRIL directly regulates the expression of this transcript.  
However, the first exon of the ANRIL transcript does cover the promoter region of p14ARF; 
therefore a decrease in ANRIL expression could allow for potential repressor complexes to bind to 
the promoter of this transcript and cause the decrease in expression that is observed. 
To see whether ANRIL has any osteoblast specific functions that affect phenotype, we 
looked at the expression of differentiation and mineralisation markers in SaOS-2 cells where 
ANRIL expression had been knocked down.  Our results show that upon ANRIL knock down 
differentiation markers significantly increase, as shown by increases in both RUNX2 expression (an 
early stage differentiation marker) and ALP expression (a late stage differentiation marker).  No 
significant changes were seen with regards to the mineralisation maker osteocalcin (BGLAP).  
These results suggest that knock down of ANRIL enhances differentiation down the osteogenic 
lineage, regardless of the effect on p16INK4A, all siRNAs also effected the expression of these 
osteogenic markers, which suggests that this change in expression could be p16INK4A independent. 
There is evidence to show that lncRNAs and other epigenetic mechanisms have a role to play in 
osteogenic differentiation.  A recent paper by Zhu et al has demonstrated that the 
downregulation of lncRNA-ANCR (anti-differentiation ncRNA) promotes osteogenic differentiation 
by regulating RUNX2 expression through associations with enchancer of zeste 2 (EZH2) (214), thus 
demonstrating the potential of ANRIL as a mediator of osteoblast differentiation.  lncRNA 
expression assays are also identifying new lncRNAs that have roles to play in the early 
differentiation of MSCs (213).  However, as there was a change in p15INK4B and p14ARF expression, 
this could suggest that the effects seen on RUNX2 expression and ALP expression could be p15INK4B 
and p14ARF dependent, rather than through direct regulation by ANRIL.  Though there is evidence 
to suggest that RUNX2 can regulate the osteoblast cell cycle. 
In cells from wild type and Runx2 deficient mice, osteoblasts from Runx2 deficient mice 
proliferated at a higher rate than those from wild type mice.  When Runx2 was reintroduced to 
the cells, it caused a decrease in cell proliferation, suggesting that stringent cell cycle control had 
been restored (305).  This could explain the decrease in p14ARF and p15INK4B expression seen upon 
ANRIL knock down, with RUNX2 potentially acting as a compensatory mechanism in order to 
maintain cell cycle control, or that the increase in RUNX2 expression causes the decrease in the 
expression of these two inhibitors. 
There is evidence demonstrating that RUNX2 can have an anti-proliferative effect in 
osteoblasts by causing cell cycle arrest at the G0/G1 phase of the cycle.  Galindo et al have 
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demonstrated that an increase in RUNX2 expression in MC3T3 cells (a murine osteoblast cell line) 
suppresses proliferation and causes an increase in the number of cells being held in G1 phase 
(306).  This effect was also seen in primary murine calvarial cells.  Pratap et al have also shown 
that MC3T3 and primary calvarial cells that do not express Runx2 (Runx2-/-) or express a protein 
that lacks the Runx2 COOH terminus (Runx2C/C), which is essential for the interaction of this 
protein with several different pathways, exhibit an increase rate of cell growth.  When Runx2 was 
then reintroduced to the cells through use of an adenovirus, the rate of cell growth reduced to a 
rate that was comparable to the control cells (305). 
RUNX2 has been shown to have a role in pathways that regulate cell proliferation, such as 
Smad and MAPK pathways (305) as well as G protein-coupled signalling pathways (307).  
However, it is also known to be regulated by cell signalling pathways that are involved in bone 
homeostasis (308), such as the BMP, Wnt and IHH pathways.  If ANRIL has a role in regulating one 
of these pathways, when it’s expression is knocked down it could lead to an increase in RUNX2 
expression, which could, in turn, lead to a reduction in cell growth and proliferation.   Either of 
these scenarios could potentially explain the increase in RUNX2 that is seen in SaOS-2 cells that 
have been treated with siRNAs against ANRIL. 
 
4.5 Summary 
We sought to demonstrate that ANRIL expression is cell type and tissue type specific by 
looking at the expression of three different ANRIL exons across a range of cell types.  Our results 
show that ANRIL expression does differ across cell types, with ANRIL expression being lower in 
cells that have undergone osteogenic differentiation when compared to undifferentiated hBMSCs. 
We sought to establish the functional effects of ANRIL in the osteoblast-like cell line SaOS-
2 by transfecting these cells with siRNA against ANRIL and knocking down its expression.  We 
showed that ANRIL knock down caused a decrease in cell number, which is most likely due to an 
increase in pro-apoptotic pathways as p16INK4A and p15INK4B expression did not increase upon 
ANRIL knock down.  This suggests that the cells were not becoming senescent or undergoing cell 
cycle arrest.  Our results show that RUNX2 and ALP expression, both markers of osteogenic 
differentiation, significantly increase when ANRIL expression is knocked down.  This suggests that 
ANRIL may have a role in the regulation of these two proteins. 
In order to confirm our findings experiments need to be repeated in primary osteoblasts 
as there are limitations to using cell lines.  SaOS-2 cells do not have Rb, which is a downstream 
repressor of E2F and is indirectly regulated by p16INK4A, or p53, both of which have roles in the cell 
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cycle pathway, which is why we may have seen a decrease in p15INK4B expression and no change in 
p16INK4A expression. 
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Chapter 5 
Characterisation of ANRIL in Human 
Bone Marrow Stromal Cells and Primary 
Osteoblasts 
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5.1 Introduction 
 lncRNAs are non-coding RNA transcripts that are over 200bp in length which are often 
developmentally regulated (181).  To date, very little is known about the specific functions of 
lncRNAs, however they are known to contain RNA-, DNA- and protein-binding domains, which 
allows them to be classed into three main groups: scaffolds, decoys and guides (188).   Though 
there is no direct evidence of a role for ANRIL in the regulation of osteoblast differentiation, there 
are studies linking the CDKN2A locus and ANRIL to replicative senescence, which could have an 
adverse effect on osteoblast differentiation, bone homeostasis and frailty.  Studies have 
demonstrated that replicative senescence can alter the differentiation abilities of mesenchymal 
stem cells into osteoblasts.  Banfi et al (309) and Kretlow et al (310) have both demonstrated, in 
human and mice respectively, that as stem cells undergo replicative senescence their ability to 
differentiate into osteoblasts decreases. 
The CDKN2A locus has been linked with cellular senescence (244) and it has been 
suggested that an increase in p16INK4A expression can be used as a biomarker for aging (239).  
ANRIL is known to negatively regulate the expression of the CDKN2A locus transcripts via the 
recruitment of the Polycomb repressive complexes (PRC) 1 and 2 (283), which consequently leads 
to the trimethylation of lysine 27 on histone 3.  Yap et al have demonstrated a role for ANRIL in 
the regulation of senescence in a variety of cell lines as well as cancerous prostate epithelial cells 
(283).  This study showed that chromobox 7 (CBX7), a subunit of PRC1 that binds to chromatin, 
binds to ANRIL and that this interaction allows CBX7 to carry out its function, as well as allowing 
for correct recognition of H3K27 methylation.  When the interaction between ANRIL and CBX7 
was disrupted, it affected the ability of CBX7 to negatively regulate the CDKN2A locus and control 
senescence, suggesting that ANRIL could have a senescence-dependent role in proliferation.  If 
ANRIL expression becomes deregulated it could lead to premature cellular senescence, which, in 
terms of osteoblast differentiation and bone homeostasis, could have adverse consequences.  
 
5.2 Aims 
Having shown that ANRIL is important for the growth and survival of SaOS-2 cells, the aim 
of this chapter was to determine whether ANRIL played a similar role in human primary bone 
marrow stromal cells (hBMSCs) and primary osteoblast and whether ANRIL acts via p16INK4A or 
p15INK4B or independently of the pathways as has been reported recently in other cell types. 
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5.3 Results 
5.3.1 ANRIL knock down causes a decrease in hBMSC and primary osteoblast cell number 
To determine whether ANRIL has an effect on bone cell growth and cell proliferation, 
primary hBMSCs and osteoblasts were transfected with 10nM of the ANRIL siRNAs, Congrains E1 
and Congrains E19, which are designed against different exons of ANRIL using Lipofectamine 
RNAiMAX, using a similar protocol to that used with SaOS-2 cells.  Cells were also transfected with 
‘scrambled’ and a cell death siRNAs as negative and positive controls respectively.  Cells were 
treated with the siRNAs, and incubated for 6hrs at 37oC, when the media was removed and 
replaced with either fresh complete MEMα or osteogenic supplemented medium for another 
66hrs, after which they were either trypsinised and counted or treated with TRI Reagent for RNA 
extraction and expression analysis using RT-qPCR. 
To confirm that there was successful knock down of ANRIL expression at the 
transcriptional level in both hBMSCs and osteoblasts, RT-qPCR assays were run using primers for 
exons 1-2, 5-6 and 18-19, as described in previous chapter.  Results show that there was 
significant knock down of ANRIL expression with both siRNA treatments, however this level of 
reduction in ANRIL expression was exon dependent (Figures 5.1 and 5.2). 
In hBMSCs, exon 1-2 expression was significantly reduced after transfection with 
Congrains E1 siRNA (p=0.016; Figure 5.1A) when compared to control by 1.9-fold but is unchanged 
when cells are treated with Congrains E19 siRNA, which targets exon 19.    Exon 5-6 expression 
was unchanged in comparison to the control when hBMSCs are treated with either siRNA (Figure 
5.1B), suggesting that ANRIL transcripts in these cells which contain the exon 5-6 boundary do not 
also contain exon 1 or exon 19. Expression of the exon 18-19 was significantly decreased in 
hBMSCs treated with both Congrains E1 siRNA (p=0.042) and Congrains E19 siRNA (p=0.0001) by 
1.9-fold and 2.2-fold respectively (Figure 5.1C).   
In primary osteoblasts, there was a similar effect of the siRNAs on ANRIL as seen in 
hBMSCs though there are slight differences (Figure 5.2).  Exon 1-2 and exon 18-19 expression 
were significantly knocked down upon treatment with Congrains E1 siRNA (p=0.035) by 1.8-fold 
and 1.3-fold respectively.  Treatment with Congrains E19 siRNA also caused a significant decrease 
in exon 1-2 expression when compared to the control by 1.3-fold (p=0.048; Figure 5.2A) and exon 
18-19 by 2-fold (p=0.0014; Figure 5.2C).  As with hBMSCs, there was no change in exon 5-6 
expression with either Congrains E1 siRNA or Congrains E19 siRNA treatment (Figure 5.2B).   
To determine whether a reduction in ANRIL expression affected cell growth, live cells 
were counted after a 72hr period.  There were significant decreases in the number of live cells in 
wells treated with the positive cell death control when compared to the negative ‘scrambled’ 
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control for both hBMSCs (Figure 5.3A) and osteoblasts (Figure 5.3B).  There was also a significant 
decrease in the numbers of hBMSCs when they were treated with each of the ANRIL siRNAs 
(p<0.0001 for both; Figure 5.3A).  This was also seen in the primary osteoblasts, when treatment 
with Congrains E1 siRNA and Congrains E19 siRNA once again caused a significant decrease in the 
number of live cells (p<0.0001 for both; Figure 5.3B). 
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Figure 5.1: Results from RT-qPCR confirming knockdown of (A) ANRIL exons 1-2, (B) exons 5-6 and (C) 
exons 18-19 in transfected hBMSCs (n=5).   Results shown as mean ±SEM *p≤0.05; ***p≤0.001 
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Figure 5.2: Results from RT-qPCR confirming knockdown of (A) ANRIL exons 1-2, (B) exons 5-6 and (C) 
exons 18-19 in transfected primary osteoblasts (n=6).  Results shown as mean ±SEM *p≤0.05; **p≤0.01 
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Figure 5.3: Number of live (A) human bone marrow stromal cells (n=5) and (B) human primary osteoblasts 
(n=6) after 72hr transfection.  Cells were plated at 30,000 cells/well and were incubated with 10nM 
‘scrambled’, cell death, Congrains E1 and Congrains E19 siRNAs for 6hrs, after which media was changed to 
fresh basal or osteogenic medium for the remainder of the 72hrs.  Results shown as mean ±SEM 
****p<0.0001 
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5.3.2 ANRIL knock down does not have an effect on the viability of primary cells 
 To investigate whether there was a decrease in cell viability, as seen in SaOS-2 cells, 
hBMSCs and osteoblasts were plated in 96-well plates at 5,000 cell/well and treated with 
‘scrambled’ control, cell death control and both Congrains E1 and E19 siRNAs to determine if the 
knock down of ANRIL expression causes a change in cell viability.  To determine the viability of the 
cells, each of the wells were treated with CellTiter-Glo 2.0 luciferase assay (Promega) according to 
manufacturer’s instructions.  The ATP produced by the viable metabolically active cells reacts with 
the luciferase to produce a luminescent signal, which was then measured using a VarioSkan Flash 
Luminometer to determine the number of viable cells in each well as the ATP produced is directly 
proportional to the number of viable cells. 
 hBMSCs showed a significant decrease in luminescent signal in the cells treated with the 
cell death control siRNA (p=0.0005; Figure 5.4A); however, cells treated with either Congrains E1 
or Congrains E19 siRNAs did not show any significant change in luminescent signal when 
compared to the ‘scrambled’ control.  The results were the same for primary osteoblasts with 
cells treated with the cell death siRNA also caused a significant decrease in the luminescent signal 
(p<0.0001; Figure 5.4B).  As with the hBMSCs, primary osteoblasts did not show any significant 
change in luminescence, and therefore viability, when compared to cells treated with the 
‘scrambled’ control.  This would suggest that knock down of ANRIL does not have an effect on cell 
viability and that the decrease seen in cell number is not due to an increase in cell death. 
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Figure 5.4: Relative luminescent signal from (A) viable hBMSC (n=5) and (B) viable primary osteoblasts 
(n=6) compared to control.  Cells were plated in a 96-well plate at 5000 cells/well and treated with 10nM 
‘scrambled’, cell death, Congrains E1 and Congrains E19 siRNAs for 6hrs, after which media was replaced 
with either fresh basal or osteogenic medium for the remainder of the 72hrs.  CellTitre-Glo 2.0 luciferase 
assay determined the amount of viable cells via the luminescent signal detected produced by ATP 
metabolism. Results shown as mean ±SEM ****p≤0.0001 
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5.3.3 Knock down of ANRIL expression causes a decrease in the proliferation of primary cells 
 ANRIL knock down could be affecting the proliferation pathway, by modulating levels of 
the cell cycle inhibitor p16INK4A.  To determine if there is a change in the proliferation of both 
hBMSCs and osteoblasts upon treatment with ANRIL siRNAs, cells were plated in 96-well plates at 
5,000 cells/well and treated with 10nM ‘scrambled’ control, cell death control, Congrains E1 or 
Congrains E19 siRNAs for 6hrs, after which media was replaced and cells incubated at 37oC for 
another 66hrs.  24hrs before the end of the transfection, cells were treated with 1x BrdU reagent 
to allow incorporation into the DNA of proliferating cells.  Cells were then analysed using the BrdU 
Cell Proliferation ELISA Kit (Abcam) according to manufacturer’s instructions.  Absorbance was 
determined using a plate reader at λ450nm and analysed relative to ‘scrambled’ control 
absorbance. 
 There is a significant decrease in the proliferation of hBMSCs treated with the cell death 
control siRNA (p=0.0041; Figure 5.5A) when compared to cells treated with ‘scrambled’ control.  
There is also a significant decrease in the proliferation of hBMSCs treated with both Congrains E1 
and Congrains E19 siRNAs (p=0.018 and p=0.035 respectively).  A similar effect is seen with 
primary osteoblasts (Figure 5.5B).  Once again, the proliferation of the osteoblasts is significantly 
decreased in the wells treated with the cell death control siRNA (p=0.023).  Primary osteoblasts 
treated with 10nM of Congrains or Congrains E19 siRNA showed a significant decrease in 
proliferation (p=0.046 and p=0.043 respectively). 
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Figure 5.5: Relative absorbance of (A) viable hBMSC (n=5) and (B) viable primary osteoblasts (n=6) 
compared to control at λ450nm.  Cells were plated in a 96-well plate at 5000 cells/well and treated with 
10nM ‘scrambled’, cell death, Congrains E1 and Congrains E19 siRNAs for 6hrs, after which media was 
replaced with either fresh basal or osteogenic medium for the remainder of the 72hrs.  Cells were treated 
with 2x BrdU 24hrs before end of transfection and incorporation of BrdU into DNA was determined through 
an ELISA.  The amount of BrdU incorporation is used as a measure of cellular proliferation. Results shown as 
mean ±SEM *p≤0.05; **p≤0.01 
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5.3.4 Knock down of ANRIL expression causes cell cycle arrest in hBMSCs and primary 
osteoblasts 
 To determine whether this decrease in cell number was due to cell cycle arrest, FACS 
analysis was carried out.  hBMSCs and osteoblasts were transfected with either the ‘scrambled’ 
siRNA or the two ANRIL siRNAs.  After transfection cells were fixed with 70% ethanol and stained 
with propidium iodide.  The DNA content of 5000 cells was then analysed using FACS to determine 
which phases of the cell cycle the cells were in. 
 Upon treatment with Congrains E1 and Congrains E19 siRNAs, there was a significant 
increase in the percentage of hBMSCs being held in G0/G1 phase when compared to ‘scrambled’ 
control (p=0.045 and p=0.022 respectively; Figure 5.6A).  However, in transfected osteoblasts, 
only Congrains E19 siRNA caused an increase in the percentage of cells being held in G0/G1 phase 
compared to control (p=0.016; Figure 5.6B).  
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Figure 5.6: Percentage of (A) hBMSCs (n=5) and (B) primary osteoblasts (n=6) in G0/G1 phase relative to 
control determined through FACS analysis.  Cells were treated with 10nM of ‘scrambled’, Congrains E1 and 
Congrains E19 siRNAs for 6hrs, after which media was changed to fresh basal or osteogenic medium for the 
remainder of the 72hrs.  Cells were collected, lysed and DNA was stained with propidium iodide.  The DNA 
content of 5000 cells was then analysed using FACS to determine which stage of the cell cycle the cells were 
in.  Results shown as mean ±SEM. *p≤0.05 
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5.3.5 Does ANRIL mediate its affect through altered expression of the CDKN2A/B locus in 
primary cells? 
 To determine whether the decrease in proliferation rate seen in primary cells is due to an 
increase in the expression of the cell cycle inhibitors p16INK4A and p15INK4B, RT-qPCR was used to 
see what affect ANRIL knockdown had on the expression of these transcripts. 
 Knock down of ANRIL expression in hBMSCs had no effect on p16INK4A when cells are 
treated with either siRNA (Figure 5.7A), however transfection of hBMSCs with Congrains E1 siRNA, 
caused a significant decrease in p15INK4B expression (p=0.039; Figure 5.7B).  In primary osteoblasts, 
neither Congrains E1 siRNA nor Congrains E19 siRNA mediated knockdown of ANRIL expression 
lead to a change in p16INK4A (Figure 5.8A) or p15INK4B expression (Figure 5.8B).   
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Figure 5.7: Expression of p16
INK4A
 (A) and p15
INK4B
 (B) in hBMSCs after knock down of ANRIL expression 
(n=5).  Cells were plated in a 96-well plate at 5000 cells/well and treated with 10nM ‘scrambled’, cell death, 
Congrains E1 and Congrains E19 siRNAs for 6hrs, after which media was replaced with either fresh basal or 
osteogenic medium for the remainder of the 72hrs.  There is no change in p16
INK4A
 expression with either 
siRNA treatment, but there is a decrease in p15
INK4B
 expression only with Congrains E1 siRNA treatment 
(p=0.039). 
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Figure 5.8:  Expression of p16
INK4A
 (A) and p15
INK4B
 (B) in human primary osteoblasts after knock down of 
ANRIL expression (n=6).  Cells were plated in a 96-well plate at 5000 cells/well and treated with 10nM 
‘scrambled’, cell death, Congrains E1 and Congrains E19 siRNAs for 6hrs, after which media was replaced 
with either fresh basal or osteogenic medium for the remainder of the 72hrs.  There is no change in either 
p16
INK4A
 or p15
INK4B
 expression with either of the siRNA treatments 
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5.3.6 hBMSCs and primary osteoblasts treated with siRNAs against ANRIL are not undergoing 
replicative senescence 
 To confirm whether hBMSCs (n=5) and primary osteoblasts (n=6) were becoming 
senescent or not, cells were stained for senescence-associated -galactosidase (SA -
galactosidase).  After primary cells had been treated with ‘scrambled’, Congrains E1 and Congrains 
E19 siRNAs, cells were incubated overnight with X-gal (20mg/mL) after 72hrs.  Cells were then 
examined under the microscope for the presence of a blue precipitate that results from the 
cleavage of X-gal, signalling that there is SA -galactosidase activity.  As the assay is carried out at 
pH6, only the cells that have become senescent will stain blue, any immortal, quiescent or 
presenescent cells will remain unstained. 
 When both hBMSCs and primary osteoblasts are stained for senescence-associated -
galactosidase activity after treatment with 10nm ‘scrambled’, Congrains E1 and Congrains E19 
siRNAs, there is no visible difference in -galactosidase activity between the different treatments 
in either of the primary cell types (Figure 5.9), though there is visibly less staining when compared 
to positive control cells.  This would suggest that neither the hBMSCs nor the primary osteoblasts 
are undergoing senescence when ANRIL expression is knocked down. 
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5.4 Discussion  
 To determine the effect of reducing ANRIL expression in primary human bone marrow 
stromal cells and primary human osteoblasts, cells were transfected with two siRNAs against 
ANRIL (Congrains E1 and Congrains E19) and the effect on cell number, cell cycle stage, viability 
and proliferation assessed. Congrains E1 and E19 siRNAs were used in the primary cells, as these 
were shown to have the strongest effects in previous experiments.  The Ambion E1 siRNA, used in 
SaOS-2 cells, was not used in these experiments due to the constraints in growing large numbers 
of primary cells and keeping the passage number low.  Although hBMSCs were used, which 
represent a heterogeneous population of cells comprising of stem cells, osteoprogenitors, 
chondroprogenitors, osteoblasts, fibroblasts, etc, these cells did not show any positive alkaline 
phosphatase staining (as shown in Chapter 2; Figure 2.1) and preliminary testing showed that 
results between hBMSCs and STRO1+ selected stem cells were not different between the two cell 
populations. 
Transfection with siRNAs directed against exons 1 and 19 of ANRIL induced a decrease in 
ANRIL expression in both hBMSCs and primary osteoblasts.  Only Congrains E1 effectively reduced 
ANRIL exon 1-2 expression in hBMSCs, however in primary osteoblasts both the Congrains E1 and 
E19 induced a decrease in exon 1-2 expression.  This would suggest that different transcripts 
might be expressed in the different cell types and that in hBMSCs those transcripts, which contain 
exon 1, do not contain exon 19, whereas in primary osteoblasts those that contain exon 1 also 
contain exon 19.  Transfection of SaOS-2 cells with the siRNAs induced a similar pattern, with both 
siRNAs inducing a decrease in exon 1 and exon 19 expression, which is consistent with report that 
SaOS-2 expression analysis shows a similar profile to that of primary osteoblasts (290).  Both 
Congrains E1 and Congrains E19 siRNAs were found to also reduce expression of ANRIL exons 18-
19 containing transcripts in both primary cell types, which is consistent with the earlier findings. 
Interestingly, neither Congrains E1 nor E19 affected the expression of ANRIL exon 5-6 
transcripts in either hBMSCs or primary osteoblasts suggesting that those transcripts containing 
exons 1 and exon 19 do not contain the exons 5/6.  Previous studies have shown that some ANRIL 
transcripts do not contain exon 5/6 (238) and Holdt et al have discovered a novel ANRIL transcript 
in PBMCs that does not contain either exon 5 or 6 but does contain exons 1 and 19 (282).  
However, results of cell line assay from Chapter 3 do show that some of the ANRIL transcripts in 
hBMSCs and primary osteoblasts do express the exon 5-6 boundary, but these may be a minor 
proportion of the transcripts containing exon 5-6. 
Treatment with Congrains E1 and E19 caused a significant decrease in ANRIL expression in 
hBMSCs and primary osteoblasts; however, the expression levels of the exon 18-19 boundary was 
not reduced by the same fold across the two siRNA treatments.  In hBMSCs, Congrains E1 reduced 
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expression by 1.9-fold and Congrains E19 by 2.2-fold and in primary osteoblasts Congrains E1 
caused a 1.3-fold decrease in expression and Congrains E19 a 2-fold decrease; however, in both 
cases, there is no significant difference between the knock down in expression cause by both 
ANRIL siRNAs.  In hBMSCs as exon1-2 expression was only knocked down by Congrains E1 
treatment, whereas exon 18-19 expression was knocked down by both, this would suggest that 
some transcripts which exon 19 also contain exon 1, whereas others do not.  Though the majority 
of ANRIL transcripts do contain exon 1, there are a few that are known to lack this exon (238).  
However, in primary osteoblasts, as exon 1-2 and exon 18-19 expression is reduced in the 
presence of both Congrains E1 and E19 siRNAs, it would suggest that the majority of ANRIL 
transcripts in this cell type contain both exon 1 and exon 19. 
A reduction in ANRIL expression induced a significant decrease in both hBMSC and 
osteoblast cell number when treated with either Congrains E1 or E19 ANRIL siRNAs against ANRIL; 
however, this does not seem to be caused by an increase in cell death, as the cell viability assay 
did not show an increase in the number of cells undergoing apoptosis.  The FACS data for both cell 
types showed a significant increase in the number of cells being held in the G0/G1 phase of the cell 
cycle, except for primary osteoblasts treated with the Congrains E1 siRNA, which would suggest 
that the cell are exiting the cell cycle or that they could be undergoing premature senescence.  
The BrdU incorporation assay confirmed that the proliferation rate of the cells was decreased in 
both primary cell types with both siRNA treatments, which we would expect when ANRIL 
expression is knocked down as this lncRNA, as stated previously, negatively regulates cell cycle 
inhibitors and would be caused by cell cycle exit or when cells become senescent.  However, 
p16INK4A expression, a marker for senescence and cell cycle arrest, is not increased in either of the 
primary cell types upon ANRIL knockdown and when cells are stained for senescence-associated 
-galactosidase activity, there is no visible difference between control and ANRIL siRNA treated 
cells. 
A gene expression profile carried out by Jia et al has revealed the top 30 transcripts that 
are expressed in hBMSCs.  Out of these 30 genes, 13 have a role in cell structure/motility, 13 a 
role in cell signalling and communication, 2 that are related to gene/protein expression and 2 
whose roles are unknown (311).  These genes include transforming growth factor -induced 
(TGFBI), fibronectin, osteonectin and many members of the collagen family.  Certain proteins on 
this list have been shown to have a role in regulating cell cycle or proliferation such as fibronectin 
and TGFBI.  TGFBI has been shown in mice to have an effect on cell proliferation by Zhang et al.  
When mice are deficient in TGFBI it leads to an increased rate of proliferation, which is caused by 
unregulated activation of the CREB-Cyclin D1 pathway (312).  However, when TGFBI protein is 
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reintroduced to the cells, the activation of the CREB cycle becomes suppressed, as does cyclin D1 
expression.  Fibronectin has also been shown to inhibit the terminal differentiation of human 
keratinocytes (313), which could potentially suggest a role for fibronectin in preventing the 
differentiation of hBMSCs.  If ANRIL has a role in regulating either of these pathways, it could 
explain why there is a decrease in cell number and proliferation rate with the knock down of 
ANRIL expression. 
Unexpectedly, p15INK4B expression does not increase when ANRIL expression is knocked 
down and, as ANRIL is the antisense sequence to this gene, we would expect an increase in 
expression.  Similarly to what was seen with SaOS-2 cells, there is a decrease in p15INK4B 
expression when hBMSCs are treated with the Congrains E1 siRNA.  This could be because the 
decrease in ANRIL expression allows for the recruitment of other repressive complexes to the 
p15INK4B locus.  Both Basu et al and Staller et al have demonstrated that p15INK4B expression is 
suppressed through interactions of two different proteins with Myc-interacting zinc finger 
protein-1 (Miz-1): Gfi-1 and Myc (314,315).  Both of these groups showed that, when these 
proteins are recruited to the CDKN2B gene locus and form a complex with Miz-1, there is a 
decrease in p15INK4B expression. 
It is clear that the effects we see on cell number, cell proliferation and cell cycle phase 
due to the knock down of ANRIL do not primarily occur through the cis-function of regulating the 
CDKN2A/B gene locus.  This would suggest that ANRIL could be having some trans-functional 
effects in both hBMSCs and primary osteoblasts. 
 
5.5 Summary 
 We sought to demonstrate that knock down of ANRIL expression in hBMSCs and primary 
osteoblasts had similar effects to those observed in SaOS-2 cells.  Our results show that when 
ANRIL expression is knocked down in both hBMSCs and primary osteoblasts there is a decrease in 
cell number and proliferation rate with both siRNA treatments; however in primary osteoblasts 
only the Congrains E19 siRNA caused an increase in the number of cells being held in the G0/G1 
phase of the cell cycle, whereas both Congrains E1 and Congrains E19 cause this effect in hBMSCs.  
Cell viability was unaffected, which informs us that a decrease in ANRIL expression does not lead 
to an increase in apoptosis in these two cell types. 
 We determined through RT-qPCR and senescence-associated -galactosidase staining that 
the cells were not becoming senescent as there was no increase in either p16INK4A or p15INK4B, both 
markers of senescence, and cells did not stain positive for -galactosidase activity.  However, 
p15INK4B expression did decrease in hBMSCs treated with Congrains E1, which suggests that with 
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ANRIL expression knocked down, this could allow for other repressive complexes to be recruited 
to CDKN2B and suppress p15INK4B expression. 
 These results suggest ANRIL could have a potential trans-functional role in these two cell 
types, as knock down of ANRIL expression does not seem to have an effect on CDKN2A/B gene 
expression.  In order to determine whether ANRIL has any effects elsewhere in the genome, RNA 
samples from cells treated with siRNAs against ANRIL can be analysed with a gene expression 
array to see if this knock down causes a change in the expression of any other genes. 
 
5.6 Further work 
 A way to continue this work further would be to stably transfect hBMSCs with an ANRIL 
siRNA and then try to differentiate these cells in primary osteoblasts to determine whether ANRIL 
has a potential role during this process.  We could also introduce an ANRIL construct into both cell 
types to see what effect ANRIL overexpression would have on the cells, if any. 
 The results presented in this chapter hint that there may potentially be different ANRIL 
transcripts expressed in the different cell types.  It could be interesting to determine what the 
sequences of these transcripts actually are as ANRIL expression has not previously been 
investigated in hBMSCs or bone cells thoroughly.  This could potentially be done through rapid 
amplification of cDNA ends (RACE), which would allow for the transcripts to be amplified so that 
they could be sent off for sequencing.  Another way of looking at currently known ANRIL 
transcript expression would be through a literature search for ANRIL PCR primers and running 
them with DNA from hBMSCs and primary osteoblasts.  This would allow us to determine what 
transcripts are being expressed in these bone-related cells. 
 It would also be interesting to determine the effect that ANRIL has on MSC differentiation 
into osteoblasts, if any.  To do this, ANRIL siRNA would be transfected into hBMSCs using a 
lentiviral vector, which would allow for a stable transfection.  A transient transfection could not 
be used for this experiment, as the differentiation process takes longer than three days, which is 
the maximum time that a transient transfection has an effect.  This would allow us to determine if 
a reduction in ANRIL expression has an adverse effect on the development of osteoprogenitors 
and mature osteoblasts. 
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Chapter 6 
Effects of ANRIL knock down on gene 
expression in primary human 
osteoblasts  
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6.1 Introduction 
The down regulation of ANRIL expression in both SaOS-2 cells and primary human 
osteoblasts leads to a decrease in cell number and a decrease in proliferation; however this was 
not accompanied by an increase in p16INK4A expression.  ANRIL has been reported to function both 
in cis and in trans.  In cis, ANRIL can act by down regulating the expression of p15INK4B and p16INK4A 
by recruiting PRCs to the promoters of the CDKN2A/B gene locus and causing trimethylation of 
lysine 27 of histone 3 (243,283).  This prevents the binding of transcriptional machinery and so 
suppresses p16INK4A and p15INK4B expression, thus preventing cell cycle progression.  ANRIL also 
regulates p15INK4B through an antisense mechanism where it binds directing to its complementary 
sequence in the CDKN2B locus and prevents the transcription of this gene (288).  In trans, ANRIL 
has been shown to regulate genes that are involved in atherogenic pathways and are not found 
on the chromosome as CDKN2A. 
Trans-regulation is defined as intermolecular interactions where gene products regulate 
the expression of distant genes, for example, genes that encode transcription factors, as opposed 
to cis-regulation, where the gene acts in an intramolecular fashion to regulate the action of the 
same molecule or the same gene (316,317).  It has been suggested that a potential function of 
lncRNAs is to act as trans-regulators of transcription.  One well characterised lncRNA that acts in 
this way is HOX transcript antisense RNA (HOTAIR).  This lncRNA is transcribed from the HOXC 
gene located on chromosome 12 and was the first lncRNA to be shown to influence transcription 
on another chromosome (190).  Rinn et al found that, through interactions with PCR2, HOTAIR 
repressed the expression of HOXD found 40 kilobases away from HOXC on chromosome 2 via 
chromatin remodelling (279). 
Although there are not any studies looking at a potential trans-function of the lncRNA 
ANRIL specifically in bone differentiation or homeostasis, there have been studies suggesting that 
ANRIL may have a trans-regulatory role in other tissues.  In HeLa cells, Sato et al have suggested 
that a novel isoform of ANRIL may be involved in the regulation of the nucleus (277).  When this 
isoform was overexpressed in these cells, using gene ontology enrichment analysis, it was found 
that the expression of 38 genes involved in nucleus regulation were altered – 36 genes were down 
regulated and 2 genes were upregulated.  However, it was not definitively shown that ANRIL was 
specifically binding to the promoters of the genes that showed differential expression.  This could 
mean that the changes observed could be p16INK4A and p15INK4B dependent.  Holdt et al have also 
demonstrated through overexpression of certain ANRIL transcripts, that ANRIL trans-regulates 
genes that are involved in cellular adhesion, cellular proliferation and apoptosis.  Through ChIP 
assays they also revealed that these trans-regulatory effects were dependent on Alu motifs in the 
promoters of target genes (282).  This group postulated that ANRIL acts as a scaffold for PRC1 and 
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2 through binding to CBX7 and SUZ12 respectively and that ANRIL then directs epigenetic changes 
to chromatin by binding to Alu elements found in the promoters of target genes.  These data 
suggest that Alu elements could be essential for ANRIL binding to trans-regulated target genes. 
 
6.2 Aims 
In primary osteoblasts, although ANRIL induced a decrease in cell proliferation and cell 
number, there was no effect on p16INK4A expression, suggesting that these effects may be induced 
via ANRIL acting in trans.  To determine, therefore, what genes and pathways were affected by a 
decrease in ANRIL expression, RNA was extracted from osteoblasts that had been treated with 
‘scrambled’ and Congrains E1 siRNAs and mRNA expression in these samples was analysed using 
the Illumina Human HT12 Gene Expression Array.   
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6.3 Results 
6.3.1 Validation of Illumina Human H12 Gene Expression Array results 
To determine whether knock down of ANRIL had an effect on gene expression in human 
primary osteoblasts, RNA from primary osteoblasts treated with ‘scrambled’ and Congrains E1 
siRNAs (n=5) was analysed using Illumina Human H12 Gene Expression Array (Genome Centre, 
Barts and the London Medical School).  After QC and normalisation, the Genome Centre 
performed signal extraction, and AVG_Signal and Detection_Pvalue values were obtained for each 
of the 47,229 probes on the array. Only the 14,757 probes that achieved detection p-value <0.05 
in all ten samples were retained for analysis. Paired t-tests were performed by Prof Joanna 
Holbrook on AVG_Signal values to determine the probes varying by treatment within each cell 
line pair. 274 probes (mapping to 260 unique genes) were significantly differentially expressed 
with respect to treatment after multiple testing correction (FDR corrected p-value<0.05), of these 
128 were upregulated and 132 were down regulated.  The top twenty upregulated and down 
regulated genes that showed the greatest fold change are shown in Table 6.1.  All genes that were 
shown to have significant differential expression after multiple testing correction are shown in 
Appendix, Table 9.1. 
 
 
 
 
Table 6.1: Twenty upregulated and twenty down regulated genes with the highest fold changes.  Of the 
136 upregulated genes and the 138 downregulated genes, the ones listed above showed the greatest 
fold change with an FDR corrected p-value ≤0.05. 
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In order to validate the results from the array, RT-qPCR was used to determine whether 
the changes in expression between the treatment and control group seen in the array can be 
replicated using a different platform.  Interestingly, the array did show that the expression of both 
p16INK4A and p15INK4B, were unaffected by a decrease in ANRIL expression.  This agreed with what 
has been shown in the previous chapter using RT-PCR in that p16INK4A and p15INK4B expression was 
unchanged in osteoblasts upon treatment with siRNA against ANRIL (Section 5.3.5). 
Six genes were selected for validation based on their known associations with osteoblast 
regulation or bone homeostasis and the level of differential gene expression.  The upregulated 
gene chosen for validation were HIF1A, MAPK3 and IGF2 and the down regulated genes were 
ETS1, TWSG1 and CYR61 from the list of down regulated genes were chosen to validate the array 
data.  RT-qPCR analysis showed that treatment with Congrains E1 siRNA caused an increase in the 
expression HIF1A (Figure 6.1A), IGF2 (p=0.043; Figure 6.1B) and MAPK3 (p=0.032; Figure 6.1C), 
although HIF1A only showed a trend towards significance (p=0.09).  The change in expression was 
in the same direction as that shown on the array, though the fold differences were not replicated.  
On the array both IGF2 and MAPK3 showed a 1.62-fold increase in gene expression when cells 
were treated with Congrains E1 siRNA, whereas using RT-qPCR demonstrated a 3.6-fold increase 
in IGF2 expression and a 2.8-fold increase in MAPK3 expression.  When the change in gene 
expression was examined in the down regulated genes, only ETS1 expression was significantly 
decreased between the Congrains E1 siRNA treated cells and the control cells (Figure 6.1D), 
whereas both CYR61 and TWSG1 did not reach significance (Figure 6.1E and 6.1F respectively), 
although CYR61 showed a trend towards significance in the same direction as shown on the array 
(p=0.066).  The fold changes of ETS1 gene expression between the array and RT-qPCR did not 
replicate as the fold expression for this gene on the array was -2.3-fold decrease, whereas the fold 
change determined by RT-qPCR was -1.3-fold decrease. 
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Figure 6.1:  Gene expression levels of (A) HIF1A, (B) IGF2, (C) MAPK3, (D) ETS1, (E) CYR61 and (F) TWSG1 
in primary osteoblasts compared to control when cells have been treated with a siRNA against exon 1 of 
ANRIL.    Treatment with Congrains E1 siRNA caused an increase in IGF2 and MAPK3 expression and caused 
a decrease in ETS1 expression.  This agrees with what was shown on the Illumina Human H12 array. Results 
shown as mean ±SEM **p≤0.01; *p≤0.05. n=5 
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Expression of these genes were also examined in primary osteoblasts that had been 
treated with Congrains E19 siRNA, which targets exon 19 of ANRIL, as treatment with this siRNA 
had also been shown to have an effect on primary osteoblast cell proliferation and cell number.  
Treatment with this siRNA caused a significant increase in both HIF1A (p=0.0015; 2.1-fold increase) 
and IGF2 expression (p=0.044; 2.7-fold increase), but MAPK3 expression was unchanged. In the 
genes that demonstrated down regulation on the array, there was a significant decrease in ETS1 
(p=0.013; -2.1-fold decrease) and CYR61 expression (p=0.041; -2.4-fold decrease) and a significant 
increase in TWSG1 expression (p=0.0085; 3.3-fold increase), when cells were treated with 
Congrains E19 siRNA. 
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Figure 6.2: Gene expression levels of (A) HIF1A, (B) IGF2, (C) MAPK3, (D) ETS1, (E) CYR61 and (F) TWSG1 in 
primary osteoblasts compared to control when cells have been treated with a siRNA against exon 19 of 
ANRIL.  Treatment with Congrains E19 siRNA caused an increase in HIF1A, IGF2 and TWSG1 expression and 
caused a decrease in ETS1 and CYR61 expression.  Results shown as mean ±SEM ***p≤0.001; **p≤0.01; 
*p≤0.05. n=5 
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6.3.2 ANRIL knock down in primary osteoblasts alters osteoblast-specific pathways. 
In order to determine whether particular pathways were altered between the ANRIL 
siRNA treated osteoblasts and the control group, Ingenuity Pathway Analysis (IPA) software 
(Qiagen, California) was used to determine how the 274 genes that showed differential 
expression relate to pathways with biological function.    Genes were divided into two main 
subcategories: molecular and cellular functions and physiological system development and 
function.  These categories are further subdivided into functionally related pathways. 
Within molecular and cellular functions, the top two most altered pathways were those 
related with cellular development, growth and proliferation, showing a total of 75 altered genes, 
which is more than 50% of the altered genes associated with this subcategory (Figure 6.3A).  
Within the physiological system development and function subcategory, the top pathway with the 
most altered genes is tissue development, showing 19 altered genes (Figure 6.3B).  The second 
most altered pathway is skeletal and muscular system development and function, which contains 
12 altered genes.  
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Figure 6.3: Break down of biological functions and the number of genes with changed expression 
associated with those functions. (A) Molecular and cellular functions and (B) Physiological system 
development and function. 
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Pathways within these main categories were investigated further and altered genes 
within these pathways were found to have specific functions in osteoblast-related pathways.  
Genes that were altered in the cellular development pathway were shown to have roles in 
osteoblast differentiation, differentiation of bone cell lines, osteoblast proliferation and the 
differentiation of stem cells (Figure 6.4A).  In the cellular growth and proliferation pathways, the 
genes that were altered were shown to have roles in the proliferation of osteoblasts, 
development of bone marrow cells and the colony formation of cells (Figure 6.4B).   
In the tissue development pathways, genes that were altered fell under two categories, 
ones that were involved in osteoblast regulation and ones that were involved with connective 
tissue development.  Those that were involved in osteoblast regulation were shown to have roles 
in osteoblast cell viability, the development of bone marrow cells and the proliferation, adhesion, 
differentiation and migration of osteoblasts (Figure 6.5A).  Those that were involved with 
connective tissue development had roles in pathways that regulated the differentiation, 
proliferation and growth of connective tissue cells, as well as the deposition of fibrous tissue, S 
phase entry of fibroblasts and the senescence of fibroblasts (Figure 6.5B). 
In the skeletal and muscular system development and function pathways, the genes that 
were altered by ANRIL knock down were once again involved in adhesion, cell viability, 
proliferation, differentiation and migration of osteoblasts as well the differentiation of bone cell 
lines (Figure 6.6).  These were also the pathways shown to contain altered genes in the tissue 
development pathways and involve many of the same genes. 
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Figure 6.4: The top two altered pathways under the molecular and cellular function subcategory that 
showed relation to osteoblast function.  (A) Altered genes that are involved in cellular development 
pathways and (B) altered genes that are involved in cellular growth and proliferation pathways. Red 
symbols denote upregulated genes and green symbols denote downregulated genes.  The intensity of 
the colour denotes the magnitude of the change in expression. 
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Figure 6.5:  Tissue development pathways that involve genes altered by ANRIL knock down. (A) Altered 
genes involved in pathways that regulate osteoblasts and (B) altered genes involved in pathways that 
regulate the growth of fibroblasts and connective tissue.  Red symbols denote upregulated genes and 
green symbols denote downregulated genes.  The intensity of the colour denotes the magnitude of the 
change in expression. 
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Figure 6.6: Skeletal and muscular system development and function pathways that involve genes 
altered upon ANRIL knock down. Network shows those genes involved with osteoblast and bone specific 
pathways. Red symbols denote upregulated genes and green symbols denote downregulated genes.  The 
intensity of the colour denotes the magnitude of the change in expression. 
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 To gain further insight into the pathways changed upon decrease in ANRIL expression, the 
Gene Ontology Consortium (http://geneontology.org/page/go-enrichment-analysis) and the 
Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
(https://david.ncifcrf.gov/) analysis packages were used to determine what biological processes, 
molecular function and functional categories the differently expressed genes were involved in 
gene ontology enrichment analysis was used.  The two biological processes that were enriched 
were protein transport and cellular processes.  Of the 260 genes that showed altered gene 
expression, only 218 were able to be mapped to the database, which could be explained by the 
fact that some of the genes included on the Illumina array map to predicted gene locations.  Of 
the genes that were differentially expressed, 69 genes were involved in protein transport, with 37 
being upregulated and 32 being down regulated (Figure 6.7A).  183 of these genes were shown to 
be involved with cellular processes, with 89 being upregulated and 94 being down regulated 
(Figure 6.7B).  The only molecular function that was shown to be significantly enriched was 
protein binding, of which 152 of the genes were involved, with 67 being upregulated and 85 being 
down regulated (Figure 6.8). 
The top five functional categories that were enriched were phosphoprotein, alternate 
splicing, nucleus, cytoplasm and acetylation.  123 genes of the 218 that mapped to the database 
came under the phosphoprotein category, with 48 being upregulated and 75 being 
downregulated (Figure 6.9A) and 104 genes are involved in alternate splicing, of these 39 are 
upregulated and 65 are down regulated (Figure 6.9B).  More of the differentially expressed genes 
had roles in the nucleus than in the cytoplasm (62 and 60 respectively).  Of the genes involved in 
nuclear processes, 28 were upregulated and 34 were down regulated (Figure 6.9C), whereas 23 
genes involved in cytoplasmic processes were upregulated and 37 were downregulated (Figure 
6.9D).  The final category that was enriched was acetylation, which involved 57 genes of the 218 
that mapped to the database.  28 of these genes were upregulated and 29 of these genes were 
downregulated (Figure 6.9E). 
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Figure 6.7:  The number of up and downregulated genes involved in (A) protein transport and (B) 
cellular processes in osteoblasts upon ANRIL knock down.  Gene ontology enrichment analysis revealed 
that the genes which showed altered expression upon ANRIL knock down were mainly involved in two 
biological processes. 
 
 
Figure 6.8:  The number of up and downregulated genes involved protein transport. Gene ontology 
enrichment analysis revealed that the genes which showed altered expression upon ANRIL knock down 
were involved in one molecular function. 
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Figure 6.9: Top five enriched functional categories – (A) phosphoprotein, (B) alternate splicing, (C) 
nucleus, (D) cytoplasm and (E) acetylation.   Gene ontology enrichment analysis revealed the top five 
functional categories that the genes which showed altered expression upon ANRIL knock down were 
involved in. 
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6.4 Discussion 
 To determine the mechanism by which a decrease in ANRIL expression affects primary 
osteoblast growth and differentiation, cells were treated with Congrains E1 siRNA against ANRIL 
and ‘scrambled’ control (n=5) as previously described, RNA was extracted and analysed by 
Illumina Human H12 Gene Expression array.  Although treatment with both Congrains E1 and E19 
siRNAs caused a decrease in ANRIL expression in primary osteoblasts and also caused changes in 
cell number and proliferation of primary human bone marrow stromal cells, only RNA from 
primary osteoblasts treated with Congrains E1 siRNA was sent off for gene expression analysis as 
it showed the most consistent results across each experiment. 
 Transfection of primary osteoblasts with a siRNA against exon 1 of ANRIL caused 
significant differential expression of 260 genes when compared to the ‘scrambled’ control.  Of 
these genes 128 showed an increase in expression and 132 showed a decrease in expression 
when compared to control samples.  Interestingly, the list of altered genes did not contain 
CDKN2A or CDKN2B from which p16INK4A and p15INK4B are transcribed and which ANRIL has been 
reported to negatively regulate in cis.  This agrees with what was shown in the previous chapter 
by RT-qPCR, in that knock down of ANRIL expression did not cause any alteration in p16INK4A or 
p15INK4B expression.  The array validated this previous finding using another platform and suggests 
that the decrease in cell proliferation and cell number is not dependent on p16INK4A or p15INK4B but 
is caused by an alternative mechanism. 
 The expression of six genes with known associations with osteogenesis and osteoblast 
differentiation, were chosen for RT-qPCR analysis to validate the results from the array.  RT-qPCR 
analysis showed that ANRIL downregulation induced an increase in HIF1A, IGF2 and MAPK3 
expression and caused a decrease in ETS1, TWSG1 and CYR61 expression, consistent with the 
findings from the array, although while IGF2, MAPK3 and ETS1 showed significant changes in 
expression between Congrains E1 siRNA treated cells and control cells, HIF1A and CYR61 showed 
a trend towards significance.  These differences in the statistical significance is likely to reflect the 
different methodologies used but does suggest overall that the differences seen on the array are 
genuine. 
As a number of the validation genes play roles in bone development and function, we also 
examined whether the siRNA directed against exon 19 of ANRIL also effected the expression of 
these genes. HIF1A, IGF2 and TWSG1 showed an increase in expression and ETS1 and CYR61 
showed a significant decrease in expression.  These differences in expression were in the same 
direction as what had been shown on the array for cells treated with Congrains E1 siRNA, apart 
from TWSG1, suggesting that in this case isoforms of ANRIL containing exon 19 may have different 
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effects on gene expression to those containing exon 1.  Holdt et al have previously shown that 
overexpression of different isoforms of ANRIL containing different exons have different effects on 
cell adhesion and cell number in HEK293 cells, an embryonic kidney cell line (282). 
In bone, HIF1α expression has been shown to have a role in promoting BMP9-induced 
osteogenic differentiation and suppressing the proliferation of osteoblasts (318,319).  IGF2 has 
also been shown to potentiate the same BMP9-induced osteogenic differentiation pathway and 
bone formation and has been shown to promote osteogenic differentiation in murine embryonic 
stem cells (320,321).  MAPK3 is a downstream signal transducer in the FGF signalling pathway and 
it has been demonstrated that inhibition of this kinase greatly decreases both osteoblast 
differentiation and matrix deposition (322).  ETS1 has been shown to have a role in controlling the 
proliferation of osteoblasts (323,324), as has CYR61 (325). TWSG1 has been shown to regulate 
BMP2 dependent osteoblast differentiation, in that overexpression of TWSG1 has been shown to 
act as an antagonist for BMP2 signalling (326).  This alteration in gene expression caused by a 
knock down in ANRIL expression seems to lead to a change in the pathways that regulate 
osteoblast differentiation, mineralisation and proliferation.  This decrease in ANRIL expression 
leads to an upregulation of genes that cause differentiation and matrix mineralisation and a 
downregulation of genes that regulate cellular proliferation, such as ETS1 and CYR61.  This 
decrease in ETS1 and CYR61 could explain the decrease in cell number and proliferation that was 
seen in the ANRIL knock down experiments in the previous chapter, thus suggesting that ANRIL 
regulates pathways other than those that involve CDKN2A/B transcripts. 
The amplitude of the expression changes were not consistent across the two techniques 
used for analysis.  This may be due to the different technologies used, as the probes used in the 
array may target different regions of the mRNA compared to the primer and probe sets used in 
the TaqMan RT-qPCR assays, thus explaining the differences seen in fold change.  This could also 
explain why the changes in HIF1A, CYR61 and TWSG1 expression did not reach significance in 
osteoblasts treated with Congrains E1 siRNA against ANRIL. 
Pathway analysis was carried out on the 260 significantly changed genes found upon 
treatment of cells with siRNA against exon1 of ANRIL using IPA. Pathways implicated in cellular 
development, cellular growth and proliferation, tissue development and skeletal and muscular 
system development and function were identified, with the highest number of genes changed in 
the molecular and cellular functions and physiological system development and function 
subcategories.   Interestingly, each of these pathways contained genes that were directly linked to 
osteoblast proliferation, differentiation, migration, cell viability and adhesion as well as genes that 
were linked to pathways such as stem cell differentiation, development of bone marrow cells, 
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colony formation of cells and differentiation of bone cell lines.  The tissue development pathways 
also showed altered genes that are involved in connective tissue generation, including those that 
regulate proliferation, growth and differentiation of connective tissue cells as well as genes that 
regulate the entry into S phase of fibroblasts, fibroblast senescence and deposition of fibrous 
tissue by fibroblasts.  Along with cartilage and bone cells, fibroblasts make up the connective-
tissue cell family, and are specialised for the secretion of extracellular matrix, and they can play an 
important role in bone repair and formation as they can act as a source of precursors for 
osteoblasts and osteoclasts (327). 
The range of processes affected by ANRIL down regulation occurred in the absence of a 
change in the levels of p16INK4A and p15INK4B expression.  Although ANRIL has not previously been 
shown to have any trans-functional effects in osteoblasts, Congrains et al have shown that knock 
down of ANRIL expression, using the same siRNA that has been used in these experiments, has 
effects on genes involved in atherogenesis in human VSMCs.  When ANRIL expression was 
knocked down in VSMCs, HBEGF and CDH5 expression decreased and the expression of BCL2A1 
and SERPINE increased, which are all key components in atherogenesis.  One of the genes that 
was highlighted as having a positive effect on cell viability was IGF2.  Upon knock down of ANRIL 
expression, IGF2 expression was shown to increase, which was predicted by IPA to activate cell 
viability pathways.  This agrees with what was shown in the previous chapter using the CellTitre 
Glo 2.0 assay, where a knock down in ANRIL expression did not cause a decrease in cell viability, 
suggesting that the pathway involving IGF2 maybe become activated to prevent cell death in 
osteoblasts.  Together, these results suggest that ANRIL potentially has trans-regulatory functions 
in osteoblast specific pathways and that a decrease in ANRIL expression can lead to the 
dysregulation of these pathways, which could lead to incorrect bone formation and remodelling. 
Additional gene ontology enrichment analysis revealed that in cells that had been treated 
with Congrains E1 siRNA, there was an enrichment in processes other than cell cycle regulation.  
Genes that showed differential expression on the array had roles in protein transport and binding 
as well as other cellular processes, with the top five enriched functional categories were 
phosphoproteins, alternate splicing, nucleus, cytoplasm and acetylation.  This demonstrates that 
ANRIL potentially regulates genes that are involved in a wide variety of cellular processes in 
osteoblasts.  Sato et al have previously demonstrated in HeLa cells that an overexpression of 
ANRIL lead to an enrichment of genes that were involved in nuclear regulation, most of which 
were down regulated (36 downregulated vs 2 upregulated) (277).  Other lncRNAs, such as 
MATAL1 and NEAT1, have been found to be enriched in the nucleus (328) and in osteoblasts, the 
lncRNA MATAL1 has been shown to act downstream of RANKL to inhibit cell proliferation and to 
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regulate the expression of osteoprotegerin (329).  This suggests that although ANRIL has not been 
shown to have a specific role in nuclear regulation in osteoblasts, other lncRNAs have, suggesting 
that this may also be true for ANRIL.  Another functional category that was enriched for genes 
with altered expression was those that have a role in acetylation.  Although ANRIL has not 
previously been shown to influence acetylation mechanisms, it has been shown to bind with PRC2 
and act as a scaffold to assist in histone methylation (283), another type of epigenetic regulatory 
mechanism. However, in osteoblasts, the lncRNA HIF1α-antisense 1, through the down regulation 
of HOXD10 interfered with histone acetylation and, subsequently, caused the inhibition of 
osteoblast differentiation (330), suggesting a possible role for ANRIL in regulating acetylation in 
osteoblasts. 
The results in this chapter have demonstrated the potential for ANRIL to regulate other 
genes across the genome in trans in osteoblasts, with no change to the expression of genes that 
this lncRNA regulates in cis.  However, it now needs to be determined whether the changes in 
gene expression seen is a direct effect of a decrease in ANRIL expression. 
 
6.5 Summary 
 We sought to determine whether the knock down of ANRIL expression using a siRNA 
targeted against exon 1 of ANRIL (Congrains E1 siRNA) caused a change in gene expression in 
osteoblasts using the Illumina Human H12 Gene Expression Array.  This showed that 260 genes 
had significantly altered expression between treated and control cells – 128 upregulated and 132 
downregulated.  Both CDKN2A and CDKN2B expression was unaltered on the array, confirming 
what had already been seen with RT-qPCR.  HIF1A, IGF2 and MAPK3 showed increased expression 
on the array with ANRIL knock down, whereas ETS1, CYR61 and TWSG1 showed decreased 
expression on the array, with all of these genes having been linked to osteoblast specific 
pathways in the literature.  Using RT-qPCR, only IGF2, MAPK3 and ETS1 expression changes 
reached significance, with HIF1A and CYR61 showing trends towards significance, all in the same 
directions as shown on the array.  With Congrains E19 siRNA treated cells, HIF1A, IGF2, ETS1, 
CYR61 and TWSG1 expression was significantly altered when compared to control cells, 
suggesting that ANRIL may trans-regulate other genes beside CDKN2A and CDKN2B. 
 Using IPA and gene ontology enrichment analysis, it was determined that genes that 
showed significantly altered expression on the gene expression array were involved in osteoblast 
specific functions, such as differentiation, proliferation, cell viability and migration, as well as 
development of connective tissue specific pathways.  Gene ontology analysis revealed that genes 
with significantly altered expression were enriched for protein transport, protein binding, nuclear 
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regulation and acetylation, as well as many of them being phosphoproteins.  These results suggest 
that ANRIL may have a specific role in osteoblast regulation, and therefore bone formation, as 
well as roles other than the regulation of the cell cycle.  In order to determine if ANRIL is actually 
binding to these genes to cause differential expression, further work needs to be done. 
 
6.6 Future work 
 In order to determine whether ANRIL is directly binding to the promoters of the genes 
that demonstrated differential expression in the Ilumina Human H12 array, Chromatin Isolation by 
RNA Purification (ChIRP) assay can be used (331).    This method allows for the determination of 
DNA regions that are associated with a specific lncRNA and would allow us to determine if ANRIL 
was directly binding to the promoters of these genes.   Holdt et al have previously shown that 
genes which showed altered expression with ANRIL overexpression were enriched for Alu binding 
sequences (282), so we can use bioinformatic analyses of promoter regions to determine if any of 
the genes that displayed altered expression on the array also contain this motif. 
 As many of the pathways that were effected by knock down of ANRIL expression involved 
osteoblast differentiation and mineralisation, it would be interesting to see how gene expression 
changes when cells are differentiated from hBMSCs to osteoblasts, and whether this effects 
morphology and cell survival.  As the differentiation and mineralisation processes take longer than 
the window for transient transfection, a stable transfection using lentivirus would have to be 
done into hBMSCs and then these cells directed down the osteogenic lineage.  Differentiation and 
mineralisation could then be assessed to determine whether they have been affected. 
 A gene expression array using hBMSCs that had been treated with siRNAs against ANRIL 
could also be done to determine whether similar genes, or genes that are more specifically 
related with earlier stages of osteogenesis, such as SOX9, BMPs and β-catenin, are affected. 
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Chapter 7 
The association between the 
methylation status of CDKN2A, RXRA 
and NOS3 with bone outcomes at birth
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7.1 Introduction 
7.1.1 DNA methylation as a marker for later phenotype 
 Epidemiological studies measure DNA methylation within peripheral tissue in order to 
determine associations with future phenotype, as these are easily accessible tissues.  However, as 
DNA methylation patterns are tissue specific, this would suggest that methylation in proxy tissues 
may not accurately reflect methylation in tissues such as bone and the functional significance of 
differential methylation in proxy tissue in the causal pathway is unknown.  However, there are 
now studies that show that methylation patterns can be conserved across different tissue types 
(218,219).  Lu et al have demonstrated that the methylation levels of five genes are stable across 
thirteen different tissues types that are derived from different germline layers (219). 
Epidemiological studies have shown that there are associations between the methylation 
status of CpGs from umbilical cord tissue DNA and offspring anthropometric outcomes in 
childhood.  Using both the PAH and SWS cohorts, Godfrey et al demonstrated that CpG 
methylation within the RXRA promoter is positively associated with childhood %FM and total fat 
mass at 6 and 9 years in two independent cohorts (220).  The same paper also demonstrated that 
the methylation levels of a CpG within the NOS3 promoter region also had similar positive 
associations with %FM, fat mass and ratio of trunk to limb fat but these associations were only 
seen in the PAH cohort.  The methylation of these CpGs has also been investigated with regards to 
offspring bone outcomes, with the methylation of RXRA in cord tissue being negatively associated 
with bone outcomes (list) and methylation of NOS3 in cord being positively associated with 
offspring bone outcomes at 4 years and 9 years respectively (205,234). 
These studies have suggested that altered DNA methylation, even in proxy tissues, might 
provide useful biomarkers for disease risk, although whether they are simply markers or are 
causally significant is unknown.  Therefore, methylation marks that could be used to predict 
offspring bone outcomes from as soon as they are born, and persist into later life, would allow for 
intervention and prevention of those with a higher risk of disease from birth. 
 
7.1.2 Maternal vitamin D and offspring bone health 
 Vitamin D plays an important role in regulating calcium uptake and bone homeostasis, 
although there is conflicting evidence that maternal vitamin D status has an effect on offspring 
bone outcomes.  Human studies by different groups across a variety of cohorts have shown that 
offspring born to mothers that have a lower serum vitamin D concentration have significantly 
lower bone mineral content, bone area and bone mineral density when compared to those born 
to mothers with higher levels of serum vitamin D (155–157).  However, there are also conflicting 
reports: in an association study by Lawlor and colleagues using the ALSPAC cohort, where 
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mothers were split into three groups based on the serum vitamin D concentrations and 
comparisons made across the separate groups, did not find any associations between maternal 
vitamin D status and childhood bone outcomes (159). 
Prior to the MAVIDOS study, there have been several, mainly small, intervention trials 
that have been carried out over the years examining whether vitamin D supplementation during 
pregnancy is beneficial for the mother and the infants; however, there has been only one that 
specifically looks at bone mass of the infant at birth.  In these trials, mothers were either 
supplemented with daily oral doses of vitamin D, with doses ranging from 400-1,200 IU/day, or 
single/dual larger doses (5mg or 600,000 IU respectively) during the final trimester of pregnancy.  
Marya and colleagues found that biochemical parameters (calcium, inorganic phosphate and 
heat-labile alkaline phosphatase levels) in maternal serum were significantly improved in those 
mothers treated with two 600,000 IU vitamin D doses during the final trimester compared to 
those treated with daily doses throughout their third trimester, while levels did not change 
between the control and mothers that took a daily supplement of vitamin D (332).  This latter 
observation agreed with what has been seen by other research groups (333,334).  However, it has 
been shown that in infants of mothers that received daily doses of vitamin D, there are less cases 
of hypocalcaemia and that they have higher circulating concentrations of 25-hydroxyvitamin D3 
which is suggestive of improved calcium handling (333,335). 
There is evidence from these studies that vitamin D supplementation can also have an 
effect on the size of the infant as results have shown that those infants born to mothers who are 
taking vitamin D supplements have higher birth weights than those born to unsupplemented 
mothers (332), whereas other groups have not seen a significant modification in birth weight 
across treatment and control groups (334).  Congdon et al are the only group out of these earlier 
studies to specifically look at the effect of maternal vitamin D deficiency on infant skeletal 
mineralisation, which was assessed by measuring forearm BMC (336).  In this study of 45 Asian 
women with vitamin D deficiency versus 19 Asian women supplemented with 1000 IU daily dose 
of vitamin D, there were a wide variety of serum 25-hydroxyvitamin D3 concentrations across the 
groups, however there were no significant differences in the infant BMC, which would suggest 
that maternal vitamin D deficiency does not have an effect on fetal skeletal development. 
 A systematic review by Harvey et al which included 76 studies aimed to address the 
various questions regarding vitamin D deficiency, supplementation during pregnancy and how low 
maternal circulating 25-hydroxyvitamin D levels are associated with adverse neonatal and 
maternal health outcomes (337).  This study revealed that there was insufficient evidence across 
all studies to reliably answer many of the questions being asked.  Data from these 76 studies did 
173 
 
not provide sufficient evidence to determine whether maternal vitamin D supplementation during 
pregnancy leads to improvement in health outcome of the infant and/or the mother or evidence 
on the optimal dose or regimen to provide adequate levels of vitamin D throughout pregnancy. 
This was due to the heterogeneity across the studies and for most of the outcomes investigated 
there was conflicting evidence.  However, they did provide some insight as to the associations 
between health outcomes and maternal 25-hydroxyvitamin D levels in that positive relationships 
were found between maternal 25-hydroxyvitamin D levels and infant birth weight, bone mass and 
post-natal calcium concentrations. 
 
7.1.3 Maternal Vitamin D Osteoporosis Study (MAVIDOS) 
 The systematic review from Harvey and colleagues, coupled with the conflicting 
information across these smaller trials, revealed a need for a randomised controlled of vitamin D 
supplementation study using greater numbers of pregnant women and where there is a long term 
follow up of infants.  It would allow for the determination of whether intervention and correction 
of vitamin D during pregnancy has a beneficial effect on the offspring and to determine the 
optimal concentration of maternal serum 25-hydroxyvitamin D3 in order to promote ideal fetal 
development.  Due to the role of vitamin D in bone development and homeostasis, there is also a 
need for a study that specifically examines whether maternal vitamin D status is associated with 
fetal bone outcomes. 
The MAVIDOS trial was established to test the hypothesis that infants born to women 
with low vitamin D levels who have had vitamin D supplementation during pregnancy will have a 
greater BMC than those infants born to women who are supplemented with placebo.  In this 
study, women in Southampton, Oxford and Sheffield had their serum 25-hydroxyvitamin D 
assessed during week 12 of pregnancy.  Those that had a circulating concentration between 25-
100nmol/l were randomised to either receive placebo or 1000 IU cholecalciferol/day from week 
14 of pregnancy until the birth of the child (338) and were assessed at 14 and 34 weeks of 
pregnancy. 
At the 14 weeks assessment, a urine sample was obtained as well as blood, which was 
stored for analysis of 25-hydroxyvitamin D, vitamin D binding protein, calcium, bone-specific 
alkaline phosphatase and albumin levels at the end of the study.  A questionnaire was also 
completed that gathered information on parity, smoking status, alcohol intake, vitamin D dietary 
intake, exercise and sunlight exposure as well as anthropometric measurements, such as height 
and skinfold thickness. Medication was issued at the 14 week visit and pill counts were carried out 
at subsequent assessments to ensure that participants were compliant with the study medication.  
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The anthropometric measurements taken at the 14 week visit were repeated at the 34 week visit, 
as well as completing another questionnaire on maternal lifestyle and another blood sample was 
taken. 
When the infants were born, cord blood samples were taken for analysis at the end of the 
study, as well as umbilical cord and placental tissue samples.  The baby’s anthropometric indices 
were also recorded and a DXA scan is arranged to obtain measurements of the baby’s whole body 
and lumbar spine bone area, bone mineral density and bone mineral content.  Follow up 
assessments are planned at 1, 2, 3 and 4 years of age to characterise diet, exercise, health and 
anthropometric measurements, with a DXA scan being repeated at 4 years of age to determine 
whole body, lumbar spine and hip bone mass.  Currently, 2, 3 and 4 year assessments are 
ongoing, with 1 year follow ups recently completed.  Through long term follow up of offspring, 
this should give a clearer idea of the effect of maternal vitamin D status on the bone outcomes of 
children over their lifetime. 
Recently published results from the MAVIDOS study (339) have shown that daily 
supplementation of women with 1000 IU of cholecalciferol does not significantly change offspring 
total BMC at birth when compared to the placebo group.  However, when offspring bone 
outcomes are stratified by season of birth, there is a significant difference between the two 
maternal treatment groups.  Maternal cholecalciferol supplementation was shown to cause a 
significant increase in whole body BMC, BA and BMD in offspring born during the winter months.  
Results from this study have also shown that this dose of cholecalciferol is sufficient to ensure 
that most women are not vitamin D replete during pregnancy and that it is safe as no adverse 
events recorded during the study were due to the supplement of cholecalciferol. 
 
7.2 Aims 
The first aim of this chapter is to replicate the associations previously reported in the SWS 
cohort between the methylation of specific CpG loci in CDKN2A, RXRA and NOS3 and offspring 
total BMC, total BA, total BMD, size corrected BMC (scBMC) at birth.  The second aim in the 
MAVIDOS cohort was to use this as a randomised controlled trial to determine whether the 
supplementation of mothers with a daily 1000 IU dose of cholecalciferol affects the methylation 
levels of these CpG loci within CDKN2A, RXRA and NOS3 and whether maternal supplementation 
affects offspring bone outcomes at birth. 
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7.3 Results 
7.3.1 Is the methylation of CDKN2A associated with offspring bone outcomes at birth? 
7.3.1.1 SWS umbilical cord 
Previous results from Harvey et al have shown that there are associations between the 
methylation of two specific CpG loci within the CDKN2A gene at birth (CpGs -845 and -907) and 
offspring childhood bone outcomes at 4 and 6 years.  These results showed that there is a 
significant negative association with both CpG -845 and -907 and offspring total bone area, total 
BMC and areal BMD at both 4 and 6 years of age in the SWS cohort (unpublished data). 
However, as this work by Harvey et al compared methylation at birth with childhood bone 
outcomes, the associations between CDKN2A methylation in SWS umbilical cord tissue and 
offspring bone outcomes at birth was not determined.  This will allow for direct comparisons to be 
made between the SWS cohort and the MAVIDOS samples, the latter only having DXA bone 
outcome data at birth available at present.  Linear regression analysis explored the associations 
between methylation of each of the individual CpG sites in CDKN2A and offspring bone outcomes 
at birth in the SWS cohort revealed significant associations between the two after adjusting for 
sex, age at time of DXA and gestational age (Table 7.1). 
There were significant negative associations between the methylation of CpGs -796, -845 
and -907 and offspring total BMC at birth after adjusting for gestational age, sex and age at time 
of DXA (p<0.041 for all).  The methylation of CpGs -852 and -887 showed a weak trend towards 
significance with total BMC, which was also in a negative direction (p<0.089 for both). 
Linear regression analysis also determined significant associations between the 
methylation of CpGs -796 and -907 and offspring total BA at birth (p<0.03 for both), after 
adjusting for gestational age, sex and age at time of DXA.  These associations were also in a 
negative direction.  Trends towards significance were also seen between total BA and the 
methylation of CpGs -854, -852 and -887 (p<0.091 for all), which were also in a negative direction. 
The methylation of CpG -845 was also significantly associated with total BMD at birth 
after adjusting for gestational age, sex and age at time of DXA (p=0.035), whilst a trend towards 
significance was seen between total BMD and the methylation of CpG -887 (p=0.083).  Both of 
these associations were in a negative direction. 
There were no significant associations between the methylation of any of the CpGs in the 
CDKN2A region of interest and scBMC. Figure 7.1 visually demonstrates some of the significant 
associations between specific CDKN2A CpG methylation in umbilical cord and offspring total BMC, 
total BA and total BMD at birth using scatter plots. 
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Baby DXA: Total BMC (g), 
adjusted for gestational age, sex 
and age 
Baby DXA: Total BA (cm sq), 
adjusted for gestational age, sex 
and age 
n b p-value n b p-value 
CDKN2A CpG -769 292 -0.0001022 0.225 292 -0.1653897 0.232 
CDKN2A CpG -793 290 -0.0001142 0.174 290 -0.1769149 0.198 
CDKN2A CpG -796 246 -0.000229 0.035 246 -0.3848732 0.029 
CDKN2A CpG -836 334 -0.0001204 0.114 334 -0.1980114 0.113 
CDKN2A CpG -845 330 -0.0001644 0.040 330 -0.250933 0.055 
CDKN2A CpG -852 330 -0.0001242 0.088 330 -0.2020511 0.090 
CDKN2A CpG -861 321 -0.0001167 0.162 321 -0.1653978 0.227 
CDKN2A CpG -887 312 -0.0001556 0.052 312 -0.2472543 0.059 
CDKN2A CpG -907 266 -0.0002086 0.030 266 -0.3470719 0.028 
 
Baby DXA: Total BMD (g/cm sq), 
adjusted for gestational age, sex 
and age 
Baby DXA: scBMC (g), adjusted 
for gestational age, sex and age 
n b p-value n b p-value 
CDKN2A CpG -769 292 -0.0001437 0.315 291 -0.0000066 0.676 
CDKN2A CpG -793 290 -0.0001968 0.169 289 -0.0000167 0.289 
CDKN2A CpG -796 246 -0.0001885 0.309 245 -0.0000036 0.861 
CDKN2A CpG -836 334 -0.0001583 0.223 333 -0.0000091 0.529 
CDKN2A CpG -845 330 -0.0002875 0.035 329 -0.0000149 0.322 
CDKN2A CpG -852 330 -0.000149 0.232 329 -0.0000066 0.634 
CDKN2A CpG -861 321 -0.000209 0.151 320 -0.0000224 0.167 
CDKN2A CpG -887 312 -0.0002383 0.083 311 -0.000008 0.599 
CDKN2A CpG -907 266 -0.0002502 0.122 265 -0.0000045 0.787 
 
 
Table 7.1: Associations between CDKN2A CpG methylation in umbilical cord tissue and offspring bone 
outcomes at birth in SWS cohort. There are significant negative associations between methylation of CpGs 
within CDKN2A and total BMC, total BA and total BMD (p<0.05; highlighted in orange), determined by linear 
regression and adjusting for gestational age, sex and age at time of DXA.  There are also some negative 
trends towards significance (p<0.1) between CpGs within the CDKN2A region of interest and bone outcomes 
at birth (p<0.1; highlighted in blue). ‘n’ is number of subjects and ‘b’ is beta value. Linear regression analysis 
carried out by Phil Titcombe. 
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Figure 7.1: The methylation of CpGs -796, -845 and -907 in CDKN2A is shown plotted against total bone 
mineral content (BMC), total bone area (BA) and total bone mineral density (BMD)at birth.  As the 
percentage methylation of each of these CpGs increases, total BMC, total BMD and total BA decreases at 
birth (adj. p<0.04).  Linear regression analyses of methylation versus bone outcome produce a negative 
beta value, demonstrating a negative association between methylation of each of the CpGs and the bone 
outcome represented on the above graphs. p-values across all six graphs are adjusted for gestational age, 
sex and age at time of DXA in the linear regression model. 
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7.3.1.2 MAVIDOS umbilical cord 
To see if the associations seen in the SWS cohort can be replicated, associations between 
methylation of CpGs within the CDKN2A locus and offspring bone outcomes at birth were 
investigated in the MAVIDOS cohort. In this cohort, the methylation of CpGs in CDKN2A in 
offspring umbilical cord was not significantly associated with total BMC, total BA, total BMD or 
size corrected BMC (scBMC) at birth in MAVIDOS samples when adjusted for sex, age at time of 
DXA and gestational age (Table 7.2).  There were weak negative associations between the 
methylation of CpG -796, -887 and -907 and total BMC (p= 0.08, 0.083 and 0.099 respectively).  
CpG -796 also showed a weak negative association with total BMD (p<0.1) and CpG -887 a weak 
negative association with total BA (p=0.093).  There were no associations between any of the 
CpGs and scBMC. 
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Baby DXA: Total BMC (g), 
adjusted for gestational age, 
sex and age 
Baby DXA: Total BA (cm sq), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
CDKN2A CpG -769 136 -0.074 0.376 136 -0.008 0.975 
CDKN2A CpG -793 119 -0.127 0.142 119 -0.364 0.195 
CDKN2A CpG -796 106 -0.304 0.08 106 -0.589 0.289 
CDKN2A CpG -836 147 -0.081 0.325 147 -0.116 0.669 
CDKN2A CpG -845 144 -0.046 0.633 144 0.000248 0.999 
CDKN2A CpG -852 142 -0.04 0.657 142 -0.024 0.935 
CDKN2A CpG -861 137 -0.017 0.87 137 -0.056 0.867 
CDKN2A CpG -887 146 -0.159 0.083 146 -0.505 0.093 
CDKN2A CpG -907 144 -0.155 0.099 144 -0.414 0.181 
  
Baby DXA: Total BMD (g/ cm 
sq), adjusted for gestational 
age, sex and age 
Baby DXA: scBMC (g), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
CDKN2A CpG -769 136 -0.000235 0.13 136 -0.025 0.57 
CDKN2A CpG -793 119 -0.000175 0.272 119 0.008 0.857 
CDKN2A CpG -796 106 -0.001 0.099 106 -0.095 0.294 
CDKN2A CpG -836 147 -0.000195 0.204 147 -0.002 0.963 
CDKN2A CpG -845 144 -1.38E-04 0.436 144 0.017 0.728 
CDKN2A CpG -852 142 -1.12E-04 0.504 142 0.029 0.53 
CDKN2A CpG -861 137 -4.09E-06 0.983 137 0.036 0.479 
CDKN2A CpG -887 146 -0.000188 0.27 146 0.041 0.368 
CDKN2A CpG -907 144 -0.000229 0.189 144 0.027 0.574 
 
 
Table 7.2: The association between methylation of CDKN2A in umbilical cord DNA and bone outcomes at 
birth in MAVIDOS cohort.  There are no significant associations between methylation of any of the CpGs 
within the CDKN2A region of interest and bone outcomes at birth after correcting for gestational age, sex 
and age at time of DXA.  There are some trends towards significance (p=0.051-0.1) in a negative direction 
between CpGs -796, -887 and -907 and total BMC, CpG -887 and total BA and CpG -796 and total BMD. ‘n’ 
denotes number of subjects and ‘b’ denotes beta value.  Associations determined by linear regression 
model. 
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7.3.2 Is the methylation of RXRA associated with offspring bone outcomes at birth? 
7.3.2.1 SWS umbilical cord 
 Previous analyses have determined association between methylation of these CpGs and 
offspring bone outcomes at 4 years of age (205), but no associations were investigated between 
RXRA methylation and offspring bone outcomes at birth. Methylation levels of CpGs within the 
RXRA promoter had previously been measured using the Sequenom MassARRAY platform in the 
SWS cohort umbilical cord samples.  On this platform, CpGs -2686 and -2682 and CpGs -2649 and -
2642 cannot be distinguished from each other and so are paired together for analysis.   
Linear regression analysis determined that the methylation levels of CpGs -2686/-2682 
and CpG -2673 are significantly associated with offspring total BMC at birth after adjusting for 
gestational age, sex and age at time of DXA (p<0.023 for both; Table 7.3).  The methylation of CpG 
-2649/-2642 showed a weak trend towards significance with total BMC, which was also in a 
positive direction (p=0.096). 
Significant associations were also seen between CpGs -2686/-2682 and -2673 methylation 
and offspring total BA at birth, after adjustments were made for gestational age, sex and age at 
time of DXA (p<0.026 for both).  These associations were also in a positive direction, i.e. as 
percentage methylation increases, offspring total BA also increases.  A trend towards significance 
is also seen between the methylation of CpG -2649/-2642 and off spring total BA (p=0.093). 
CpG -2673 methylation was also significantly associated with total offspring BMD 
(p=0.023) in a positive direction, after adjusting for gestational age, sex and age at time of DXA.   
There were no significant associations or trends towards significance between the methylation of 
any of the other CpGs and offspring total BMD, nor were any significant associations or trends 
between the methylation levels of any of the CpGs and scBMC. 
Figure 7.2 visually demonstrates some of the significant associations between specific 
RXRA CpG methylation in umbilical cord and offspring total BMC and total BA at birth using 
scatter plots. 
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Baby DXA: Total BMC (g), 
adjusted for gestational age, 
sex and age 
Baby DXA: Total BA (cm sq), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
RXRA CpG -2686/-2682 132 0.014 0.005 132 25.431 0.004 
RXRA CpG -2673 297 0.008 0.022 297 13.092 0.025 
RXRA CpG -2649/-2642 295 0.006 0.096 295 10.515 0.093 
RXRA CpG -2554 290 -0.003 0.374 290 -4.787 0.414 
RXRA CpG -2406 298 -0.002 0.532 298 -4.993 0.394 
RXRA CpG -2357 297 -0.003 0.35 297 -4.982 0.379 
  
Baby DXA: Total BMD (g/ cm 
sq), adjusted for gestational 
age, sex and age 
Baby DXA: scBMC (g), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
RXRA CpG -2686/-2682 132 0.007 0.434 132 -0.001 0.466 
RXRA CpG -2673 297 0.011 0.081 297 -6.58E-05 0.93 
RXRA CpG -2649/-2642 295 0.006 0.363 295 -0.000171 0.832 
RXRA CpG -2554 290 -0.006 0.379 290 -0.000101 0.893 
RXRA CpG -2406 298 0.002 0.808 296 0.001 0.2 
RXRA CpG -2357 297 0.0 0.287 295 -0.000478 0.514 
 
 
Table 7.3: Associations between RXRA CpG methylation in umbilical cord tissue and offspring bone 
outcomes at birth in SWS cohort. There are significant positive associations between methylation of 
both CpGs -2686/-2682 and -2673 and total BMC and total BA at birth (p<0.026; highlighted in orange), 
determined by linear regression and adjusting for gestational age, sex and age.  There are also negative 
trends towards significance (p<0.1) between CpG -2649/-2642 within the CDKN2A region of interest and 
total BMC, total BA and total BMD at birth (p<0.1; highlighted in blue). ‘n’ is number of subjects and ‘b’ is 
beta value. 
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Figure 7.2: The methylation of CpGs -2686, -2673 and -2642 in RXRA is shown plotted against total bone 
mineral content (BMC) and total bone area (BA) at birth in the SWS cohort.  Linear regression analyses 
of methylation versus bone outcome produce a positive beta value, demonstrating a positive association 
between methylation of each of the CpGs and the bone outcome represented on the above graphs.  As 
the percentage methylation of each of these CpGs increases, total BMC and total BA also increases at 
birth.  p-values across all four graphs are adjusted for gestational age, sex and age in the linear regression 
model. 
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7.3.2.2 MAVIDOS umbilical cord 
 To try and replicate the results seen in the SWS cohort between RXRA methylation in 
umbilical cord and offspring bone outcomes at birth, associations between methylation of these 
CpGs and bone outcomes of offspring in the MAVIDOS cohort were investigated.  Methylation of 
CpGs -2686, -2682, -2673 and -2642 in RXRA in umbilical cord have a significant positive 
association with offspring total BMC at birth (p<0.035 in all cases), after adjusting for sex, age and 
gestational age (Table 7.4).  Methylation of CpG -2649 also showed a weak trend towards 
significance with offspring total BMC, which was also in the positive direction (p<0.072).  No other 
CpGs within the RXRA DMR were found to have any significant associations with offspring total 
BMC at birth (p>0.05). 
Significant associations were also found between CpGs -2682, -2673 and -2642 
methylation (p<0.04 in all cases) and offspring total BA after adjusting for sex, age and gestational 
age, which were in a positive direction.  Associations trending towards significance were also 
found between the methylation of CpGs -2682 and -2649 (p<0.06) and total BA in a positive 
direction.  There were no other significant associations measured between the remaining CpGs in 
the RXRA DMR and offspring total BA (p>0.05). 
Only CpG -2686 showed a significance positive association between percentage 
methylation and offspring total BMD (p=0.046) and there were only weak associations between 
the methylation of CpGs -2406 and -2391 and prentice BMC (p=0.064 and p=0.096 respectively), 
after adjusting for sex, age and gestational age, though these associations were in a negative 
direction.  No other CpGs within the RXRA DMR showed any significant associations between 
percentage methylation and these two offspring bone outcomes.  Figure 7.3 visually 
demonstrates some of the significant associations between specific RXRA CpG methylation in 
umbilical cord and offspring total BMC, total BA and total BMD at birth using scatter plots. 
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Baby DXA: Total BMC (g), 
adjusted for gestational age, 
sex and age 
Baby DXA: Total BA (cm sq), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
RXRA CpG -2686 123 0.217 0.018 123 0.573 0.058 
RXRA CpG -2682 125 0.273 0.011 125 0.866 0.014 
RXRA CpG -2673 133 0.207 0.021 133 0.598 0.039 
RXRA CpG -2649 134 0.155 0.071 134 0.548 0.056 
RXRA CpG -2642 144 0.173 0.034 144 0.604 0.026 
RXRA CpG -2406 143 0.09 0.519 143 0.665 0.15 
RXRA CpG -2391 139 0.058 0.607 139 0.372 0.32 
RXRA CpG -2387 135 0.114 0.38 135 0.583 0.177 
RXRA CpG -2385 129 0.062 0.61 129 0.327 0.42 
RXRA CpG -2357 147 0.138 0.402 147 0.572 0.294 
RXRA CpG -2346 94 0.018 0.826 94 -0.008 0.977 
 
Baby DXA: Total BMD (g/ cm 
sq), adjusted for gestational 
age, sex and age 
Baby DXA: scBMC (g), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
RXRA CpG -2686 123 0.000337 0.046 123 0.005 0.914 
RXRA CpG -2682 125 0.000312 0.12 125 -0.011 0.849 
RXRA CpG -2673 133 0.000271 0.117 133 -0.017 0.731 
RXRA CpG -2649 134 0.000117 0.466 134 -0.051 0.25 
RXRA CpG -2642 144 0.000145 0.341 144 -0.046 0.282 
RXRA CpG -2406 143 -0.000191 0.461 143 -0.135 0.064 
RXRA CpG -2391 139 -8.60E-05 0.681 139 -0.099 0.096 
RXRA CpG -2387 135 -5.94E-05 0.806 135 -0.101 0.141 
RXRA CpG -2385 129 -4.59E-05 0.839 129 -0.07 0.284 
RXRA CpG -2357 147 2.98E-05 0.922 147 -0.074 0.385 
RXRA CpG -2346 94 4.23E-05 0.775 94 0.012 0.758 
 
 
Table 7.4: The associations between methylation of RXRA in MAVIDOS umbilical cord DNA and bone 
outcomes at birth, determined by linear regression. There were significant associations between 
methylation of CpGs -2686, -2682, -2673 and -2642 and total BMC, with a trend seen between CpG -2649 
methylation and total BMC. Methylation of CpGs -2682, -2673 and -2642 also showed significant 
associations with offspring total BA, whereas there is a trend towards significance with CpGs -2686 and -
2649. CpG -2686 methylation was significantly associated with offspring total BMD in a positive direction, 
whereas only trends towards significance were seen between CpG -2406 and -2391 methylation and total 
prentice BMC. Significant associations are highlighted in orange and trends towards significance are 
highlighted in blue. ‘n’ is number of subjects and ‘b’ is beta value. 
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Figure 7.3: The methylation of CpGs -2686, -2673 and -2642 in RXRA is shown plotted against total bone 
mineral content (BMC), total bone mineral density (BMD) and total bone area (BA) at birth in the 
MAVIDOS cohort.  As the percentage methylation of each of these CpGs increases, total BMC, total BMD 
and total BA increases at birth (adj. p<0.047).  Linear regression analyses of methylation versus bone 
outcome produce a positive beta value, demonstrating a positive association between methylation of each 
of the CpGs and the bone outcome represented on the above graphs. p-values across all six graphs are 
adjusted for gestational age, sex and age in the linear regression model. 
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7.3.3 Is the methylation of NOS3 associated with offspring bone outcomes at birth? 
7.3.3.1 SWS umbilical cord 
It has been shown that there are strong positive correlations between the methylation of 
a CpG within the NOS3 promoter and offspring BA, BMC and aBMD at 9 years of age.  Therefore, 
linear regression analysis was used to determine whether similar associations are present 
between methylation in umbilical cord and offspring bone outcomes at birth.  These analyses 
revealed that there are no significant associations, nor trends towards significance, in SWS 
umbilical cord between the methylation of CpG -3526 in the NOS3 promoter and offspring total 
BMC, total BA, total BMD or total prentice BMC after adjusting for gestational age, sex and age at 
time of DXA (Table 7.5). 
 
 
  
Baby DXA: Total BMC (g), 
adjusted for gestational age, 
sex and age 
Baby DXA: Total BA (cm sq), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
NOS3 CpG -3526 129 0.001 0.96 129 3.258 0.851 
  
Baby DXA: Total BMD (g/ cm 
sq), adjusted for gestational 
age, sex and age 
Baby DXA: scBMC (g), 
adjusted for gestational age, 
sex and age 
n b p-value n b p-value 
NOS3 CpG -3526 129 -0.011 0.547 129 -0.001 0.637 
  
Baby DXA: Percentage BMC 
(%), adjusted for gestational 
age, sex and age 
n b p-value 
NOS3 CpG -3526 129 -0.034 0.856 
 
 
Table 7.5: The associations between methylation of NOS3 in SWS umbilical cord DNA and bone 
outcomes at birth, determined by linear regression. There are no significant associations between the 
methylation of CpG -3526 and offspring total BMC, total BA, total BMD or total prentice BMC. ‘n’ is 
number of subjects and ‘b’ is beta value. 
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7.3.3.2 MAVIDOS umbilical cord 
 To replicate what was seen in the SWS cohort, linear regression analyses between 
methylation and offspring bone outcomes at birth were carried out using data from the MAVIDOS 
cohort.  Methylation of CpG -3526 in the NOS3 promoter in umbilical cord was associated with 
percentage BMC at birth after correcting for sex, age at time of DXA and gestational age (p=0.032; 
Table 7.6).  This association is in the positive direction, with an increase in methylation leading to 
an increase in percentage BMC.  There are no other significant associations between the 
methylation of CpG -3526 and the remaining offspring bone outcomes at birth (p>0.05). 
  
 
 
 
Baby DXA: Total BMC (g), 
adjusted for gestational age, sex 
and age 
Baby DXA: Total BA (cm sq), 
adjusted for gestational age, sex 
and age 
n b p-value n b p-value 
NOS3 CpG -3526 155 0.35 0.121 155 0.795 0.286 
 
Baby DXA: Total BMD (g/ cm sq), 
adjusted for gestational age, sex 
and age 
Baby DXA: scBMC (g), adjusted 
for gestational age, sex and age 
n b p-value n b p-value 
NOS3 CpG -3526 155 0.001 0.203 155 0.172 0.117 
 
Baby DXA: Percentage BMC (%), 
adjusted for gestational age, sex 
and age 
n b p-value 
NOS3 CpG -3526 155 0.007 0.032 
 
 
Table 7.6: The associations between methylation of NOS3 in MAVIDOS umbilical cord DNA and bone 
outcomes at birth.  There is a significant association between the methylation levels of CpG -3526 in the 
NOS3 promoter and offspring percentage BMC (highlighted in orange).  There were no other significant 
associations, nor trends towards significance, between the methylation of this CpG and any other 
offspring bone outcomes. ‘n’ denotes number of subjects and ‘b’ is beta value. 
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7.3.4 Is the methylation of CDKN2A, RXRA and NOS3 associated with birth weight? 
7.3.4.1 CDKN2A 
 As birth weight has been shown to be associated with offspring bone outcomes at birth 
and in later life (118,340), analyses were run to see if the methylation of CDKN2A, RXRA and NOS3 
are affected by birth weight.  Using linear regression analysis, the methylation of CpGs in the 
CDKN2A promoter in SWS umbilical cord was not significantly associated with birth weight, after 
adjusting for sex, age at time of DXA and gestational age (Table 7.7, left). 
In the MAVIDOS cohort, the methylation of CpGs -887 and -907 in the CDKN2A promoter 
in umbilical cord was significantly associated with birth weight (p=0.014 and p=0.02 respectively), 
after adjusting for sex, age at time of DXA and gestational age, where the methylation was 
negatively associated with birth weight (Table 7.7, right).  There were no significant associations 
between methylation and any of the remaining CpGs measured within the CDKN2A differentially 
methylated region of interest and birth weight in umbilical cord. 
 
 
SWS 
Birthweight (g), 
adjusted for sex, age 
and gestational age MAVIDOS 
Birthweight (g), adjusted 
for sex, age and 
gestational age 
n b p-value n b p-value 
CDKN2ACpG -769 443 -2.16 0.451 CDKN2ACpG -769 136 -2.86 0.442 
CDKN2ACpG -793 435 -3.072 0.264 CDKN2ACpG -793 119 -4.86 0.211 
CDKN2ACpG -796 370 -5.138 0.179 CDKN2ACpG -796 106 -10.738 0.167 
CDKN2ACpG -836 499 -2.742 0.274 CDKN2ACpG -836 147 -4.438 0.234 
CDKN2ACpG -845 495 -2.662 0.310 CDKN2ACpG -845 144 -4.1 0.343 
CDKN2ACpG -852 495 -2.701 0.256 CDKN2ACpG -852 142 -4.679 0.252 
CDKN2ACpG -861 493 -1.543 0.562 CDKN2ACpG -861 137 -5.285 0.26 
CDKN2ACpG -887 479 -3.823 0.163 CDKN2ACpG -887 146 -10.141 0.014 
CDKN2ACpG -907 421 -4.647 0.114 CDKN2ACpG -907 144 -9.863 0.02 
 
 
Table 7.7: The associations between CDKN2A CpG loci methylation in SWS (left) and MAVIDOS (right) 
umbilical cord tissue and birth weight.  In the SWS cohort, methylation of the CpGs within the CDKN2A 
DMROI are not significantly associated with offspring birth weight, determined by a linear regression 
analysis and adjusting for sex, age at time of DXA and gestational age. In the MAVIDOS cohort, the 
methylation of CpGs -887 and -907 are significantly associated with offspring birth weight in a negative 
direction (p values highlighted in orange), determined by a linear regression analysis and adjusting for sex, 
age at time of DXA and gestational age. ‘n’ is number of subjects and ‘b’ is beta value. 
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7.3.4.2 RXRA 
In the SWS cohort, the methylation of CpGs -2686/-2682 in RXRA in SWS umbilical cord 
has a significant positive association with birth weight after adjustments for sex, age at time of 
DXA and gestational age have been made (p=0.038), i.e. an increase in methylation is associated 
with an increase in birth weight (Table 7.8, left). The remaining CpGs do not show any significant 
associations between methylation and birth weight (p>0.05 in all cases). 
In the MAVIDOS cohort, the methylation of CpGs -2686 to -2642 in RXRA in MAVIDOS 
umbilical cord has a significant positive association with birth weight after adjustments for sex, 
age and gestational age have been made (p<0.039 in all cases) (Table 7.8, right), i.e. an increase in 
methylation is associated with an increase in birth weight. The remaining CpGs do not show any 
significant associations between methylation and birth weight (p>0.05 in all cases). 
 
 
SWS 
Birthweight (g), 
adjusted for sex, age 
and gestational age MAVIDOS 
Birthweight (g), 
adjusted for sex, age 
and gestational age 
n b 
p-
value 
n b 
p-
value 
RXRA CpG -2686/-2682 306 165.2 0.038 RXRA CpG -2686 123 8.184 0.049 
RXRA CpG -2673 563 120.43 0.287 RXRA CpG -2682 125 10.859 0.026 
RXRA CpG -2649/-2642 561 119.81 0.459 RXRA CpG -2673 133 8.425 0.037 
RXRA CpG -2554 556 113.85 0.557 RXRA CpG -2649 134 9.728 0.026 
RXRA CpG -2406 564 112.43 0.904 RXRA CpG -2642 144 8.94 0.019 
RXRA CpG -2357 564 108.21 0.21 RXRA CpG -2406 143 5.083 0.441 
  
   
RXRA CpG -2391 139 2.874 0.578 
  
   
RXRA CpG -2387 135 3.82 0.518 
  
   
RXRA CpG -2385 129 1.288 0.818 
  
   
RXRA CpG -2357 147 3.708 0.623 
  
   
RXRA CpG -2346 94 0.208 0.955 
 
 
Table 7.8: The associations between specific RXRA CpG loci methylation in SWS (left) and MAVIDOS 
(right) umbilical cord tissue and birth weight.  In the SWS cohort, the methylation of CpGs -2686/-2684 are 
significantly associated with offspring birth weight in a positive direction (p-values highlighted in orange), 
determined by a linear regression analysis and adjusting for sex, age and gestational age. In the MAVIDOS 
cohort, the methylation of CpGs -2686 to -2642 are significantly associated with offspring birth weight in a 
positive direction (p-values highlighted in orange), determined by a linear regression analysis and adjusting 
for sex, age and gestational age. ‘n’ is number of subjects and ‘b’ is beta value. 
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7.3.4.3 NOS3 
In both the SWS and MAVIDOS cohorts, there were no significant associations, nor trends 
towards significance, between the methylation of CpG -3526 within the NOS3 promoter and birth 
weight in umbilical cord samples (Table 7.9, left and right respectively). 
 
SWS 
Birthweight (g), adjusted 
for sex, age and 
gestational age MAVIDOS 
Birthweight (g), adjusted 
for sex, age and 
gestational age 
n b p-value n b p-value 
NOS3 CpG -3526 292 13.32 0.967 NOS3 CpG -3526 155 7.327 0.478 
 
 
Table 7.9: The associations between specific NOS3 CpG loci methylation in SWS (left) and the MAVIDOS 
(right) umbilical cord tissue and birth weight.  In both the SWS and MAVIDOS cohorts there are no 
significant associations between the methylation of CpG -3526 in the NOS3 promoter and birth weight after 
adjusting for gestational age, sex and age at DXA, determined by linear regression. ‘n’ is number of subjects 
and ‘b’ is beta value. 
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7.3.4.4 The association between birth weight and offspring bone outcomes at birth 
 When previously significant associations between methylation of CpGs within the 
CDKN2A and RXRA regions of interest and offspring total BMC were adjusted for sex, age at time 
of DXA and birthweight, these associations are no longer significant in either cohort (Table 7.10).  
However, the association between RXRA CpG -2686 methylation and total BMC in the MAVIDOS 
cohort shows a trend towards significance (p=0.078).  Linear regression revealed that there was a 
significant positive association between birth weight and offspring total BMC at birth in both the 
SWS and MAVIDOS cohorts (Figure 7.4).   
 
SWS 
Total BMC (g), adjusted for 
sex, age and birthweight 
MAVIDOS 
Total BMC (g), 
adjusted for sex, age 
and birth weight 
n b 
p-
value 
n b 
p-
value 
CDKN2A CpG -796 443 -5.38E-05 0.374 CDKN2A CpG -887 146 0.012 0.816 
CDKN2A CpG -845 495 -6.62E-05 0.257 CDKN2A CpG -907 144 0.008 0.881 
CDKN2A CpG -907 421 -0.000116 0.064 RXRA CpG -2686 123 0.096 0.078 
RXRA CpG -2686/-2682 306 0.006 0.125 RXRA CpG -2682 125 0.095 0.146 
RXRA CpG -2673 563 0.004 0.126 RXRA CpG -2673 133 0.08 0.14 
  
   
RXRA CpG -2649 134 0.064 0.197 
  
   
RXRA CpG -2642 144 0.064 0.181 
 
 
Table 7.10: The associations between CDKN2A and RXRA CpG methylation in umbilical cord and offspring 
total BMC at birth in the SWS (left) and MAVIDOS (right) cohorts. When associations between CDKN2A 
and RXRA CpG methylation and offspring total BMC at birth determined by linear regression are adjusted 
for sex, age at time of DXA and birth weight, all previous significant associations become non-significant.  
Association between methylation RXRA CpG -2686 and total BMC shows a trend towards significance 
(highlighted in blue). ‘n’ is number of subjects and ‘b’ is beta value. 
 
 
Figure 7.4: The association between birth weight and offspring total BMC at birth in the SWS cohort (left) 
and the MAVIDOS cohort (right).  In both cohorts there is a significant positive association between birth 
weight and total BMC at birth determined by linear regression. ‘b’ is beta value. 
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  When previously significant associations between methylation of CpG loci within 
CDKN2A and RXRA and offspring total BA were adjusted for sex, age at time of DXA and birth 
weight, these associations are no longer significant in either cohort (Table 7.11), with the 
exception of the methylation of CpGs -2686/-2682 and -2673 in the RXRA region of interest.  In 
the SWS cohort, the associations of the methylation for these CpGs and total BA remained 
significant after adjusting for birth weight. Linear regression revealed that there was also a 
significant positive association between birth weight and offspring total BA at birth in both the 
SWS and MAVIDOS cohorts (Figure 7.5). 
 
 
SWS 
Total BA (cm sq), 
adjusted for sex, age 
and birthweight MAVIDOS 
Total BA (cm sq), adjusted 
for sex, age and birth 
weight 
n b p-value n b p-value 
CDKN2A CpG -796 443 -0.084 0.379 CDKN2A CpG -887 146 0.09 0.598 
CDKN2A CpG -907 421 -0.185 0.062 CDKN2A CpG -907 144 0.16 0.36 
RXRA CpG -2686/-2682 306 10.54 0.046 RXRA CpG -2686 123 0.091 0.599 
RXRA CpG -2673 563 9.23 0.014 RXRA CpG -2682 125 0.235 0.256 
  
   
RXRA CpG -2673 133 0.117 0.491 
  
   
RXRA CpG -2649 134 0.183 0.25 
  
   
RXRA CpG -2642 144 0.186 0.222 
 
 
Table 7.11: The associations between CDKN2A and RXRA CpG methylation in umbilical cord and 
offspring total BA at birth in the SWS (left) and MAVIDOS (right) cohorts. When associations between 
CDKN2A and RXRA CpG methylation and offspring total BA at birth determined by linear regression are 
adjusted for sex, age at time of DXA and birth weight, all previous significant associations become non-
significant in both cohorts, with the exception of  RXRA CpGs -2686/-2682 and -2673 in the SWS cohort, 
which remain significant (highlighted in orange). ‘n’ is number of subjects and ‘b’ is beta value. 
 
 
Figure 7.5: The association between birth weight and offspring total BA at birth in the SWS cohort (left) 
and the MAVIDOS cohort (right).  In both cohorts there is a significant positive association between birth 
weight and total BMC at birth determined by linear regression. ‘b’ is beta value. 
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When previously significant associations between methylation of CpGs within the 
CDKN2A and RXRA regions of interest and total offspring BMD were adjusted for sex, age at time 
of DXA and birth weight, these associations are no longer significant in either cohort (Table 7.12).  
However, in the MAVIDOS cohort, the association between RXRA CpG -2686 methylation and 
total BMC shows a trend towards significance (p=0.086). Linear regression revealed that there 
was also a significant positive association between birth weight and offspring total BMD at birth in 
both the SWS and MAVIDOS cohorts (Figure 7.6).   
 
 
SWS 
Total BMD (g/cm sq), 
adjusted for sex, age and 
birth weight MAVIDOS 
Total BMD (g/cm sq), 
adjusted for sex, age and 
birth weight 
n b p-value n b 
p-
value 
CDKN2A CpG -845 495 -0.000178 0.21 CDKN2A CpG -887 146 -2.44E-05 0.874 
     
CDKN2A CpG -907 144 -7.92E-05 0.615 
     
RXRA CpG -2686 123 0.000261 0.086 
     
RXRA CpG -2682 125 0.000144 0.43 
     
RXRA CpG -2673 133 0.000175 0.263 
     
RXRA CpG -2649 134 6.77E-05 0.638 
     
RXRA CpG -2642 144 6.91E-05 0.616 
 
 
Table 7.12: The associations between CDKN2A and RXRA CpG methylation in umbilical cord and 
offspring total BMD at birth in the SWS (left) and MAVIDOS (right) cohorts. When associations between 
CDKN2A and RXRA CpG methylation and offspring total BMD at birth determined by linear regression are 
adjusted for sex, age at time of DXA and birth weight, all previous significant associations become non-
significant in both cohorts. The association between methylation RXRA CpG -2686 and total BMD shows a 
trend towards significance (highlighted in blue).  ‘n’ is number of subjects and ‘b’ is beta value. 
 
 
Figure 7.6: The association between birth weight and offspring total BMC at birth in the SWS cohort 
(left) and the MAVIDOS cohort (right).  In both cohorts there is a significant positive association between 
birth weight and total BMD at birth determined by linear regression. ‘b’ is beta value. 
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7.3.5 Is the methylation of CDKN2A, RXRA and NOS3 measured in MAVIDOS umbilical cord 
tissue affected by maternal vitamin D supplementation? 
 As the active metabolite of vitamin D3 has been shown to induce the demethylation of 
DNA, we looked at whether there were any significant differences between CpG methylation in 
umbilical cord tissue across the three genes of interest between the mothers on placebo and the 
mothers supplemented daily with 1000 IU cholecalciferol. 
 This trial showed that there was a significant difference in maternal serum vitamin D 
concentrations between the placebo and cholecalciferol supplemented groups at 14 and 34 
weeks gestation.  There was no difference in the serum 25-hydroxyvitamin D concentrations 
between the two treatment groups at 14 weeks gestation, though this would be expected as this 
is when mothers began taking daily supplements of cholecalciferol (Figure 7.7A); however there 
was a significant difference in serum 25-hydroxyvitamin D concentrations between the placebo 
and cholecalciferol supplemented group at 34 weeks gestation (Figure 7.7B).  At this time point 
there was a significant increase in maternal serum vitamin D concentrations when compared to 
the placebo group. 
 
 
 
 
Figure 7.7: Comparison of maternal serum 25-hydroxyvitamin D concentrations between cholecalciferol 
supplemented and placebo groups at (A) 14 weeks and (B) 34 weeks gestation. At 14 weeks there was no 
significant difference in maternal serum vitamin D concentrations between the supplementation (n=77) and 
placebo (n=79) groups (A).  At 34 weeks gestation there was a significant increase in serum vitamin D 
concentrations in mothers who were taking daily cholecalciferol supplements (n=75) when compared to the 
mothers taking placebo (n=78) (p=9.219x10
-11
).  Both p-values were determined by an unpaired t-test. 
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7.3.5.1 CDKN2A 
Figure 7.8 shows that the methylation of CpGs within the CDKN2A region of interest in 
umbilical cord tissue from the offspring is not significantly different between the placebo and 
treatment groups, determined by a Mann-Whitney U test (p>0.05).  When the analysis was 
stratified by season of birth, the methylation of CpG -836 was significantly different between the 
placebo and treatment groups for those babies born in the spring months.  No other differences 
were seen for any other CpGs during any other season of birth. 
 
 
  
 
 
 
 
 
 
Figure 7.8: The methylation of CDKN2A in umbilical cord tissue of offspring of mothers on placebo or 1000 
IU cholecalciferol/day. The methylation of the CpGs within the CDKN2A DMR was not significantly different 
in the umbilical cord tissue between mothers on 1000 IU cholecalciferol/day and mothers on placebo, 
determined by a Mann-Whitney U test (p>0.05). 
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7.3.5.2 RXRA 
Methylation of CpGs -2673 to -2357 within the RXRA region of interest was significantly 
different between the placebo and treatment groups (Table 7.13), determined by an independent 
t-test.  As the methylation levels of CpGs -2686, -2673, -2391, -2385 and -2335 were not normally 
distributed, the data had to be transformed before independent t-tests could be used.  Data was 
log transformed, with the exception of CpG -2346, which was squared as the data was negatively 
skewed.  CpGs -2673 to -2357 all showed a significant difference in methylation levels of umbilical 
cord tissue between the mothers taking placebo and the mothers treated with 1000 IU 
cholecalciferol/day (p<0.043 for all CpGs, highlighted in orange).  The methylation of the 
remaining CpGs within the RXRA region of interest in offspring umbilical cord tissue was not found 
to be significantly different between the two treatment groups. 
 
 
  n p-value 
Mean diff. % 
methylation 
95% Confidence 
Intervals 
Lower Upper 
RXRA CpG -2686 (log transformed) 123 0.535 -0.0130 -0.0543 0.0283 
RXRA CpG -2682 125 0.148 -2.0703 -4.8847 0.7442 
RXRA CpG -2673 (log transformed) 133 0.042 -0.0371 -0.0728 -0.0013 
RXRA CpG -2649 134 0.037 -3.0375 -5.8832 -0.1919 
RXRA CpG -2642 144 0.019 -3.5889 -6.5680 -0.6099 
RXRA CpG -2406 143 0.005 -2.4872 -4.2106 -0.7638 
RXRA CpG -2391 (log transformed) 139 0.038 -0.0186 -0.0361 -0.0010 
RXRA CpG -2387 135 0.034 -2.0612 -3.9697 -0.1526 
RXRA CpG -2385 (log transformed) 129 0.027 -0.0172 -0.0324 -0.00198 
RXRA CpG -2357 147 0.011 -1.9506 -3.4544 -0.4469 
RXRA CpG -2346 (squared) 94 0.857 -46.7609 -561.24 467.72 
 
 
Table 7.13: Independent t-test analysis of the RXRA CpG methylation in umbilical cord tissue between 
offspring of mothers supplemented with 1000 IU cholecalciferol/day and mothers taking placebo. The 
methylation of CpGs -2673 to -2357 is significantly different between the umbilical cord tissue of offspring 
from mothers supplemented with cholecalciferol and mothers taking placebo, determined by an 
independent t-test.  The methylation of any of the other CpGs did not show significant differences across 
the two treatment groups. ‘n’ is the number of subjects and significant values, where p<0.05, are 
highlighted in orange. 
 
Figure 7.9 visually demonstrates the significant differences in CpG methylation between 
the cholecalciferol supplemented group and the placebo group.  Minimum to maximum box and 
whisker plots are shown for each of the CpGs determined to have a significant difference in 
methylation between the two treatment groups.  For each CpG, the methylation levels were 
significantly lower in the umbilical cord tissue from offspring of mothers that have been 
supplemented with 1000 IU cholecalciferol per day than in the umbilical cord tissue from mothers 
in the placebo group. 
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Figure 7.9: The methylation of RXRA in umbilical cord tissue of offspring of mothers on placebo or 1000 IU 
cholecalciferol/day. The methylation of RXRA CpGs -2673 to -2357 was significantly decreased in the 
umbilical cord tissue between mothers on placebo and mothers on 1000 IU cholecalciferol/day, determined 
by an independent t-test (p>0.043 for all). 
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 The associations between RXRA CpG methylation and maternal treatment group were 
then stratified by season of birth to determine whether there were any seasonal effects on the 
methylation levels of CpG loci within the RXRA promoter.  The results of an independent t-test 
show that methylation of specific CpG sites of the RXRA promoter in umbilical cord was 
significantly lower in the offspring of mothers supplemented with cholecalciferol for babies born 
during summer and autumn (Table 7.14). 
 CpGs -2682, -2649 to -2406, -2387 and -2357 show a significant change in methylation 
between the placebo and treatment groups for those babies born in the summer months, 
whereas CpGs -2673, -2391 and -2357 only show a trend towards a significant change in 
methylation between the two maternal treatment groups.  There were no other significant 
differences in CpG methylation between the two treatment groups for babies born between June 
and August. For babies born in the autumn months, there was a significant difference in 
methylation of CpGs -2682 and -2673 in the umbilical cord of offspring that were born to mothers 
taking daily supplements of cholecalciferol when compared to mothers taking placebo.  The 
methylation of CpGs -2642, -2391, -2385 and -2357 showed trends towards significance between 
the two treatment groups, whereas no other CpGs showed a significant change in methylation. 
 The methylation of the CpG sites within the RXRA promoter was not significantly different 
between the placebo and supplement groups in either spring or winter. 
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7.3.5.3 NOS3 
Unlike RXRA, there was no significant difference in the methylation levels of NOS3 CpG -
3526 in umbilical cord tissue between offspring of mothers in the placebo group and mothers in 
the 1000 IU cholecalciferol supplemented group (Table 7.15 and Figure 7.10).  This suggests that 
maternal vitamin D3 supplementation does not have an effect on the methylation status of CpG -
3526 within NOS3 in offspring umbilical cord tissue. 
 
  n p-value 
Mean diff. % 
methylation 
95% Confidence Intervals 
Lower Upper 
NOS3 CpG -3526 123 0.469 0.3935 -1.465 0.678 
 
 
Table 7.15: Independent t-test analysis of NOS3 CpG -3526 methylation in umbilical cord tissue between 
placebo and daily 1000 IU cholecalciferol groups.  There is no significance difference in the methylation 
levels of CpG -3526 in umbilical cord tissue of offspring between mothers supplemented with 1000 IU 
cholecalciferol/day and mothers on placebo. ‘n’ is the number of subjects. 
 
 
Figure 7.10: The methylation of NOS3 CpG -3526 in umbilical cord tissue of offspring of mothers on 1000 
IU cholecalciferol/day or placebo.  The methylation of CpG -3526 within the NOS3 region of interest was 
not significantly different in the offspring umbilical cord tissue between mothers on 1000 IU 
cholecalciferol/day and mothers on placebo, determined by an independent t-test (p>0.05). 
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7.4 Discussion 
7.4.1 CDKN2A CpG methylation in umbilical cord and offspring bone outcomes 
 As with the associations at 4 and 6 years, there are significant negative associations 
between the methylation of CpG -907 in SWS umbilical cord and total BMC and total BA at birth.  
CpG -845 methylation is also significantly associated with total BMC and total BMD at birth, with a 
trend towards significance with total BA in a negative direction also seen.  There are also 
associations between CpG methylation and bone outcomes at birth that are lost at 4 and 6 years.  
CpG -796 methylation shows a significant negative association with total BMC, total BA and total 
BMD at birth and there is a trend towards significance between methylation of CpG -887 and total 
BMC, total BA and total BMD at birth, all in a negative direction. 
As none of the associations reached significance in the MAVIDOS cohort, the findings 
shown in the SWS cohort were not replicated.  This could be because a smaller sample size from 
the MAVIDOS cohort was used for the regression analyses; therefore there is less power to detect 
a similar effect as there was less samples in the MAVIDOS cohort.  However, as there were 
associations seen in the SWS cohort at 4 and 6 years, this may also be true of the MAVIDOS 
cohort, though this data is not yet available. 
 
7.4.2 RXRA CpG methylation in umbilical cord and offspring bone outcomes 
Previous results from Harvey and colleagues have shown that there are negative 
associations between the methylation of specific CpG loci in the promoter region of the RXRA 
gene and childhood bone outcomes (205).  This paper revealed significant associations between 
the methylation levels of CpGs -2649/-2642, CpG -2554, CpG -2406 and CpG -2357 and scBMC at 4 
years of age. However, there were no associations between these CpGs and BMC adjusted for 
total fat, total lean and height, nor where there any associations between any of the CpGs 
analysed and whole body BMC, BA or aBMD. 
 Linear regression analysis of CpG methylation in SWS umbilical cord and bone outcomes 
at birth revealed that, unlike at 4 years, there were no significant associations between 
methylation of any of the CpG sites and total prentice BMC. Whilst there were no significant 
associations between any of the CpGs and BMC, BA and aBMD at 4 years, total BMC and total BA 
showed significant positive associations with CpG -2686/-2682 and -2673 methylation at birth.  
The methylation of CpG -2649/-2642 showed a trend towards significance with both total BMC 
and total BA at birth, also in a positive direction.  There was also a significant association between 
the methylation of CpGs -2673 and total BMD, once again in a positive direction, which were not 
seen at 4 years of age. 
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When comparing the associations between RXRA methylation and bone outcomes in the 
MAVIDOS cohort at birth to those seen in the SWS at birth, the results are a lot more consistent 
across the two cohorts.  As the methylation analysis on the MAVIDOS cohort was done using 
pyrosequencing, the CpG sites that had previously been analysed together on the Sequenom 
MassARRAY platform (CpG -2686/-2682 and CpG -2649/-2642) could now be analysed individually 
and the methylation of previously unanalysed CpGs could now be examined.  Unfortunately, due 
to sequence design, CpG -2554 could not be analysed on this platform due to sequence design 
constraints.  Even though methylation levels have been assessed using two different platforms, it 
has been reported that methylation measurements are comparable across the two techniques 
(341). 
Results from this chapter show that there are significant positive associations between 
methylation of CpGs -2686, -2682, -2673 and -2642 and total BMC at birth, with a trend towards 
significance with CpG -2649, also in a positive direction.  This is also true of the SWS cohort to a 
certain extent as CpG -2649/-2642 came up as significant in the SWS cohort, whereas CpG -2649 
only tended towards significance in MAVIDOS.  The methylation of CpGs -2682, -2673 and -2642 
are significantly associated with total BA in a positive direction across both cohorts, whereas the 
methylation of CpG -2686 only shows a significant association with total BMD in the MAVIDOS 
cohort, and the methylation of CpG -2673 shows a trend towards significance with BMD in the 
SWS cohort only.   
This would suggest that, for at least some of the CpGs investigated, the associations seen 
in the SWS cohort between CpG methylation and offspring bone outcomes at birth have been 
replicated using samples from the MAVIDOS cohort.  This gives us an indication that the results 
seen here for CpGs -2682, -2673 and -2642 are reproducible across independent cohorts and 
could be used as predictors of offspring bone outcomes at birth.  As MAVIDOS data for childhood 
bone outcomes becomes available, it would be interesting to see whether these associations 
persist into childhood and whether they mimic what has already been seen in the SWS cohort. 
7.4.3 NOS3 CpG methylation in umbilical cord and offspring bone outcomes 
 Previous research has demonstrated that there are associations between the methylation 
of CpG -3526 within the NOS3 promoter and offspring bone outcomes at 9 years of age (234).  
Methylation levels of this specific CpG site were widely varied across tested subjects and showed 
significant positive associations with whole-body BA, BMC and aBMD, after adjusting for sex and 
age.  There was a trend towards a positive association between methylation and scBMD, which 
did not reach significance, nor did the negative association with percentage BMD. 
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 The analysis between the methylation status of this CpG in SWS umbilical cord and 
offspring bone outcomes at birth, showed that there are no significant associations between 
methylation and total BMC, BA, and BMD.  There are also no trends towards significance between 
CpG -3526 methylation and either scBMC or percentage BMC, which does not mimic what was 
seen at 9 years of age. 
However, when compared to those seen in the MAVIDOS umbilical cord at birth, there are 
no associations between the methylation status of CpG -3526 and total BMC, BA or BMD at birth, 
which is consistent with what has been shown in the SWS cohort.  Unfortunately scBMD was not 
calculated in the MAVIDOS cohort and so cannot be compared across the two.  Where there is no 
association between methylation and percentage BMC at birth in the SWS cohort, there is a 
significant positive association between the two in the MAVIDOS cohort. 
These findings show replication with the results seen in the SWS cohort between the 
methylation of CpG -3526 in the NOS3 promoter and total BMC, BA and BMD using samples from 
the MAVIDOS cohort.  However, as these associations did not reach significance they cannot be 
used as predictors of bone outcomes at birth.   
 
7.4.4 CDKN2A, RXRA and NOS3 methylation and birth weight 
In the MAVIDOS cohort, the methylation of CpGs -887 and -907 in CDKN2A in umbilical 
cord was negatively associated with offspring birth weight, whereas there were no significant 
associations between CDKN2A CpG methylation and birth weight found in the SWS cohort 
through linear regression.  With regards to RXRA, the methylation of CpG -2686/-2682 in the SWS 
cohort was positively associated with offspring birth weight, as was CpGs -2682 to -2642 in the 
MAVIDOS cohort.  This could suggest that site-specific methylation of these two genes may be 
able to predict birth weight and other research groups have previously shown that the 
methylation status of CpGs in other genes, such as CDK2 and APOE, has been associated with 
birth weight (342–344).  However, in the case of CDKN2A, as the results were not replicated 
across the two cohorts this may not be the case.  Instead this could be due to the difference in 
sample size tested, as the number of MAVIDOS samples tested was a lot smaller than those in the 
SWS cohort, therefore these significant associations may disappear when a greater number of 
MAVIDOS samples are investigated. 
However, when our statistical model is adjusted for birth weight, the majority of 
associations seen previously between the methylation of these CpG loci in CDKN2A and RXRA and 
offspring bone outcomes at birth disappear, suggesting that birth weight is significantly associated 
with bone outcomes at birth.  Linear regression showed significant positive associations between 
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birth weight and total BMC, BA and BMD in both the SWS and MAVIDOS cohorts, suggesting that 
birth weight highly influences bone outcomes at birth.  A study by Beltrand et al has 
demonstrated that total BMC at birth is determined by birth weight (340) and there are various 
other studies to show that birth weight is associated with bone measurements in both childhood 
and later life (118,345,346). 
As there are many components that contribute to birth weight, such as skeleton and fat 
mass, it cannot be said for certain that there is a direct link between a change in methylation 
leads to a change in birth weight and therefore a direct change in total BMC.  Linear regression 
shows that birth weight and bone outcomes at birth are highly correlated with each other, i.e. as 
one increases so does the other, however we cannot elucidate which is the primary association as 
there are other factors to consider.  The methylation of CDKN2A and RXRA may be having effects 
on downstream processes that could lead to an increase in birth weight by altering pathways that 
increase adiposity or regulate organ development.  A longitudinal study by Simpkin et al showed 
that associations between methylation and developmental phenotypes, such as height, weight, 
fat mass and bone mass, can be influenced by birth weight (347).  However by 7 years of age 
methylation levels have stabilised, suggesting a potential ‘catch-up’ period of methylation 
differences in the earlier years of childhood.  This suggests that although site-specific CpG 
methylation may not be a good indicator of offspring bone outcomes at birth due to the influence 
of birth weight on the associations, it may still have a purpose in the prediction of offspring bone 
outcomes during childhood. 
 
7.4.5 CDKN2A, RXRA and NOS3 methylation and maternal vitamin D supplementation 
 There is now evidence to suggest that the active metabolite of vitamin D3, 1α,25-
dihydroxyvitamin D3, can induce demethylation, though the exact mechanisms are not clear (196).  
Research groups have demonstrated that serum 25-hydroxyvitamin D3 status, which is 
hydroxylated to 1α,25-dihydroxyvitamin D3 in the kidney, was associated with lower levels of CpG 
methylation in the APC, DKK1 and WNT5A genes in either cell line or primary cells (198,199).  As 
fetuses receive vitamin D across the placenta from their mothers in utero, an increase in maternal 
25-hydroxyvitamin D could lead to an increase in fetal 25-hydroxyvitamin D levels, and potentially 
a decrease in methylation of genes associated with offspring bone outcomes. 
It has previously been demonstrated by Prof Harvey and colleagues (205) that an inverse 
relationship exists between maternal free 25-hydroxyvitamin D index (a ratio of serum 25-
hydroxyvitamin D to vitamin D binding protein (VDBP) concentrations) and methylation of CpG -
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2649/-2642 within the RXRA promoter.  However, neither the maternal 34-week serum 25-
hydroxyvitamin D nor VDBP relationships with methylation reached significance. 
Similar to results seen in the SWS cohort, associations between 34-week serum 25-
hydroxyvitamin D concentrations and RXRA CpG methylation levels did not reach significance 
(data not shown).  VDBP concentrations for MAVIDOS are not available at present, therefore the 
association between VDBP, or the calculated maternal free 25-hydroxyvitamin D index, and 
methylation could not be examined.  However, the MAVIDOS cohort is novel in that it allows us to 
directly compare changes in offspring outcomes between mothers taking placebo and mothers 
taking the cholecalciferol supplement.  Statistical analysis revealed that there is a significant 
increase in maternal serum 25-hydroxyvitamin D at 34 weeks gestation in the treatment group 
when compared to the control group, suggesting that supplementation is increasing serum 25-
hydroxyvitamin D levels in mothers during the later stages of pregnancy. 
Results in this chapter suggest that maternal vitamin D supplementation with 1000 IU 
cholecalciferol/day has an effect on the methylation levels of specific CpG loci within the RXRA 
promoter region in offspring umbilical cord. The methylation of CpGs -2673 to -2357 in offspring 
umbilical cord was significantly lower in the maternal vitamin D supplemented group when 
compared to the placebo group, determined by independent t-test.  No such effect was seen on 
the methylation of the remaining CpG loci within the RXRA promoter region of interest or those 
within the CDKN2A or NOS3 regions of interest. 
This could suggest that, in the neonates of the mothers supplemented with 
cholecalciferol, the increased vitamin D could be having an effect on the epigenetic regulation of 
the RXRA promoter.  There are studies suggesting that vitamin D is associated with promoter 
demethylation (196,198,348) and it is well documented that a decrease in promoter methylation 
levels is associated with an increase in gene transcription (349–352).  However, as CDKN2A and 
NOS3 methylation levels are unaffected, this would suggest that the actions of maternal vitamin D 
supplementation are specific to RXRA. 
Although a thorough literature search has not revealed any existing data demonstrating 
that these CpGs are important for RXRA expression, it has been demonstrated by Li and 
colleagues, through the use of a reporter construct containing the RXRA promoter, that when the 
area of the promoter region -2494 to -1500 upstream of the transcription start site is deleted 
from the construct, there is a significant decrease in luciferase activity (222) and that when this 
same region alone is ligated into luciferase reporter constructs, there is an increase in luciferase 
promoter activity when compared to control.  This suggests that this region is important for 
promoter activity and that transcriptional enhancers may potentially bind to this 994bp region of 
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the promoter.  Moreover, another reporter construct containing the region -2494 to -5114 from 
the TSS showed decreased luciferase activity when compared to control, suggesting that the 
region between these positions could contain potential binding sites for negative regulatory 
elements.  Harvey and colleagues have also demonstrated using EMSAs, that methylation of CpG -
2406 reduces transcription factor binding, suggesting that, at least for this CpG, methylation may 
have a functional role in RXRA expression (unpublished). 
When the associations between RXRA methylation and supplement group were stratified 
by season, associations only remained significant in the summer and autumn months.  The 
mothers of infants born in these seasons would have been exposed to more sunlight during the 
final months of their pregnancy than those mothers whose babies were born in the spring and 
winter months, which is when most placental 25-hydroxyvitamin D3 transfer occurs due to infant 
bone mineralisation.  This could lead to a natural increase in synthesis of maternal 25-
hydroxyvitamin D3 due to increased exposure to sunlight, which could have a cumulative effect in 
those mothers on the daily cholecalciferol supplement so that the amount of 25-hydroxyvitmain 
D3 transferred to the fetus is increased further.  This would lead to a larger decrease in 
methylation levels when compared to those mothers whose infants were born in the winter 
months. 
However, as RXRα is a key mediator of the vitamin D signalling, as well as having an 
important role in the activation of other nuclear receptors that regulate bone homeostasis, such 
as PPARγ (353), the decrease in methylation seen in the RXRA CpG loci between the placebo and 
treatment groups could be caused as an indirect effect of increased levels of vitamin D, rather 
than vitamin D having an active role in the demethylation process, as an increase in vitamin D 
levels would cause a positive feedback loop, increasing the transcription of RXRA.  When we also 
consider that the methylation of CpGs within CDKN2A and NOS3 was unchanged, this would 
suggest a pathway specific incident rather than a genome-wide occurrence. 
   
7.5 Summary 
 We sought to demonstrate that the associations found between methylation of CDKN2A, 
RXRA and NOS3 in SWS umbilical cord and offspring bone outcomes at birth could be replicated in 
the MAVIDOS cohort.  Results from this chapter show that both the associations seen between 
RXRA and NOS3 in the SWS cohort were replicated in the MAVIDOS cohort.  The associations 
between CDKN2A methylation and offspring bone outcomes at birth did not reach significance in 
the MAVIDOS cohort, though the trends were in the same direction as seen in the SWS samples.  
It was also shown that methylation of some of the CpG sites investigated within these genes were 
significantly associated with birth weight, which was shown to have significant positive 
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associations with total BMC, total BA and total BMD.  As birth weight is a consequence of bone 
mass, fat mass, lean mass, etc., this suggests that methylation potentially causes a change in 
pathways that lead to a change in birth weight, which in turn could be driving the changes in 
offspring bone outcomes at birth in the MAVIDOS cohort. 
 We also sought to demonstrate whether maternal treatment group was having an effect 
on umbilical cord methylation and offspring bone outcomes.  It was confirmed that a daily 1000 
IU supplement of cholecalciferol caused an increase in maternal serum 25-hydroxyvitamin D at 34 
weeks of pregnancy.  For RXRA, it was demonstrated that methylation levels of CpGs -2673 to -
2357 were significantly reduced in the umbilical cord of offspring from mothers that were 
supplemented daily with cholecalciferol when compared to mothers on placebo.  Vitamin D 
supplementation did not have any effects on the methylation of CpGs within CDKN2A or NOS3, 
which suggests that vitamin D is potentially having a specific effect on RXRA promoter 
methylation.  When these results were stratified by season of birth, it showed that the significant 
changes in methylation between the two groups were occurring in the umbilical cords of babies 
that had been born during the summer and autumn months, which is potentially due to increased 
sunlight in the final trimester leading to increased maternal 25-hydroxyvitamin D3 synthesis.  This 
would mean that there was more 25-hydroxyvitamin D3 available for transfer to the fetus, thereby 
potentially causing the decrease in methylation that are seen in these months when compared to 
those seen in spring and winter months. 
 
7.6 Further work 
 As some of the associations between umbilical cord methylation and offspring bone 
outcomes have been replicated across the SWS and MAVIDOS cohorts at birth, it would be 
interesting to see whether the associations between methylation and offspring bone outcomes 
during childhood seen in the SWS cohort can also be replicated in the MAVIDOS cohort.  As the 
childhood data became available from the MAVIDOS cohort, linear regression analyses could be 
done between umbilical cord methylation and childhood bone outcomes to see if the associations 
seen at birth persist or change. 
As well as fetal tissue, methylation levels of these CpGs within the CDKN2A, RXRA and 
NOS3 genes could also be investigated in other peripheral tissues such as umbilical cord blood and 
venous blood samples taken throughout childhood.  This would allow us to see if the methylation 
marks seen in umbilical cord tissue DNA are consistent across different tissue types or whether 
each tissue has a specific methylation pattern. 
As vitamin D supplementation was shown to have a positive effect on the bone outcomes 
of offspring born in the winter months, it would be interesting to see if these effects persist into 
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childhood as childhood bone outcome data became available.  As lifestyle and environmental 
factors after birth have been known to effect bone development (354), it would be interesting to 
see if these babies born to mothers who were supplemented with vitamin D still have a higher 
total BMC and total BA compared to those babies whose mothers were taking placebo or whether 
the environmental factors have a greater effect on the childhood development of the offspring.  
Though there is evidence to suggest that maternal vitamin D concentration may be an important 
determinant of skeletal growth trajectory during childhood (150).  If maternal vitamin D 
supplementation during pregnancy does indeed allow for better bone development in utero and 
during childhood, this would allow for children to obtain a higher peak bone mass, and therefore 
put them at less of a risk of developing osteoporosis in later life. 
As umbilical cord is a proxy tissue and as methylation profiles have been shown to be 
tissue specific in some cases, it is not known whether these CpGs investigated in the RXRA 
promoter region have a specific role in the regulation of RXRA expression in bone-related tissue.  
Therefore functional work in the form of dual luciferase assays, where plasmids containing the 
RXRA promoter region of interest with each of the CpGs mutated are transfected into SaOS-2 
cells, can be used to determine whether these CpGs are important for the regulation of RXRA 
gene expression. 
As maternal vitamin D treatment was shown to change to the methylation of CpGs within 
the RXRA promoter, if RNA can be extracted from umbilical cord, it could be determined whether 
this also caused a change in RXRA expression between the placebo and treatment group offspring.  
Primary osteoblasts could also be treated with vitamin D to determine if treatment causes any 
phenotypic changes to bone cells directly and whether it causes a change in the expression of 
markers associated with bone differentiation and mineralisation. 
  
209 
 
Chapter 8 
Discussion
210 
 
 
  
211 
 
8. Discussion 
 As people live longer, diseases that are associated with age, such as osteoporosis, are 
becoming more frequent and are becoming a major burden on the healthcare system.  The risk of 
developing osteoporosis in later life is determined by a number of factors, though epidemiological 
studies have suggested that childhood bone outcomes can be indicative of bone health in later life 
(151,153). Although CpG methylation within certain genes has been shown to potentially predict 
childhood bone outcomes, a future risk of fracture, and the mechanisms by which such 
methylation changes affect bone function is unknown or whether such methylation changes are 
simply markers of the disease process rather than causally involved.  The aim of this study was to 
determine whether methylation of specific CpGs within the CDKN2A gene can be used as a 
biomarker for later risk of developing osteoporosis, and whether its gene products actually have a 
direct functional role in osteoblast regulation and bone formation. 
  
8.1 Summary of main findings 
 Functional studies in vitro demonstrated that the CDKN2A CpGs associated with later 
bone outcomes may have an important role in the transcriptional regulation of ANRIL, a long non-
coding RNA transcribed from the CDKN2A gene locus. These results have demonstrated that 
mutation of specific CpGs within CDKN2A alters ANRIL promoter activity in osteoblasts and that 
methylation of CpGs -887 and -907 decreased binding of transcription factors to this region.  Of 
the transcription factor consensus sequences that were investigated, GAS and SMAD3/4 showed 
the strongest binding to this region, both of which play an important part in osteoblast 
differentiation and RUNX2 activity.  
 The results in chapter 4 show that ANRIL expression differs across cell types and that 
ANRIL expression is lower in cells that have undergone osteogenic differentiation.  Transfection of 
an osteosarcoma cell line with siRNAs against ANRIL showed that a decrease ANRIL expression 
leads to a decrease in cell number that was not explained by upregulation of cell cycle arrest, but 
did show a significant increase in the expression of RUNX2 and ALP, two markers of osteogenic 
differentiation.   
These knock down experiments were repeated in primary hBMSCs and osteoblasts, which 
also showed that ANRIL knock down induces a similar decrease in cell number as was seen in the 
osteosarcoma cell line.  In addition, in the primary cells, there was a decrease in cell proliferation 
rate, though no change was seen regarding cell viability between the siRNA treated cells and 
controls. This suggests that the decrease in cell number is not due to differences in cell viability 
but due to a decrease in cell proliferation.  Interestingly, RT-qPCR showed that the expression of 
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p16INK4A and p15INK4B were unchanged in primary osteoblasts, suggesting that ANRIL does not 
cause a decrease in proliferation rate and cell number through cis-regulatory mechanisms, but 
may have some trans-functional effects in these cells. 
A gene expression array using RNA from cells that had been treated with a siRNA against 
exon 1 of ANRIL revealed significant differential expression of 260 genes that were altered upon 
ANRIL knock down, with 128 being upregulated and 132 being down regulated.  Pathway analysis 
revealed genes that were involved in osteoblast specific pathways, such as differentiation, 
migration, cell viability and adhesion, as well as pathways that were involved in connective tissue 
deposition and development.  Gene ontology enrichment analysis also revealed that the top five 
enriched functional categories were phosphoprotein, alternate splicing, nucleus, cytoplasm and 
acetylation, suggesting that ANRIL may affect other cellular processes as well as the cell cycle. 
 Finally, the associations between methylation of CpGs within the CDKN2A gene and bone 
outcomes at birth in the SWS cohort were not replicated in the MAVIDOS cohort.  The 
methylation of CpGs within the RXRA and NOS3 genes were shown to have a significant positive 
association with offspring total BMC, total BA, total BMD and percentage BMC at birth in both the 
SWS and MAVIDOS cohorts.  It was also shown that the methylation of these CpGs were positively 
associated with offspring birth weight and when this was adjusted for in the statistical model, all 
significant associations between CpG methylation and offspring bone outcomes at birth were 
removed.  When the MAVIDOS cohort samples were examined as a randomised control trial, 
methylation of CpGs within RXRA was shown to be significantly different between the placebo 
and cholecalciferol supplemented group, with significant decreases in CpG methylation shown 
between treatment groups for babies born in the summer and autumn months. 
  
8.2 Discussion of main findings 
 Even though CDKN2A methylation at birth has been shown to be negatively associated 
with offspring bone outcomes at 4 and 6 years of age in the SWS cohort (Harvey et al, 
unpublished), it is not known whether these CpGs are functionally important in the regulation of 
CDKN2A and whether the products of this gene are important in regulating osteoblast function.  
Luciferase reporter assays revealed that CpGs within a 300bp region of CDKN2A influenced the 
level of ANRIL promoter activity.  As CpGs -887 and -907 had been shown to have the strongest 
associations with offspring bone outcomes, the effect of differential methylation of these two 
CpGs loci was explored further using EMSA, to determine whether methylation affected 
transcription factor binding to the ANRIL promoter. 
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Methylation is generally associated with a reduction in transcription factor binding  as the 
methyl group blocks the binding site, or recruits repressive complexes through methyl binding 
proteins which occupy the site (262).  The results in chapter 3 have shown that the methylation of 
CpGs -887 and -907 decreases the binding affinity of transcription factors to this region.  Two 
transcription factors were found to potentially bind to this region: IFN-gamma activation 
sequence (GAS) and SMAD3/4.  In osteoblasts, these two transcription factors have been shown 
to regulate RUNX2, but in opposite directions, with IFNγ signalling causing an increase in function 
of RUNX2 (265) and SMAD3/4 binding causing a decrease in RUNX2 function (270), suggesting 
that these two signalling pathways work together to regulate appropriate bone differentiation.  
Although no direct interaction between STAT1 and SMAD3/4 has been observed, STAT1 has been 
shown to induce the transcription of SMAD7, an antagonist SMAD, which binds to SMAD3 and 
prevents its interaction with the TGF-β receptor (272).  Chromatin immunoprecipitation assays 
could be used to determine whether GAS and SMAD3/4 bind in vivo to the ANRIL promoter and 
how binding is affected by osteoblast differentiation.  Although methylation has been shown to 
inhibit the binding of STAT1 to the promoter of its target genes (355), this has not been 
investigated with regards to SMAD3/4.  If methylation at these CpG sites caused a decrease in 
transcription factor binding affinity, this may lead to a decrease in ANRIL expression, leading to 
decreased cell proliferation and the onset of differentiation, potentially prior to the appropriate 
differentiation signals with consequences on bone structure and risk of fracture in later life by 
altering bone mineral content and bone mineral density.  
 
 
 
Figure 8.1: Methylation of specific CpG loci within the CDKN2A gene causes a decrease in ANRIL 
expression.  CpG -887 in the CDKN2A 300bp differentially methylated region was shown to regulate the 
expression of ANRIL.  EMSAs revealed that GAS and SMAD3/4 consensus sequences bound over this 
region and that methylation of the CpG attenuated transcription factor binding, which is often associated 
with a decrease in gene expression. 
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Because the CpGs within the CDKN2A locus were shown to alter the expression of ANRIL 
and as methylation was shown to reduce transcription factor binding, the effects of a knock down 
in ANRIL expression was examined firstly in an osteosarcoma cell line.  SaOS-2 cells were 
transfected with three siRNAs against ANRIL, with two targeting exon 1 and the other targeting 
exon 19 of ANRIL.  The results from chapter 4 demonstrated that in SaOS-2 cells, there was a 
decrease cell number, however neither p16INK4A nor p15INK4B expression increased, suggesting that 
the effect on cell proliferation may be independent of p16INK4A and p15INK4B.   
The mechanism by which ANRIL induces cell cycle arrest independently of a change in p16 
expression is currently unknown, however ANRIL may directly affect p16INK4A protein activity, or 
the expression/activity of other members of this pathway.  As the p16INK4A pathway is so 
important in preventing unregulated proliferation, it would seem logical to suggest that there 
would be other ‘back up’ mechanisms to regulate the expression of this cell cycle inhibitor.  For 
Congrains E1 and Congrains E19 siRNAs, the decrease in cell number was seen along with an 
increase in cell death, suggesting a potential increase in pro-apoptotic pathways.  This agrees with 
a previous study by Wan et al, where a decrease in ANRIL has previously been seen to cause 
apoptosis in cells (356). 
These experiments were repeated in primary hBMSCs and osteoblasts using the Congrains 
E1 and E19 siRNAs.  ANRIL knockdown with siRNA directed against exon 1 and exon 19 also 
induced a decrease in hBMSCs and osteoblast cell number.  The finding of similar effects on cell 
growth in both SaOS-2 cells and primary cells strongly supports a role for ANRIL in osteoblast and 
mesenchymal cell growth.  There were differences however between the cell line and primary 
cells, in SaOS-2 cells, ANRIL knock down led to a decrease in cell viability, while in primary cells 
this was not seen.  SaOS-2 cells have, however, mutations within p53 and the p53 pathway which 
regulates apoptosis so this may explain the difference seen in apoptosis.  However, the 
proliferation rate was decreased in both primary cell types upon ANRIL knock down, even though 
p16INK4A expression was unchanged in both primary cell types, suggesting that ANRIL may have a 
trans-functional effect in both hBMSCs and osteoblasts.  As decrease in ANRIL expression induced 
by higher methylation may therefore cause a decrease in cell number and proliferation rate of 
both hBMSCs and osteoblast, this could cause a decrease in bone formation and mass, and 
therefore increase risk of fracture.  Osteoblast number has been linked both directly and 
indirectly to bone formation and bone mass, in that a decrease in the number of osteoblasts 
present correlates with a decrease in both of these (64,68,101).  This further supports a role for 
ANRIL in osteoblast regulation and bone formation, and its potential for a part in the 
pathogenesis of osteoporosis. 
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Figure 8.2: Decrease in ANRIL expression leads to an increase in differentiation markers and a decrease 
in cell number.  In osteosarcoma cells, a knock down in ANRIL expression caused a significant increase in 
the differentiation markers RUNX2 and ALP.  A decrease in cell number that was not explained by an 
increase in either p16
INK4A
 or p15
INK4B
 expression occurred in both the osteosarcoma cell line and the 
primary osteoblasts. 
 
 lncRNAs, such as HOTAIR, have been shown to have trans-functional effects, where they 
regulate genes that are 100,000 bps away from where they are transcribed.  For example, HOTAIR 
is transcribed from the HOXC gene on chromosome 12 and regulates HOXD gene expression on 
chromosome 2 through the recruitment of the PRC2.  lncRNAs have also been shown to have 
roles in regulating osteoblast function, such as lncRNA-ANCR.  This lncRNA inhibits RUNX2 
expression through the recruitment of EZH2 (214), which is a component of the PRC2.  Although 
ANRIL to date has not been shown to have any specific functions in osteoblasts or osteoblast-
specific pathways, it has been shown to have trans-functional effect in a variety of other cell lines 
and causes transcriptome wide change in gene expression (237,277).  To this end, a gene 
expression array using RNA treated with a siRNA against exon 1 of ANRIL (Congrains E1) was 
carried out to determine what genes and pathways a decrease in ANRIL expression would affect in 
primary osteoblasts.  The results presented in chapter 6 confirm that there is no change in 
p16INK4A and p15INK4B expression when ANRIL expression is knocked down in osteoblasts, but there 
were 260 genes that showed differential expression – 128 of these were upregulated and 132 of 
these were down regulated.  Genes that have previously been shown to have roles in osteoblast 
function were shown to be altered on the array (HIF3A, IGF2, MAPK3 and TWSG1 expression was 
upregulated and ETS1 and CYR61 was down regulated) and the top pathways that contained the 
most altered genes were those relating to osteoblast differentiation, viability, adhesion and 
migration as well as those that related to the deposition of connective tissue and growth of 
connective tissue cells causing a dysregulation of these pathways.  This further suggests that a 
down regulation in ANRIL expression could have adverse effects on bone formation and mass as 
key pathways that ensure correct bone development are altered.  A knock down in ANRIL 
expression also had an effect on biological processes and functions.  The expression of genes that 
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are involved in protein transport and binding processes, as well as those that encode for 
phosphoproteins, molecules involved in alternative splicing, nuclear regulation and acetylation, 
were significantly altered.  Research has shown that ANRIL may implement its trans-regulatory 
effect through Alu elements (282), which are repeat sequences that have been shown to have a 
role in the regulation of gene expression, and in the paper by Holdt et al, they demonstrated that 
many of the genes that they found to be regulated by ANRIL contained Alu elements in their 
promoters or enhancers.  It has been shown that many of the genes that are involved in 
alternative splicing and protein translation mechanisms contain Alu elements in their regulatory 
regions (357).  This suggests a potential mechanism by which ANRIL regulates the expression of its 
target genes.  The results shown in this chapter are the first step in elucidating a potential 
mechanism for ANRIL trans-regulation.  The next step would be to determine where in the 
genome ANRIL binds in osteoblasts.  To this end, a ChIRP assay could be used, where 
oligonucleotide probes would be used to tile the ANRIL RNA and regions of the chromosomes 
bound by ANRIL identified.  This would allow for the discovery of primary ANRIL target genes.  
 
 
 
Figure 8.3: A potential mechanism by which CDKN2A methylation can cause dysregulation of bone 
homeostasis leading to an increased risk for osteoporosis.  An increase in methylation of specific CpG 
loci within the CDKN2A gene can prevent transcription factor binding and thus cause a decrease in the 
expression of the lncRNA ANRIL.  This would lead to altered expression of genes that cause an increase in 
osteoblast differentiation but at the same time inhibit pathways that cause osteoblast proliferation.  This 
would cause an imbalance in bone homeostasis, which could lead to an increase risk of developing 
osteoporosis in later life as bone would not be forming and remodelling correctly. 
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 Although the focus of this discussion has been bone forming osteoblasts and how the 
dysregulation of these cells could lead to adverse bone formation and potentially contribute to 
osteoporosis by preventing development of optimal peak bone mass, this is not the only 
mechanism involving osteoblasts that could contribute to the onset of osteoporosis.  As the 
hallmarks of osteoporosis are increased osteoclast number, enhanced bone resorption activity 
and dysregulated bone remodelling, and due to the relationship between osteoblasts and 
osteoclasts, this is potentially another mechanism which may contribute to the regulation of the 
loss of bone mass seen with osteoporosis.  It would also be interesting to see in ANRIL has a 
specific role in osteoclasts and their progenitors, therefore the experiments that have been 
carried out in this thesis could be repeated in osteoclasts to determine the role of ANRIL within 
these cells. 
There is evidence to suggest that prenatal and early life environment can potentially 
induce differentially methylated loci, which, if associated with a particular disease or phenotype, 
has the potential to act as a biomarker for disease/phenotype risk.  As CpG methylation with 
CDKN2A was shown to be associated with offspring bone outcomes in childhood, pyrosequencing 
and linear regression analysis was used on two separate cohorts to determine whether the same 
associations were seen between methylation and offspring bone outcomes at birth and whether 
the associations seen could be replicated across the SWS and MAVIDOS cohorts.  The results from 
chapter 7 show that the methylation of CpG loci in CDKN2A was shown to be negatively 
associated with offspring bone outcomes at birth in the SWS cohort, independent of adjustments 
made for sex, age at time of DXA and gestational age, which agrees which what had previously 
been seen at 4 and 6 years of age, suggesting that methylation levels of this gene could 
potentially be used as a predictive mark from birth for bone health in later life.  However, these 
results were not replicated in the MAVIDOS cohort, though this analysis used significantly reduced 
numbers than those used in the SWS analysis, which could explain the discrepancies between the 
two cohorts.  It will be important to determine the robustness of such methylation marks 
predictive of later phenotype and replication is a key step in this process.  However, to ensure 
studies are adequately powered, large numbers of subjects would need to be analysed and this is 
becoming more feasible with the advent of the 450k, and more latterly, the 850k array.  Consortia 
are also being established to combine data sets to increase the number of subjects analysed.  
Genome wide approaches using the 450k/850k array would also allow for a more systematic 
approach to screening for biomarkers, as it would give us a better picture of the epigenome and 
whether specific CpG sites display altered methylation across numerous cohorts. 
218 
 
The results in chapter 7 also showed that methylation of CpG loci within RXRA at birth 
was positively associated with offspring total BMC, total BA and total BMD at birth in both the 
SWS and the MAVIDOS cohorts.  The previous associations seen between RXRA methylation and 
scBMC at 4 years shown by Harvey et al (205) are not replicated at birth in the SWS cohort but 
associations between perinatal RXRA methylation and scBMC at birth show a weak negative 
association in the MAVIDOS cohort.  However, the rest of the associations seen between RXRA 
methylation and offspring bone outcomes at birth were in a positive direction, whereas Harvey et 
al (205) did not find any associations between these bone outcomes and RXRA methylation at 4 
years of age in the SWS cohort.  Perinatal methylation of CpGs within NOS3 at birth only showed 
significant associations with percentage BMC at birth in the MAVIDOS cohort, this was not 
observed in the SWS cohort.   
 Maternal diet is a potential factor that could alter the fetal methylation profile and 
maternal lifestyle has been shown to have influences of offspring bone health in childhood (150).  
Vitamin D is essential for the uptake of calcium and mineralisation of the skeleton in utero and 
through life.  Studies have shown that maternal vitamin D status has an effect on skeletal 
development of the offspring (205,358), and could be a factor that determines peak bone mass of 
the child, and therefore future fracture risk.  In the MAVIDOS trial, daily maternal supplement of 
cholecalciferol was shown to significantly increase the BMC, BA and BMD of babies born during 
the winter months (339).  The results in chapter 7 demonstrate that an increase in maternal 
vitamin status causes a decrease in the methylation of CpGs within the RXRA gene, and that these 
associations are only significant for babies born during the summer and autumn months.  Vitamin 
D has recently been shown to cause demethylation of CpGs (196); however, due to the 
interactions between RXRA and vitamin D, it’s hard to elucidate whether this demethylation is 
caused by a direct or indirect interaction with vitamin D.  However, the direction of association 
between vitamin D supplementation and RXRA methylation was not consistent with the direction 
of associations between RXRA methylation and BMC seen at birth.  For instance, higher RXRA 
methylation was associated with higher BMC at birth, whereas maternal vitamin D 
supplementation caused a decrease in the methylation of RXRA and an increase in the BMC, BA 
and BMD of offspring at birth.  However results in Chapter 7 showed that the relationships 
between offspring bone outcomes at birth and birth weight showed a strong positive correlation 
and it could be this that is driving the positive association between offspring bone outcomes and 
RXRA methylation.  Harvey and colleagues did show that there was a trend towards significance 
between methylation of CpG -2649/-2642 and birth weight in the SWS cohort (205) and other 
studies have shown that birth weight can be associated with CpG methylation (220,347). 
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A limitation of this research is that methylation levels were measured in umbilical cord, a 
proxy tissue, and it is unknown how this relates to the methylation profile in bone tissue.  This 
makes it difficult to potentially prove causality of these marks in influencing later bone health.  
Animal studies can be used to determine whether prenatal environment has an effect on the 
methylation status of these CpGs in bone tissue, as well as other tissues.  In the future, 
CRISPR/Cas9 could be used to investigate the causality of this altered methylation.  This technique 
allows for gene specific methylation by using zinc finger protein tags in DMNT1 or TET to direct 
the methylation machinery to the target site.  This would allow us to see whether methylation of 
these CpGs in CDKN2A has a direct adverse effect on skeletal development. However, this 
technique still exhibits off-target methylation and so cannot be used at present. 
Taken together, the results from this thesis demonstrate a novel role for ANRIL in 
osteoblast function as there is evidence to suggest that it potentially regulates genes that are 
involved in specific skeletal development and functional pathways.  The CpG loci identified in 
CDKN2A having associations with offspring bone outcomes during childhood are important for the 
regulation of the lncRNA ANRIL, suggesting that this lncRNA may have some functional effects in 
human osteoblasts and that alterations to the expression of this lncRNA could have deleterious 
effects on bone development, assisting in the onset of osteoporosis in later life.  This is a novel 
finding, as a direct function for this lncRNA in osteoblasts has never been suggested before and 
these results could suggest the discovery of a new regulator of bone cell differentiation and cell 
growth.  The results in this thesis also suggest that the methylation of CDKN2A may not be able to 
predict childhood bone health at birth as in both the SWS and MAVIDOS cohorts the associations 
were highly influenced by birth weight.  Further studies are needed to understand the 
relationship between birth weight and CDKN2A methylation, in order to elucidate what is the 
driver of the association.  However, it may be possible to use these methylation marks to predict 
childhood bone outcomes, when birth weight may not have as much of an influence over bone 
health as the environment that the child is exposed to after birth, as these stimuli may have an 
effect on their epigenome.  The influence of maternal vitamin D on the methylation levels of RXRA 
CpGs in the offspring umbilical cord DNA is interesting, especially as there seems to be a seasonal 
component that also influences the effects seen; however due to the interactions between 
vitamin D and RXRA, this relationship needs to be investigated further. 
 
8.3 Implications for human health 
 It is well understood that prenatal and early life environment can alter the epigenetic 
regulation of genes, which can influence bone development and risk of osteoporosis in later life.  
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Results from this study have shown that altered expression of the lncRNA ANRIL can affect the 
regulation of genes involved in the differentiation and proliferation pathways of osteoblasts.  A 
better understanding of the epigenetic regulation of these processes would help with identifying 
potential therapeutic targets and would potentially help identify those individuals as risk for 
developing a reduced peak bone mass and therefore at higher risk of developing osteoporosis in 
later life. 
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9.1 Appendix 
9.1.1 Illumina Human H12 Gene Expression Array 
Table 9.1: List of 260 genes that had significantly altered differential expression with ANRIL 
siRNA treatment on the Illumina Human H12 Gene Expression Array. 
UPREGULATED GENES DOWNREGULATED GENES 
Gene 
Fold 
Change 
Raw p-
value 
False 
Discovery 
Rate 
Gene 
Fold 
Change 
Raw p-
value 
False 
Discovery 
Rate 
BCYRN1 2.14 0.00083 0.0496 ETS1 -2.30 0.00037 0.0440 
HS.570988 2.14 0.00043 0.0440 CAV2 -2.03 0.00008 0.0408 
PTGES 2.05 0.00003 0.0395 CPD -1.97 0.00080 0.0496 
LOC100130
516 
1.94 0.00008 0.0408 PLEKHB2 -1.92 0.00027 0.0416 
LSM14A 1.91 0.00041 0.0440 GALC -1.78 0.00010 0.0408 
OLFML3 1.89 0.00074 0.0496 ATP2B1 -1.74 0.00043 0.0440 
HIF1A 1.81 0.00003 0.0395 HOXA9 -1.72 0.00038 0.0440 
IL10RB 1.79 0.00078 0.0496 HDDC2 -1.71 0.00011 0.0408 
NT5DC2 1.79 0.00027 0.0416 NIN -1.67 0.00001 0.0395 
TOP1MT 1.75 0.00014 0.0408 GMFB -1.67 0.00001 0.0395 
CHPF 1.74 0.00013 0.0408 TFPI -1.66 0.00018 0.0408 
LAMP2 1.73 0.00080 0.0496 NQO1 -1.63 0.00038 0.0440 
ROD1 1.71 0.00005 0.0395 EIF4EBP2 -1.63 0.00085 0.0496 
POLR3E 1.68 0.00015 0.0408 C2ORF28 -1.59 0.00065 0.0496 
SCAMP1 1.67 0.00069 0.0496 EAF1 -1.57 0.00029 0.0425 
GAMT 1.65 0.00070 0.0496 ARL8B -1.57 0.00079 0.0496 
ATP11C 1.64 0.00039 0.0440 PIGA -1.54 0.00090 0.0496 
MAPK3 1.62 0.00080 0.0496 ZFYVE26 -1.53 0.00014 0.0408 
SAR1B 1.62 0.00061 0.0494 C2CD2 -1.51 0.00038 0.0440 
IGF2 1.62 0.00047 0.0458 TOMM20 -1.51 0.00023 0.0408 
IPO11 1.58 0.00025 0.0416 TMEM9B -1.50 0.00069 0.0496 
TLN1 1.58 0.00015 0.0408 ANTXR1 -1.49 0.00066 0.0496 
DAP3 1.56 0.00071 0.0496 TWSG1 -1.49 0.00020 0.0408 
LOC644879 1.51 0.00048 0.0461 HS.348514 -1.49 0.00041 0.0440 
PLXNB2 1.51 0.00020 0.0408 DNAJB4 -1.49 0.00017 0.0408 
GCNT1 1.49 0.00013 0.0408 DCP2 -1.47 0.00018 0.0408 
FGFRL1 1.47 0.00012 0.0408 CRIM1 -1.47 0.00052 0.0485 
SNRNP27 1.46 0.00081 0.0496 CYR61 -1.46 0.00061 0.0494 
CMBL 1.45 0.00059 0.0494 SEL1L3 -1.45 0.00024 0.0415 
IVNS1ABP 1.45 0.00011 0.0408 FAM176A -1.45 0.00031 0.0434 
GNB1 1.45 0.00010 0.0408 ICK -1.44 0.00006 0.0395 
UST 1.45 0.00070 0.0496 DAB2 -1.42 0.00039 0.0440 
ICMT 1.44 0.00029 0.0425 DPY19L1 -1.42 0.00026 0.0416 
SOCS4 1.44 0.00026 0.0416 OKL38 -1.41 0.00062 0.0494 
TMEM158 1.42 0.00039 0.0440 SLC30A7 -1.41 0.00030 0.0431 
CYB5R4 1.41 0.00055 0.0488 BCL7B -1.40 0.00087 0.0496 
RIT1 1.41 0.00063 0.0496 LONRF1 -1.40 0.00076 0.0496 
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CXCL16 1.40 0.00012 0.0408 PGM2 -1.39 0.00056 0.0488 
PDCD2 1.39 0.00033 0.0440 LOC729009 -1.39 0.00088 0.0496 
SDC4 1.38 0.00050 0.0473 TDG -1.38 0.00069 0.0496 
SEC24A 1.38 0.00080 0.0496 KIAA1949 -1.38 0.00074 0.0496 
NICN1 1.38 0.00014 0.0408 C9ORF80 -1.38 0.00013 0.0408 
SHISA5 1.37 0.00048 0.0461 KHDRBS3 -1.37 0.00020 0.0408 
TMEM41A 1.37 0.00085 0.0496 EFEMP1 -1.37 0.00065 0.0496 
PRMT2 1.36 0.00006 0.0408 SENP2 -1.37 0.00042 0.0440 
GSTM2 1.35 0.00030 0.0434 KIAA0494 -1.37 0.00068 0.0496 
LOC728969 1.34 0.00073 0.0496 WIPI2 -1.37 0.00084 0.0496 
ATP1B1 1.34 0.00040 0.0440 BNIP2 -1.36 0.00037 0.0440 
DTWD1 1.33 0.00072 0.0496 FAM49B -1.36 0.00042 0.0440 
SPATA18 1.33 0.00087 0.0496 MTMR9 -1.36 0.00002 0.0395 
DSCR3 1.32 0.00058 0.0493 KRAS -1.36 0.00021 0.0408 
C2ORF24 1.32 0.00059 0.0494 NEDD4 -1.36 0.00040 0.0440 
SLC22A18 1.32 0.00046 0.0454 EXOC5 -1.35 0.00023 0.0408 
GOPC 1.32 0.00038 0.0440 TRAM1 -1.34 0.00055 0.0488 
AKTIP 1.32 0.00026 0.0416 AZIN1 -1.34 0.00000 0.0320 
CASK 1.31 0.00012 0.0408 HS.535028 -1.34 0.00029 0.0425 
PCOLCE 1.31 0.00080 0.0496 BDNF -1.34 0.00043 0.0440 
TSKU 1.31 0.00044 0.0440 ATRN -1.33 0.00069 0.0496 
LGMN 1.29 0.00058 0.0493 OTUD6B -1.32 0.00090 0.0496 
ANO10 1.29 0.00036 0.0440 DIXDC1 -1.31 0.00091 0.0496 
RPF2 1.28 0.00086 0.0496 TUG1 -1.31 0.00040 0.0440 
ATP6V1G2 1.28 0.00080 0.0496 TATDN3 -1.30 0.00073 0.0496 
C12ORF45 1.28 0.00001 0.0395 NEK1 -1.30 0.00019 0.0408 
CTNNB1 1.28 0.00022 0.0408 AHCTF1 -1.29 0.00016 0.0408 
LOC729926 1.28 0.00079 0.0496 IFNAR1 -1.29 0.00033 0.0440 
PUS7 1.27 0.00082 0.0496 KBTBD2 -1.28 0.00021 0.0408 
ERGIC1 1.27 0.00044 0.0440 GAPVD1 -1.28 0.00085 0.0496 
TBC1D7 1.27 0.00040 0.0440 RRAS2 -1.28 0.00035 0.0440 
ATP10A 1.27 0.00048 0.0461 C21ORF7 -1.28 0.00038 0.0440 
THOC4 1.26 0.00057 0.0488 NDUFB5 -1.27 0.00005 0.0395 
LAGE3 1.26 0.00086 0.0496 CYP4V2 -1.26 0.00061 0.0494 
ASAP3 1.26 0.00020 0.0408 PTTG1IP -1.26 0.00019 0.0408 
TACC2 1.25 0.00006 0.0408 LSM1 -1.26 0.00010 0.0408 
TTYH3 1.25 0.00080 0.0496 USP46 -1.26 0.00043 0.0440 
ANKRD9 1.25 0.00082 0.0496 AP4E1 -1.26 0.00069 0.0496 
CLPP 1.25 0.00044 0.0442 KLC1 -1.25 0.00018 0.0408 
LOC100192
378 
1.25 0.00084 0.0496 EXT2 -1.24 0.00021 0.0408 
CS 1.24 0.00007 0.0408 OSBPL9 -1.23 0.00040 0.0440 
SLC25A4 1.24 0.00061 0.0494 WNK1 -1.23 0.00092 0.0498 
LOC100129
034 
1.24 0.00036 0.0440 MTMR14 -1.23 0.00008 0.0408 
DCUN1D1 1.24 0.00047 0.0458 MAPKAP1 -1.23 0.00031 0.0434 
PHF21A 1.23 0.00056 0.0488 SBF1 -1.23 0.00041 0.0440 
IAH1 1.23 0.00012 0.0408 PHIP -1.22 0.00023 0.0408 
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HIST1H2BK 1.23 0.00068 0.0496 PRKCD -1.22 0.00023 0.0408 
NLGN2 1.22 0.00020 0.0408 LOC647597 -1.22 0.00082 0.0496 
PHLDA3 1.22 0.00091 0.0496 CRADD -1.21 0.00011 0.0408 
CCT8 1.22 0.00075 0.0496 NCK2 -1.21 0.00048 0.0461 
ZNF239 1.22 0.00090 0.0496 CYTSA -1.20 0.00076 0.0496 
NCL 1.21 0.00037 0.0440 TM2D3 -1.20 0.00005 0.0395 
NSA2 1.20 0.00025 0.0416 C4ORF41 -1.20 0.00070 0.0496 
C12ORF5 1.20 0.00037 0.0440 ZNF275 -1.20 0.00075 0.0496 
THNSL1 1.19 0.00016 0.0408 PSMC2 -1.19 0.00041 0.0440 
MGC39900 1.18 0.00004 0.0395 NHLRC3 -1.19 0.00027 0.0416 
TAF10 1.18 0.00069 0.0496 C20ORF24 -1.19 0.00012 0.0408 
TRIM33 1.18 0.00084 0.0496 TFDP2 -1.19 0.00088 0.0496 
PSTPIP2 1.17 0.00074 0.0496 LRRC57 -1.19 0.00068 0.0496 
ZNF558 1.17 0.00072 0.0496 SSU72 -1.19 0.00035 0.0440 
C9ORF142 1.17 0.00090 0.0496 ZNF322A -1.18 0.00083 0.0496 
FAM125B 1.17 0.00089 0.0496 CPSF2 -1.18 0.00005 0.0395 
C11ORF51 1.17 0.00055 0.0488 MRLC2 -1.18 0.00005 0.0395 
TMEM5 1.17 0.00066 0.0496 KIAA1715 -1.18 0.00058 0.0493 
ANKRA2 1.16 0.00081 0.0496 HS.571502 -1.17 0.00061 0.0494 
STAG2 1.16 0.00004 0.0395 DCK -1.17 0.00020 0.0408 
LOC728139 1.16 0.00074 0.0496 FBXO28 -1.17 0.00017 0.0408 
LOC728098 1.15 0.00023 0.0408 RC3H2 -1.17 0.00069 0.0496 
HIST1H2BD 1.15 0.00064 0.0496 CALR -1.17 0.00052 0.0482 
DHX40 1.15 0.00023 0.0408 ADAR -1.16 0.00029 0.0425 
C7ORF55 1.14 0.00062 0.0494 BCL2L12 -1.16 0.00023 0.0408 
DCUN1D4 1.14 0.00014 0.0408 PPP1R12A -1.15 0.00018 0.0408 
MRPL32 1.13 0.00079 0.0496 GSTO1 -1.15 0.00053 0.0485 
ATP5G2 1.13 0.00001 0.0395 MTMR3 -1.15 0.00093 0.0498 
RPAIN 1.13 0.00042 0.0440 B4GALNT4 -1.15 0.00023 0.0408 
HS.534680 1.13 0.00009 0.0408 CLDN15 -1.15 0.00012 0.0408 
PTDSS1 1.13 0.00092 0.0497 ARHGAP21 -1.14 0.00090 0.0496 
ARD1A 1.12 0.00019 0.0408 ASPH -1.14 0.00055 0.0488 
ZNF627 1.12 0.00089 0.0496 FLJ20254 -1.14 0.00011 0.0408 
CXXC5 1.11 0.00004 0.0395 PSMA1 -1.13 0.00054 0.0488 
FICD 1.11 0.00026 0.0416 
LOC100133
888 
-1.13 0.00055 0.0488 
SLC16A2 1.11 0.00080 0.0496 TP53BP2 -1.13 0.00051 0.0477 
MIR185 1.10 0.00005 0.0395 RBM22 -1.11 0.00066 0.0496 
LOC646753 1.10 0.00037 0.0440 KIAA1429 -1.11 0.00008 0.0408 
CYB5R1 1.09 0.00086 0.0496 HS.582988 -1.11 0.00080 0.0496 
SREBF1 1.09 0.00010 0.0408 CLEC11A -1.11 0.00027 0.0416 
LRRC8E 1.08 0.00017 0.0408 SNRNP40 -1.10 0.00042 0.0440 
NME5 1.08 0.00033 0.0440 HS.436679 -1.10 0.00057 0.0488 
RBM4 1.08 0.00061 0.0494 CHD9 -1.09 0.00034 0.0440 
C19ORF60 1.07 0.00008 0.0408 CHEK2 -1.09 0.00057 0.0492 
RABL2B 1.05 0.00064 0.0496 SON -1.09 0.00088 0.0496 
    
HIST2H2AA
3 
-1.08 0.00031 0.0434 
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PRR13 -1.08 0.00024 0.0408 
    
SOD1 -1.06 0.00078 0.0496 
    
TFG -1.05 0.00081 0.0496 
 
 
9.1.2 Optimisation of primary cell siRNA transfection 
hBMSCs were seeded at 30,000 and 50,000 cells per well in a 24-well plate and were 
transfected with 10nM ‘scrambled’ and ‘cell death’ using Lipofectamine RNAiMAX for 6, 24, 48 
and 72hrs, with all cells being trypsinised and counted at 72hrs or fixed for FACS analysis.  Cells 
transfected with ‘scrambled’ control were also counted at 24 and 48hr intervals to determine 
whether cells were still dividing over the 72hr period. 
A seeding density of 30,000 cells per well with a 6hr siRNA treatment time was chosen for 
hBMSCs as cell numbers increased over the 72hr period (Figure 9.1A).  Cell numbers did not 
increase after 48hrs with 24 and 48hr siRNA treatments; however, with 72hr siRNA treatment, cell 
number increased again at 72hrs after staying the same at 24 and 48hrs, though this was not to 
the same level as those cells treated with siRNA for 6hrs.  FACS analysis revealed that there was 
an increase in the number of cells undergoing apoptosis in those cells treated with cell death 
siRNA for 6hrs compared to those treated with the ‘scrambled’ control siRNA, and that there was 
a decrease in the number of cells in the G0/G1 phase of the cell cycle (Figure 9.1B).   
Using 6hr and 24hr treatment times as a starting point, the same optimisation was carried 
out on primary osteoblasts.  A 6hr treatment time using a starting seeding density of 30,000 cells 
per well was found to be the most effective.  For the 24hr treatment time at this seeding density 
there was no increase in cell numbers at 48hrs but they seemed to recover at 72hrs, however this 
number was still less that those seen at 72hrs with the 6hr siRNA treatment (Figure 9.2A).  FACS 
analysis showed that there was not much different between the ‘scrambled’ siRNA treated wells 
at 6 and 24hrs, though there was a greater increase in the number of apoptotic cells when cells 
treated with cell death siRNA for 24hrs.  However, as cells treated for 24hrs with siRNA did not 
grow as well as when they were treated with siRNA for 6hrs, this treatment time was not used for 
experiments. 
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Figure 9.1: Optimisation of hBMSCs for transfection with siRNAs against ANRIL using 
Lipofectamine RNAiMAX and a 30,000 cell seeding density.  Wells seeded with 30,000 cells and transfected 
with 10nM ‘scrambled’ and ‘cell death’ siRNAs for 6, 24, 48 and 72hrs.  (A) ‘Scrambled’ siRNA transfected 
cells were trypsinised and counted at 24, 48 and 72hr intervals to determine if cells continue to divide 
during this time frame.  (B) Cells were trypsinised at 72hrs and fixed for FACS analysis to determine if the 
positive control ‘cell death’ siRNA is having an effect on the number of live cells after treatment for 6, 24, 48 
and 72hrs. 
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Figure 9.2: Optimisation of primary osteoblasts for transfection with siRNAs against ANRIL using 
Lipofectamine RNAiMAX and a 30,000 cell seeding density.  Wells seeded with 30,000 cells and transfected 
with 10nM ‘scrambled’ and ‘cell death’ siRNAs for 6 and 24hrs.  (A) ‘Scrambled’ siRNA transfected cells were 
trypsinised and counted at 24, 48 and 72hr intervals to determine if cells continue to divide during this time 
frame.  (B) Cells were trypsinised at 72hrs and fixed for FACS analysis to determine if the positive control 
‘cell death’ siRNA is having an effect on the number of live cells after treatment for 6 and 24hrs. 
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 For comparison 50,000 seeding density optimisation experiment graphs are shown in 
Figure 9.3 for hBMSC graphs and Figure 9.4 for primary osteoblast graphs.  A seeding density of 
50,000 hBMSCs still showed continual growth with a 6hr treatment time (Figure 9.3A); however 
FACS analysis showed that the hBMSCs which had been treated with cell death control siRNA did 
not show as much of an increase in the number of apoptotic cells compared to their 30,000 cell 
seeding density counterpart (Figure 9.3B).  In addition to this, when cells were observed down a 
microscope, the wells were close to confluency (data not shown), which could affect downstream 
results. 
For primary osteoblasts, a 50,000 cell seeding density showed no increase in cell number 
at from 48hr to 72hrs with a 24hr siRNA treatment time (Figure 9.4A) and as the cell numbers and 
FACS analysis with a 6hr siRNA treatment were comparable to that seen with a 30,000 cell 
seeding density (Figure 9.4B), it was decided to use the same conditions as used for the hBMSCs. 
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Figure 9.3: Optimisation of hBMSCs for transfection with siRNAs against ANRIL using 
Lipofectamine RNAiMAX with 50,000 cell seeding density.  Cells treated with 10nM ‘scrambled’ 
and ‘cell death’ siRNAs for 6, 24, 48 and 72hrs.  After 72hrs, cells were trypsinised and counted (A) 
or fixed for FACS analysis (B).   
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Figure 9.4: Optimisation of primary osteoblasts for transfection with siRNAs against ANRIL using 
Lipofectamine RNAiMAX with 50,000 cell seeding density.  Cells treated with 10nM ‘scrambled’ 
and ‘cell death’ siRNAs for 6 and 24hrs.  After 72hrs, cells were trypsinised and counted (A) or 
fixed for FACS analysis (B).  
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